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Introduction
A revolution in medicine
In the early hours of the morning, on September 3, 1928, Alexander Fleming made 
a discovery that would change history. Fleming was a biologist and studied Staphy-
lococcus bacteria. By accident, one of his bacterial cultures was contaminated with 
a fungus, while he was on holiday leave. Upon return, he noticed that the bacteria 
surrounding the fungus were destroyed. Fleming’s famous words: “That’s funny” 
heralded the discovery of the first antibiotic, penicillin1.  
The effects of antibiotics were revolutionary, lethal infectious diseases were treat-
able for the first time2,3. Infectious diseases such as pneumonia, the world’s leading 
cause of death in these days, could now be treated3-5. The enormous effects of an-
tibiotics became apparent after the second world war, when the average life-ex-
pectancy rose as an effect of the decrease in mortality from bacterial infections6. 
The use of antibiotics has increased exponentially since their introduction6,7. Today, 
antibiotics are mostly used in hospitals and other healthcare settings for treatment 
and prophylaxis of infections, and in the livestock industry, to prevent and treat 
diseases in farm animals8,9. 
Resistance
In his Nobel prize speech in 1945, Alexander Fleming already warned that bacteria 
could become resistant to antibiotics10. Antibiotic resistance is a prime example of 
natural selection. Charles Darwin described this theory in his book “On the origin of 
species by means of natural selection”, where he stated that organisms less suited 
to their environment die, and organisms with favorable traits survive and repro-
duce11. 
In treatment with antibiotics, most bacteria will die, but some bacteria are neither 
killed, nor affected in reproduction by the effects of antibiotics. These micro-organ-
isms have acquired mechanisms of resistance to antibiotics, and can multiply at the 
expense of non-resistant micro-organisms because of selection pressure7,12. 
The use of broad spectrum antibiotics has increased in recent years. This widespread 
use of broad spectrum antibiotics is considered as one of the main causes of the 
increase of resistant microorganisms12-14. The consequences of antibiotic resistance 
are disastrous. The world health organization has declared antibiotic resistance as 
one of the biggest threats to global health today15. In Europe, estimated costs as-
sociated with antibiotic resistance are in the range of 1.5 billion euros annually16. 
Since the discovery of antibiotics, the problem of antibiotic resistance has grown so 
extensively, that scientists fear a so-called post-antibiotic era. In this scenario, we 
would see that antibiotics lose their effectiveness due to resistant bacteria. Con-
sequently, a re-emergence of many infectious diseases that become untreatable 
would greatly increase global morbidity and mortality17. 
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Antimicrobial stewardship
To counter the threat of antibiotic resistance, global initiatives were started to re-
duce the overuse of antibiotics in healthcare18,19. Antimicrobial stewardship is de-
fined as coordinated interventions to optimize antimicrobial use among patients 
in order to improve patient-centered outcomes, ensure cost-effective therapy and 
reduce adverse sequelae of antimicrobial use. Antimicrobial stewardship strategies 
can be implemented throughout healthcare systems. These strategies include ed-
ucation on antibiotic resistance, optimal selection of antibiotics, optimizing regi-
mens, dosage and duration of antibiotics prescriptions. Other strategies consist of 
clinical guidelines and decision-making aids for physicians, such as treatment algo-
rithms20-23. 
The emergency department
Every day, numerous patients visit emergency departments (EDs) worldwide. Many 
of these patients have complaints and symptoms that may be caused by infectious 
diseases. Patients with suspected infections are considered a diagnostic dilemma 
for physicians in the ED24,25. These patients may have clinical signs of an infection, 
such as fever, coughing, or redness of the skin. However, initially, the etiology (e.g. a 
bacterial, viral or fungal origin, or a noninfectious cause) of the patients’ complaints 
is often unclear. Physicians in the ED may have a clinical suspicion of the etiology, 
which is based on findings in patients’ history and physical examination, specific 
laboratory investigations, such as leukocyte count, and focused image techniques, 
such as chest X-rays. Definitive determination of the pathogen can only be per-
formed using techniques such as cultures and polymerase chain reaction analysis 
(PCR). The results of these techniques take several days to become available.
However, in the ED, there is a limited time window to start treatment. Patients usu-
ally stay in the ED for only a few hours. Therefore, the results of the time-consuming 
techniques of cultures and PCR are not available to physicians in the ED. Withhold-
ing antibiotics to patients with sepsis and septic shock increases mortality in these 
patient categories26. International guidelines of the surviving sepsis campaign rec-
ommend administering broad spectrum antibiotics to patients with suspected sep-
sis to reduce sepsis associated mortality27. Consequently, physicians start antibiotics 
on empiric grounds, without an accurate diagnosis of etiology. This practice results 
in wide administration of broad spectrum antibiotics in EDs, despite the knowledge 
of the effects of broad spectrum antibiotics on antibiotic resistance.
The core of the problem - to treat or not to treat - lies in discriminating patients who 
will benefit from antibiotics, (i.e. patients with bacterial infections) from patients 
who will not benefit (i.e. patients without bacterial infections). 
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Biomarkers
Biological markers, or biomarkers in short, are defined as characteristics that are 
objectively measured and evaluated as an indicator of normal biological process-
es, pathogenic processes or pharmacologic responses to a therapeutic interven-
tion28. For example, in current practice, C-reactive protein (CRP) is one of the most 
commonly used biomarkers29. This is an acute phase protein, which is significantly 
increased in patients with bacterial infections, compared to patients who are not 
ill30,31. One of the most important advantages of CRP, compared to other diagnostic 
modalities, is that the results are usually available within one hour, so CRP results 
can be used in medical decision-making in the ED. However, the specificity of CRP is 
far from perfect, because CRP levels are not only increased in patients with bacterial 
infections, but in patients with viral infections and non-infectious diseases as well29.
Procalcitonin
One of the more recent strategies for diagnosing bacterial infections, and conse-
quently reducing the prescription antibiotics in the ED, is procalcitonin (PCT) guided 
therapy. PCT is a precursor protein of calcitonin. Calcitonin is a hormone which is 
involved in the calcium homeostasis. In healthy individuals, PCT levels are unde-
tectably low. However, in patients with bacterial infections, blood concentration of 
PCT is greatly increased. In contrast, the calcitonin blood concentration only varies 
slightly. Therefore, PCT can be used as a biomarker for bacterial infections32. PCT 
has been studied in several selected populations, and these studies showed PCT 
to be a more accurate biomarker than CRP in differentiating between bacterial and 
non-bacterial disease33. Still, despite the existing evidence, the real value of PCT in 
the ED has not yet been determined. 
Biomarkers for viral disease
Similar to biomarker strategies that rule-in bacterial infections, biomarkers can be 
used to rule-in viral diseases. Combinations of these strategies may improve accura-
cy of determining the etiology. Two candidate biomarkers for ruling-in viral disease 
are tumor necrosis factor(TNF)-related apoptosis-inducing ligand (TRAIL) and in-
terferon-gamma induced protein-10 (IP-10), also known as C-X-C motif chemokine 
10 (CXCL10). TRAIL is a member of the TNF family of cytokines and plays a role in 
apoptosis of various cell lines during activation of the immune system in response 
to viral infections34,35. IP-10 is a chemokine that is secreted in response to interfer-
on-gamma in case of inflammation. IP-10 has several functions in activating both 
the innate and adaptive immune system. These roles include activating T1 lympho-
cytes and natural killer cells, identifying infected cells and regulating cell growth and 
apoptosis36. Blood concentrations of both biomarkers are significantly increased in 
patients with viral infections, compared to patients with bacterial and non-infec-
tious disease37. A recent study by van Houten et al. showed promising results using 
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TRAIL and IP-10 in combination with CRP in diagnosing bacterial disease in young 
children with respiratory infections38. However, the value of this combined strategy 
in a general emergency department remains unclear. 
Sepsis and severity of disease
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated 
host response to infection39. Sepsis is no single disease, but a complex condition in-
volving multiple systems, including the immune system, the coagulation system and 
the endothelium40,41. The surviving sepsis campaign guidelines advise to administer 
broad spectrum antibiotics to patients with sepsis. The rationale of this advice is 
that early administration of antibiotics can reduce morbidity and mortality, because 
the cause of sepsis is treated26,27. However, not all patients with an infection develop 
sepsis41. Therefore, hypothetically, only patients with sepsis should be treated im-
mediately, and in patients without sepsis, treatment could be delayed until a specif-
ic diagnosis is made. If patients who are at risk of becoming critically ill due to sepsis 
can be identified in the ED, broad spectrum antibiotics may be reserved exclusively 
for this specific group, and could be withheld in the patients who are not at risk for 
adverse events of sepsis. 
There are several biomarkers that are indicators of specific systems that are involved 
in sepsis. Mid-regional pro-adrenomedullin (proADM) is a prohormone of adreno-
medullin, a peptide with inflammation induced vasodilatory effects42,43. Increased 
levels of proADM in patients with community acquired pneumonia (CAP) are as-
sociated with short-term adverse outcomes, such as intensive care unit (ICU) ad-
mission and mortality44. Pro-endothelin-1 (proET-1) is a precursor of the paracrine 
hormone endothelin, and has vasoconstrictive properties45. Increase in proET-1 is 
correlated with failure of microvascular homeostasis and organ failure in septic 
patients46,47. The physiologic role of soluble urokinase-type plasminogen activator 
receptor (suPAR) is unclear at present. However, increases in suPAR blood concen-
tration levels are associated with activation of the immune system due to several 
stimuli, such as viral, bacterial and parasitic infections, and with malignancies48. In 
observational studies, suPAR predicted adverse outcomes such as readmission to 
hospital and mortality49,50. Although these biomarkers show potential, they are not 
routinely used in medical practice. 
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In summary, physicians in the ED need to make the critical decision whether to treat 
or not to treat patients with suspected infections, under diagnostic uncertainty. And 
both possibilities have potentially deleterious consequences. In order to make the 
optimal treatment decision, diagnostic uncertainty needs to be reduced as much 
as possible, using the principles of evidence based medicine51. To determine the 
likelihood of bacterial infections more accurately, we used a Bayesian approach, by 
adding the diagnostic values of new biomarkers to the diagnostic values of current 
standard tests52.
Aims of this thesis
The overall aims of this thesis were to investigate if biomarkers can improve early 
identification of bacterial infections and provide early estimation of severity of dis-
ease, and if biomarkers can be used to effectively reduce the prescription of antibi-
otics for febrile patients without bacterial infections in the ED.
Outline of thesis
Part I PCT-guided therapy
Chapter 2 This part begins with an overview of all prospective interventional studies 
on PCT-guided therapy in the ED in a systematic review. Chapter 3 is a pilot study on 
PCT-guided therapy, where patients were randomized between standard care and 
PCT-guided therapy. Chapter 4 clarifies the goals of the HiTEMP study, a randomized 
clinical trial (RCT) on PCT-guided therapy, featuring the rationale of the study and a 
thorough description of the study design, methods and statistical analysis. Chapter 
5 is the main study of this thesis, the HiTEMP study, a RCT on PCT-guided therapy, 
including an analysis of efficacy, safety, accuracy and cost-effectiveness. 
Part II Additional biomarker strategies
Chapter 6 is a report of a pilot study on the biomarkers TRAIL and IP-10 in a select-
ed patient cohort with patients with confirmed viral, bacterial and non-infectious 
diagnoses. In Chapter 7 TRAIL and IP-10 are investigated in combination with both 
CRP and PCT in a cohort of general ED patients. Chapter 8 focuses on severity of dis-
ease. We report on the value of single ED measurements of CRP, PCT and the newer 
biomarkers proADM, proET-1 and suPAR in predicting ICU admission and mortality. 
Part III General discussion
Chapter 9 is the concluding part of this thesis. Here, we discuss the findings of this 
thesis, and describe plans and possibilities for future research. 
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Procalcitonin-guided therapy for the initiation of antibiotics in the emergency department: a systematic review
ABSTRACT
Background 
Procalcitonin (PCT) is a new biomarker with a higher accuracy in the diagnosis of 
bacterial infections. Utilization of PCT may reduce the number of unnecessary anti-
biotics prescribed to patients, and consequently may decrease the rise in antibiotic 
resistance.
The aim of this systematic review is to determine if a PCT-guided algorithm can 
safely reduce the number of antibiotics prescribed to all patients with a suspected 
of infection in the emergency department(ED). 
Methods
MEDLINE, EMBASE, Web-of-science, COCHRANE central, PubMed publisher and 
Google scholar were searched. Two reviewers performed the screening inde-
pendently. The QUADAS 2 tool was used to assess quality.
 
Results
In total, 1621 articles were screened. Nine articles were included in the analysis. In 
the six studies on adult patients, only patients with respiratory tract infections were 
investigated. In these studies, a cut-off value of 0.25mcg/L was used, and PCT-guid-
ed therapy reduced the number of prescribed antibiotics significantly. Three studies 
were on pediatric patients, two on fever without source, and one on respiratory 
complaints. PCT-guided therapy did not reduce antibiotic prescription in children. 
PCT-guided therapy did not result in an increase in adverse events in any of the 
studies.
Discussion
PCT-guided therapy in the ED is only studied in subpopulations, where it was effec-
tive and safe in adult patients with respiratory tract infections, and not effective 
but safe nonetheless in specific pediatric populations. Nonadherence is a significant 
problem in prospective PCT-guided therapy studies. There is not enough evidence 
to use PCT-guided therapy in a general ED population. 
PROSPERO Systematic review registration: CRD42015023534
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INTRODUCTION
In the emergency department (ED), immediate treatment of bacterial infections is 
vital. Delay of administration of antibiotics is associated with morbidity and mortal-
ity in patients with severe sepsis and septic shock1. On the other side, the use of an-
tibiotics in the ED, without laboratory confirmation of the definitive diagnosis, may 
result in an overuse of antimicrobial therapy. Consequently, adverse drug events 
and healthcare costs may rise and antibiotic resistance may increase2-4. Antibiot-
ic resistance is a growing global problem2,3. Governments worldwide promote the 
implementation of antimicrobial stewardship programs5. Antimicrobial stewardship 
programs encourage to initiate optimal antimicrobial treatment6. Ideally, patients 
without bacterial infections would not receive antibiotics. However, in the emer-
gency situation, it is difficult to distinguish bacterial infections from viral infections 
and other febrile conditions. 
When a febrile patient presents at the ED, the standard diagnostic approach - be-
sides thorough medical history taking and physical examination - consists of lab-
oratory tests such as C-reactive protein (CRP) and leukocyte count, and different 
image modalities. Cultures and polymerase chain reaction (PCR) technology can be 
obtained in the ED, but results are not directly available and therefore not useful 
for ED decision-making. Procalcitonin (PCT) can be used as a biomarker for bacterial 
infections. Elevated levels indicate the probable presence of bacterial infections. 
As levels of PCT rise within approximately six hours after the start of bacterial in-
fection and remain relatively stable, its properties are suitable for ED-application7,8. 
Compared to CRP, PCT has been shown to be more accurate in different age groups, 
ranging from young children with fever without source(FWS)9,10, to geriatric pa-
tients11. Also, for different sites of infection, such as respiratory tract and urogeni-
tal tract12-14, and in multiple clinical settings, including primary care, intensive care 
units, and in the ED, PCT is more accurate15-17. Although the characteristics of PCT 
are promising, there may be other factors that can influence the initiation of anti-
biotic therapy. Prospective studies give more insight in these factors, because in-
tention-to-treat analyses can be compared with per-protocol analyses. Also, safety 
can be addressed in prospective studies, because unwanted undertreatment and 
consequent adverse events can be quantified. PCT-guided therapy is defined as ini-
tiation of antibiotic treatment using PCT measurements, usually using a suggested 
treatment algorithm based on the height of the PCT measurement15. The overall 
clinical value of PCT-guided therapy in the general ED population of all ages and full 
spectrum of febrile complaints remains to be investigated. 
The aim of this systematic review is to determine if a PCT-guided algorithm can safe-
ly reduce the number of antibiotics prescribed to all patients suspected of infection 
in the ED. 
24
Procalcitonin-guided therapy for the initiation of antibiotics in the emergency department: a systematic review
METHODS 
Study design
A systematic review of literature was performed according to the PRISMA guide-
lines18. The design of this systematic review is registered in the PROSPERO data-
base19, with registration number CRD42015023534 (http://www.crd.york.ac.uk/
PROSPERO/). The primary outcome measure was the effectiveness of PCT-guided 
therapy in the ED, defined as reduction in the initiation of antibiotic therapy. 
Search strategy
A comprehensive search, supported by a professional librarian of the Erasmus Uni-
versity Medical Center Rotterdam was performed. The MEDLINE, EMBASE, Web-of-
science, COCHRANE central, PubMed publisher and Google scholar, containing all 
articles up to July 1st, 2015 were searched.  The results were limited to the English 
language. Search terms are listed in Supplement 1. This review was restricted to 
articles that prospectively reported on an intervention of PCT-guided therapy in an 
ED setting. Outcome measures were: reduction of antibiotics (defined as number or 
percentage of antibiotics prescriptions), and safety of PCT-guided therapy (defined 
as hospital mortality, hospital or intensive care unit (ICU) admission and return vis-
its to the ED). Studies that were not performed in the ED, i.e. in the ICU, medical or 
surgical wards, or primary care facilities were excluded. Furthermore, studies per-
formed in specific departments such as burns units were excluded, as well as studies 
where there was no comparison between a PCT-guided therapy group and a control 
group of standard cares. There was no limit on age distribution or subpopulation 
of patients. Two authors (Y.D. and M.L.) screened titles and abstracts of the search 
results, and the full text of the selected articles. In case of disagreement a third re-
viewer (P.R.) acted as a referee. The QUADAS 2 tool20 was used for assessing quality 
and bias in the selected full text studies. The QUADAS 2 tool is the recommended 
quality assessment tool by the Cochrane library. After positive quality assessment, 
data were extracted from the remaining articles as reported in supplement 2. 
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RESULTS
Literature search
The search results are depicted in Figure 1. The search strategy identified 1621 
individual studies. Of these studies, 635 were ED based studies that investigated 
PCT. A total of 198 studies investigated the accuracy of PCT on various outcomes 
in the ED; 188 studies did not use a prospective PCT-guided therapy algorithm and 
were therefore not included for further analysis. After full text screening, 10 articles 
remained that addressed PCT-guided therapy in a prospective setting. The overall 
quality of the studies was assessed using the QUADAS 2 guidelines20. 
1 
 
 
Figure 1. Flow diagram 
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Quality assessment 
The quality assessment is described in Supplement 3, and summarized in Table 1. 
Although the study of Drozdov et al.21 was eligible for inclusion in the review based 
on the selection criteria, it was excluded in the quality assessment. Drozdov et al.21 
did not address the initiation of antibiotics, but instead reported on a PCT-guided 
stopping algorithm for patients who already received antibiotic treatment for a uri-
nary tract infection. This was not in line with the review question, and therefore 
the results of this study were not applicable. Stolz et al.22 excluded patients with 
another explanation of dyspnea than an acute exacerbation of chronic obstructive 
pulmonary disease (AECOPD) and patients with psychiatric comorbidity from the 
study population. The exclusion of a selected part of the total population resulted 
in a high risk of population selection and possible effect exaggeration, because pa-
tients with medical comorbidities were excluded, and patients with possible lower 
therapy adherence may have been excluded. There was an unclear risk of bias in 
patient selection in six studies. Lacroix et al.10 used temperature ≥38.0⁰C as an 
inclusion criterion. Patients were also included if parents had measured a tempera-
ture of ≥38.0⁰C at home. Lacroix et al.10 reported a low adherence to the combined 
Lab-score, a prediction model containing a PCT value. No reasons for nonadherence 
were reported. This raised concerns on the applicability of the results of this study. 
Furthermore, the authors reported a missed inclusion rate of 75%, but gave no de-
scription of individual reasons. This may have resulted in a selection bias. Three 
studies9,13,23 used an envelope as randomization method. This method is associated 
with an increased risk of selection bias, because allocation concealment can be de-
ciphered by holding envelopes against a lightsource24. Christ-Crain et al.13 exclud-
ed 47 of a total of 597 eligible patients because of “other reasons”. Long et al.25 
excluded 115 patients without specifying the reason of exclusion. The index test 
description had an unclear risk of bias in two studies. Baer et al.26 did not report 
a final diagnosis of the febrile episode. It is not possible to check if the antibiotics 
were indicated retrospectively. Manzano et al.9 did not give an antibiotic treatment 
advice. A concrete cut-off value for PCT with a treatment suggestion could have 
influenced the results of this study.
 
Main study results 
The selected articles are shown in Table 2. Nine randomized controlled trials met the 
selection criteria listed in figure 1 and the QUADAS 2 criteria in Table 1. These studies 
consisted of two multicenter trials (17, 26) and seven single center studies9,10,13,14,22,23,25. 
Six studies10,13,14,17,22,26 were conducted in Switzerland, five of these13,14,17,22,26 in the 
university hospital of Basel. The remaining studies were performed in China23,25 and 
Canada9. 
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Table 1. QUADAS 2
First author, year, country
PATIENT SELECTION INDEX TEST  REFERENCE STANDARD FLOW AND TIMING PATIENT SELECTION INDEX TEST  REFERENCE STANDARD
Baer 2013, Switzerland Low Unclear Unclear Low Low Unclear Low
Christ-Crain 2004, Switzerland Unclear Low Low Low Low Low Low
Christ-Crain 2006, Switzerland Unclear Low Low Low Low Low Low
Drozdov 2015, Switzerland Unclear Low Low Low High High Low
Lacroix 2014, Switzerland Unclear Unclear Low High Low Unclear Low
Long 2011, China Unclear Low Low Low Low Low Low
Manzano 2010, Canada Unclear Unclear Low Low Unclear Low Low
Schuetz 2009, Switzerland Low Low Low Low Low Low Low
Stolz 2007, Switzerland High Low Low High Low Low Low
Tang 2013, China Unclear Low Low Low Low Low Low
Risk of bias Concerns on applicability
Study populations 
Sample sizes of the studies varied widely, ranging between 15623 and 135917 pa-
tients, with six studies9,10,13,14,22,26 having sample sizes between 200 and 400 patients. 
Three studies reported on pediatric patients9,10,26, of which two9,10 reported on new-
borns and infants with FWS, and one on pediatric patients with respiratory tract 
infections26. 
Six studies reported on adult patients with subcategories of respiratory complaints: 
community acquired pneumonia14,25, acute lower respiratory tract infections13,17, AE-
COPD22 and exacerbation of asthma23. The age of patients ranged from newborn 
children between seven days and three months of age10 to septuagenarians17. The 
majority of the participants were males (>50% men in six10,13,14,17,25,26 out of the nine 
studies). One study9 did not report gender. None of the studies reported ethnicity.
 
Selection criteria studies
Inclusion criteria of the studies on lower respiratory tract infections13,14,17,25,26 includ-
ed body temperature of ≥38°C (100.4° F), combined with at least one symptom 
of infection, i.e. cough, sputum production or dyspnea, and one clinical sign, i.e. 
abnormal breath sounds or leukocytosis. The criterion for suspected community 
acquired pneumonia was an infiltrate on a chest X-ray. Inclusion criteria on asth-
ma and COPD were based on reaction to beta-2-agonist use22,23. One study used 
temperature measured at home as inclusion criterion26. Two pediatric studies on 
FWS9,10 included a measured body temperature of ≥38°C, without the presence of a 
suspected cause of fever after history and physical examination10, and the need for 
blood and urinary analysis9. Eight studies9,10,13,14,17,22,25,26 reported immunosuppres-
sion as an exclusion criterion. This criterion was not uniformly defined. Some stud-
ies gave examples of specific conditions, i.e. HIV infection with low CD4+ count13,26, 
neutropenic patients13,26,  active tuberculosis13,14,25 and cystic fibrosis13,14,22,25,26.  Four 
studies9,10,23,25 excluded patients with current antibiotics use or within 14 days of ED 
presentation. Schuetz et al.17 excluded intravenous drug users. Stolz et al.22 excluded 
‘vulnerable patients’: patients with psychiatric diagnoses, which were not defined.
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PCT cut-off values
Seven studies13,14,17,22,23,25,26 used a cut-off of 0.25 mcg/L to suggest or encourage the 
initiation of antibiotics. Two pediatric studies did not use a continuous cut-off scale. 
Lacroix et al.10 used PCT as part of the Lab-score, a decision rule that combined a 
semi-quantitative PCT result with a semi-quantitative CRP value and urinary dipstick 
outcome. The Lab-score is a severity index scale, and the outcome had no direct-
ly suggested treatment consequences. Manzano et al.9 studied PCT prospectively 
without treatment algorithm, only the PCT result was available, without treatment 
advice. 
Overruling of PCT-guided therapy protocol and nonadherence
Two studies17,26 described predefined criteria for overruling PCT-guided therapy. 
These criteria comprised of life threatening illness, defined as respiratory or hemo-
dynamic instability. Schuetz et al.17 also included a positive screening test for Le-
gionella pneumophilia as criterion. Four10,13,14,17 studies reported physician nonad-
herence, ranging from 6% to 20%. In the studies with predefined criteria, Schuetz17 
reported that 9% of the patients were excluded without meeting the nonadherence 
criteria. Baer et al.26  only mentioned predefined criteria, and did not report the 
number of physician nonadherence, nor protocol violations.
 
Antibiotics reduction
PCT-guided therapy resulted in a significant reduction of antibiotics in all studies 
in adult patients13,14,17,22,23,25 (Table 3). In the three pediatric studies, no significant 
reduction in antibiotics was noted9,10,26. No study reported an increase in initiation 
of antibiotics. All results were from the intention-to-treat analyses. 
Patient related outcomes
Five studies13,14,17,22,23 reported mortality and ICU admission. Death rates varied be-
tween 3%13 to 13%14. ICU admittance or mechanical ventilation was required for 
5%13 to 14%14 of patients. No studies reported a significant difference between 
groups for death rates or ICU admission. Seven studies9,10,13,14,17,22,26 reported hos-
pital admissions. The admission rate ranged from 26%9 to 97%14. No study found 
a significant difference between hospital admissions. Five studies13,14,17,22,26 report-
ed length of hospital stay; none found significant differences between groups. One 
study25 included patients who were sent home from the ED, and one study23 did not 
report a hospital admission number.
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First author, 
year, country
Study 
population *
Age distribution in 
years
Gender 
distribution 
(m
ale)
Inclusion criteria
Exclusion criteria
PCT cut-off value used
Overruling of algorithm
Baer 2013, 
Switzerland
337 patients
PCT group: m
edian [IQR] 
2.7 [1.1 - 5.2]. Control 
group: 2.9 [1.2 - 5.7].
PCT group: 98 
(58%). Control 
group: 98 (58%).
Pediatric patients, age 1 m
onth - 18 years, 
presenting with LRTI, defined as T ≥38⁰C (m
easured 
at hom
e or hospital), with one sym
ptom
 (cough, 
sputum
 production, pleuritic pain, poor feeding) and 
one clinical sign (tachypnea, dyspnea, wheezing, late 
inspiratory crackles, bronchial breathing, pleural 
rub).
Unwillingness or unable to provide written inform
ed consent 
by patients and care-takers, severe im
m
une suppression (HIV 
with <15% CD4 count, im
m
unosuppressive treatm
ent, 
neutropenia (<1000 x 10^9/L)), cystic fibrosis, acute croup, 
hospital stay within previous 14 days, other severe infection.
Antibiotics definitely (> 0.5 m
cg/L), probably 
(0.26–0.5 m
cg/L), probably not (0.1–0.25 
m
cg/L), and definitely not (0.1 m
cg/L).
In patients with life 
threatening infections, 
defined as severe co-
m
orbidity, em
erging ICU need 
during initial follow-up, or 
hem
odynam
ic or respiratory 
instability.
Christ-Crain 
2004, 
Switzerland
243 patients
PCT group (m
ean ± SD): 
62.8  ± 19.8. Control 
group: 65.3 ± 17.3 .
PCT group: 67 
(54%). Control 
group 61 (51%). 
Adult patients with suspected LRTI, defined as 
com
m
unity acquired pneum
onia, COPD, asthm
a, 
acute bronchitis.
Severely im
m
unocom
prom
ised patients i.e. HIV infection with 
CD4 count <200cells/m
L, neutropenic patients, stem
cell 
transplant recipients, cystic fibrosis, active tuberculosis, 
hospital acquired pneum
onia on ED presentation.
Antibiotics discouraged (0.1-0.25m
cg/L), 
suggested (0.25-0.5m
cg/L), strongly 
recom
m
ended (>0.5m
cg/L). 
Not reported.
Christ-Crain 
2006, 
Switzerland
302 patients
PCT group (m
ean ± SD): 
70 ± 17. Control group: 
70 ± 17. 
PCT group: 94 
(62%). Control 
group 93 (62%). 
Adult patients with suspected CAP, defined as 
infiltrate on chest X-ray, and one of m
ore sym
ptom
s 
or signs: cough, sputum
 production, dyspnea, tem
p 
≥38.0⁰C and up, abnorm
al breath sounds, rales on 
auscultation, leukocytosis 10 x 10^9/L and up, or less 
than 4 x 10^9/L. 
Cystic fibrosis, active pulm
onary tuberculosis, hospital 
acquired pneum
onia on ED presentation., severely 
im
m
unocom
prom
ised patients (not defined). 
Antibiotics strongly discouraged (<0.1 m
cg/L), 
discouraged (0.1-0.25m
cg/L), encouraged (0.25-
0.5m
cg/L), strongly encouraged (>0.5m
cg/L).
Not reported.
Lacroix 2014, 
Switzerland
271 patients*
Age in m
onths. PCT group 
(m
edian [IQR]) 4.8 [1.7 - 
10.4]. Control group 3.4 
[1.5 - 10.4].
PCT group: 65 
(50%). Control 
group 71 (51%).
Pediatric patients between 7 days and 3 years old 
with fever without source (FW
S): Tem
perature 
≥38⁰C, with no identified source of infection after 
thorough history and physical exam
ination. Parental 
inform
ed consent. 
Congenital or acquired im
m
unodeficiency syndrom
es, 
antibiotic adm
inistration <48h of presentation, fever >7 days.
Lab score: PCT <0.5ng/m
L (0), 0.5 - 1.99 ng/m
L 
(2), ≥2 ng/m
L (4). In com
bination with CRP value 
based score, and Urinary dipstick based score. A 
Lab score of ≥3 was used as m
arker for severe 
bacterial illness.
No algorithm
 of antibiotic 
treatm
ent advice reported. 
Therefore, overruling is also 
not reported.
Long 2011, 
China
162 patients*
PCT group (m
ean ± SD): 
44 ± 16. Control group: 
47 ± 19. 
PCT group: 46 
(60%). Control 
group 49 (62%).
Adult patients with suspected CAP, defined as 
infiltrate on chest X-ray, and one of m
ore sym
ptom
s 
or signs: fever, cough, purulent sputum
, focal chest 
signs, dyspnea or pleuritic pain. Outpatient 
treatm
ent.
Pregnancy, com
m
encem
ent of antibiotic therapy >48h before 
enrolm
ent, system
ic im
m
une deficiency, withholding life-
support and active tuberculosis.
Antibiotics strongly discouraged (<0.1 m
cg/L), 
discouraged (0.1-0.25m
cg/L), encouraged (0.25-
0.5m
cg/L), strongly encouraged (>0.5m
cg/L). 
Not reported.
M
anzano 2010, 
Canada
384 patients*
Age in m
onths. PCT 
group(m
ean ± SD): 12 ± 8. 
Control group: 12 ± 8.  
Not reported
Pediatric patients, age between 1 and 36 m
onths, a 
history of rectal tem
perature ≥38.0⁰C, no identified 
source of infection, indication for blood and urine 
analysis.
Acquired or congenital im
m
unodeficiency, current antibiotics 
use.
For intention-to-treat analysis no cut-off 
defined. Sem
iquantitative test: <0.5ng/m
L, 0.5 
ng/m
L or higher, 2 ng/m
L or higher, 10ng/m
L or 
higher. Per protocol analysis with prophylactic 
antibiotics with PCT level >0.5ng/m
L or higher.
No algorithm
 of antibiotic  
treatm
ent advice reported. 
Therefore, overruling is also 
not reported.
Schuetz 2009, 
Switzerland
1359 patients*
PCT group: m
edian [IQR] 
74 [59-82]. Control group: 
72 [59-82]. 
PCT group: 402 
(60%). Control 
group 380 (55%).
Adult patients with suspected LRTI, defined as at 
least one respiratory sym
ptom
 (cough, sputum
, 
dyspnea, tachypnea, pleuritic pain), plus either rales 
or crepitation on auscultation, or tem
perature 
>38.0⁰C, shivering, leukocytosis.
Inability to give inform
ed consent, active intravenous drug 
use, severe im
m
unosuppression other than corticosteroid 
use, life-threatening com
orbidity, com
m
unity acquired 
pneum
onia. 
Antibiotics strongly discouraged (<0.1 m
cg/L), 
discouraged (0.1-0.25m
cg/L), encouraged (0.25-
0.5m
cg/L), strongly encouraged (>0.5m
cg/L). 
Patients in need of ICU 
adm
ission, respiratory or 
hem
odynam
ic instability, 
positive Ag test for Legionella 
pneum
ophila, or after 
consulting with the study 
center.
Stolz 2007, 
Switzerland
208 patients*
PCT group: m
edian [IQR] 
69.5 [65-77]. Control 
group: 69.5 [64.8-79]. 
PCT group: 50 
(49%). Control 
group 44 (42%).
Adult patients with exacerbation of COPD, who m
et 
post bronchodilator therapy spirom
etric criteria 
according to GOLD guidelines, within 48h of ED 
adm
ission.
Patients with other explanations for presenting sym
ptom
s 
other than COPD, and "vulnerable patients" ie patients with 
psychiatric diagnoses (not specified). Im
m
unosupression, 
asthm
a, cystic fibrosism
 presence of infiltrates on chest X-ray 
on hospital adm
ission.
Antibiotics strongly discouraged (<0.1 m
cg/L), 
discouraged (0.1-0.25m
cg/L), encouraged (0.25-
0.5m
cg/L), strongly encouraged (>0.5m
cg/L). 
Not reported.
Tang 2013, 
China
156 patients*
PCT group (m
ean ± SD): 
54 ± 14. Control group: 
55 ± 15. 
PCT group: 64 
(50%). Control 
group 59 (47%).
Adult patients with suspected exacerbation of 
asthm
a, with any or all GINA asthm
a guidelines 
criteria: dyspnea, wheeze, acute cough, increased 
work of breathing, increased beta2 agonist use, O2 
saturation <95%, peakflow<80% of known best. 
Treatm
ent with antibiotics within two weeks of recruitm
ent, 
non-respiratory bacterial infection, chest X-ray confirm
ed 
pneum
onia, other chronic respiratory disease, severe organ 
dysfunction. 
Antibiotics strongly discouraged (<0.1 m
cg/L), 
discouraged (0.1-0.25m
cg/L), encouraged (0.25-
0.5m
cg/L), strongly encouraged (>0.5m
cg/L). 
Not reported.
* Studies reported both a num
ber of random
ised and num
ber of analyzed patients. Num
ber of analyzed patients is reported. For num
ber of om
m
ited patients in analysis, see table 1. CAP: Com
m
unity acquired pneum
onia. COPD: Chronic obstructive pulm
onary disease. ED: 
Em
ergency departm
ent. GINA: Global initiative for asthm
a. GOLD: Global initiative for chronic obstructive lung disease. HIV: Hum
an im
m
unodeficiency virus. ICU: Intensive care unit. IQR: Inter quartile range. LRTI: Lower respiratory tract infection. PCT: Procalcitonin. SD: Standard 
deviation.   
Table 2: Study characteristics
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DISCUSSION
Findings
The results of our study show that PCT-guided therapy is only studied prospective-
ly in distinct ED patient populations, adults with respiratory complaints13,14,17,22,23,25, 
and in young infants with respiratory complaints26 and FWS9,10. In the studies on 
adult patients with respiratory complaints, PCT-guided therapy reduced antibiot-
ic prescriptions. In the pediatric subgroups, there was no reduction. In all includ-
ed studies, there was no undertreatment and there was no increase in adverse 
events in the intervention group. This suggests that PCT-guided therapy is safe 
in the patients of these distinct ED populations. PCT-guided therapy has been 
shown to reduce antibiotic prescriptions in adult patients with respiratory com-
plaints in various clinical settings. In primary care, reduction of antibiotics was 
72%16. One hospital based study on patients with lower respiratory tract infections 
did not find a significant reduction in antibiotic prescriptions, due to a reported 
protocol nonadherence of 41%. The per-protocol did result in a 25% reduction of 
antibiotics based on a single PCT value27. PCT studies in the ICU mainly focus on 
stopping antibiotics instead of starting. Several ICU studies show a reduction in du-
ration of antibiotic treatment using PCT-guided therapy15,28,29. The most interesting 
finding was that nonadherence to PCT-guided algorithms was present in several 
included studies. Lacroix et al.10 reported that the use of a PCT-guided algorithm, 
included in the Lab-score, did not result in a reduction in antibiotics in practice. 
However, per-protocol analysis showed that the algorithm would result in reduc-
tion, had it been followed. This illustrates the point that physicians do not always 
follow the advice of a PCT-guided therapy. This is confirmed by the nonadherence 
to the PCT-guided therapy algorithms several of the other included studies10,13,14,17. 
Nonadherence is only visible in prospective studies; because, in contrary to obser-
vational studies, randomized controlled trials report an intention-to-treat analysis, 
which includes the physician factor in the results. Prospective PCT-guided therapy 
studies in other clinical settings also show nonadherence. Briel et al.16 reported a 
nonadherence rate of 15% in primary care.  Kristoffersen et al.27 reported a 41% 
nonadherence in a hospital based setting.  In the ICU setting, he PRORATA trial15 
had a protocol nonadherence for stopping antibiotic therapy based on a PCT-guided 
algorithm of 53%, a recent ICU study reported a 56% nonadherence rate when phy-
sicians were asked to stop antibiotics within 24 hours after initiation29. PCT-guided 
therapy is accompanied by protocol nonadherence, and this finding is consistent 
in multiple clinical settings. We speculate that individual clinical experience is the 
cause of the lower reduction of antibiotics in intention-to-treat results.  This may be 
caused by the lack of understanding of the factors that influence PCT levels30. The 
results of this systematic review cannot be extrapolated to a general ED population, 
because the studies included in this systematic review focused on specific subpopu-
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lations of patients with respiratory complaints. The study aim was to investigate the 
value of PCT-guided therapy for all patients in the ED. For this reason, we did not 
limit the results on specific populations, but included all ED studies from young chil-
dren to elderly patients. However, our search results only yielded specific subpop-
ulations. We can conclude that PCT-guided therapy is not studied in a wide enough 
population to use PCT as a standard biomarker for bacterial infections in the ED. 
The overall quality assessment indicated a low risk on bias in the selected articles. 
The study by Drozdov et al.21 did not give information on antibiotic initiation and 
was therefore excluded. Two studies had a high risk on bias. Stolz et al.22 excluded 
patients with possible other explanations for dyspnea than acute exacerbation of 
COPD (AECOPD). Also, patients with psychiatric comorbidities were excluded. This 
may have resulted in an exaggeration of the effect of PCT-guided therapy, because 
merely a part of the total population of patients with AECOPD was analyzed. In 
the study by Lacroix et al.10, patient selection issues were noted as well.  These 
studies were included, because the studies both used a PCT-guided algorithm and 
investigated reduction of antibiotics, and therefore give insight in the effectiveness 
of PCT-guided therapy in the ED. Because of the high risk of selection bias in these 
studies, the results cannot be generalized to either the general population of adult 
ED patients with AECOPD, or to the general population of pediatric ED patients with 
FWS.
Limitations
It was not possible to pool the data of the nine included studies, because we found 
insufficient studies with comparable study populations. A pooling of the results of 
PCT-guided therapy in adults may have resulted in a reduction of antibiotics in adult 
patients, and to no effect in pediatric patients. However, because of the highly se-
lective populations of the selected studies, these outcomes would not have had 
added value. This review was performed in 2015. There are several studies being 
performed at the time of writing, which study PCT-guided therapy, for instance the 
NeoPInS trial31. These results are not available at this moment, but may further 
clarify the value of PCT-guided therapy. The review is primarily intended for emer-
gency physicians. Therefore, only investigated ED based studies were included. The 
ED is a unique clinical setting, which has specific problems such as the diagnostic 
uncertainty at a time when emergency treatment has to be initiated. Hence, the 
choice for this setting reduces the generalizability of the results to other settings. 
Five studies10,13,14,17,23,25 reported on funding. Investigators of three of these studies 
received funding from the manufacturer of the PCT assay10,13,17. The authors of three 
studies13,14,17 reported receiving payments for speaking engagements, lecture fees 
and consultancy work for the manufacturer of the PCT assay. Conflicts of interest 
might raise concern in the appreciation of the results32.
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CONCLUSION
PCT-guided therapy is a valuable strategy in antimicrobial stewardship, and can 
theoretically reduce the number of unnecessary antibiotics prescribed to ED pa-
tients. However, protocol nonadherence is a significant problem in the prospective 
PCT-guided therapy studies. In adult patients with suspected respiratory infections, 
PCT-guided therapy may reduce antibiotic prescriptions, without increasing ad-
verse events. However, physician judgment is still crucial and cannot be replaced 
by biomarkers in these patient populations based on the available evidence. In pe-
diatric patients, PCT-guided therapy was ineffective, because nonadherence to the 
PCT-guided algorithm reverses the theoretical reduction in antibiotics. PCT-guided 
therapy can only become standard therapy in the ED when it is validated in a rep-
resentative sample. Also, additional evidence on the physiologic properties of PCT 
may result in more confidence in PCT-guided algorithms.
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Supplement 1. Search terms per database 
Embase.com 
(procalcitonin/exp OR (procalcitonin* OR (calcitonin* NEAR/3 (precursor* OR prohormone*)) OR (pct 
NEAR/3 (value* OR level* OR marker* OR biomarker* OR blood* OR sample* OR collect*))):ab,ti) AND 
('emergency treatment'/exp OR emergency/exp OR 'emergency nursing'/exp OR 'emergency health 
service'/exp OR 'emergency ward'/exp OR 'emergency medicine'/exp OR traumatology/exp  OR 'multiple 
trauma'/exp OR (emergenc* OR 'acute care' OR trauma* OR resuscitat* OR ed)) AND ([english]/lim) 
Medline (OvidSP)   
((Calcitonin/ AND Protein Precursors/) OR (procalcitonin* OR (calcitonin* ADJ3 (precursor* OR 
prohormone*)) OR (pct ADJ3 (value* OR level* OR marker* OR biomarker* OR blood* OR sample* OR 
collect*))).ab,ti.) AND (Emergencies/ OR exp Emergency Treatment/ OR emergency nursing/ OR exp 
Emergency Service, Hospital/ OR exp Emergency Medical Services/ OR exp emergency medicine/ OR 
traumatology/  OR multiple trauma/ OR (emergenc* OR acute care OR trauma* OR resuscitat* OR ed)) 
AND (english ).la. 
Cochrane central 
((procalcitonin* OR (calcitonin* NEAR/3 (precursor* OR prohormone*)) OR (pct NEAR/3 (value* OR 
level* OR marker* OR biomarker* OR blood* OR sample* OR collect*))):ab,ti) AND ((emergenc* OR 
'acute care' OR trauma* OR resuscitat* OR ed))  
Web-of-science  
TS=(((procalcitonin* OR (calcitonin* NEAR/3 (precursor* OR prohormone*)) OR (pct NEAR/3 (value* OR 
level* OR marker* OR biomarker* OR blood* OR sample* OR collect*)))) AND ((emergenc* OR "acute 
care" OR trauma* OR resuscitat* OR ed)) ) AND LA=(english ) 
PubMed as supplied by publisher  
((Calcitonin[mh] AND Protein Precursors[mh]) OR (procalcitonin*[tiab] OR (calcitonin*[tiab] AND 
(precursor*[tiab] OR prohormone*[tiab])) OR (pct AND (value*[tiab] OR level*[tiab] OR marker*[tiab] 
OR biomarker*[tiab] OR blood*[tiab] OR sample*[tiab] OR collect*[tiab])))) AND (Emergencies[mh] OR 
Emergency Treatment[mh] OR emergency nursing[mh] OR Emergency Service, Hospital[mh] OR 
Emergency Medical Services[mh] OR emergency medicine[mh] OR traumatology[mh]  OR multiple 
trauma[mh] OR (emergenc*[tiab] OR acute care OR trauma*[tiab] OR resuscitat*[tiab] OR ed[tiab])) 
AND english[la] AND publisher[sb] 
Google scholar 
Procalcitonin|"pct value|level|sample" emergency|traumatology|trauma|"acute care" 
 
37
Procalcitonin-guided therapy for the initiation of antibiotics in the emergency department: a systematic review
Supplement 2. Data extraction 
First author, Year, Country, Journal, Hospital type, Single center/multicenter/ international multicenter, 
Study design, age distribution, gender distribution, ethnicity, inclusion criteria, exclusion criteria, PCT cut-
off value used, overruling of PCT-algorithm, antibiotics reduction, hospital admission, length of hospital 
stay, ICU admission, ICU length of stay, return visits to ED, mortality, physician non-adherence with PCT 
advice. 
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Supplem
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S 2 quality assessm
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Consecutive or random
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sym
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DOM
AIN 2: Index test(s)
A. Risk of bias
B. Concerns regarding applicability
If a threshold (cut-off value) w
as used, w
as it pre-
specified? (off w
hite = yes, black = no, gray = 
unclear)
Could the conduct or interpretation of the index test 
have introduced bias?  (RISK: off w
hite = low
, black 
= high, gray = unclear)
Is there concern that the index test, its conduct, 
or interpretation differ from
 the review
 
question? (RISK: off w
hite = low
, black = high, 
gray = unclear)
Describe the reference standard and 
how
 it w
as conducted and interpreted:
Is the reference standard likely to 
correctly classify the target condition? 
(off w
hite = yes, black = no, gray = 
unclear)
It is unclear w
hat the final diagnosis of the febrile 
episode is. The choice of antibiotics in both the 
intervention and control group is based on ED 
assessm
ent, but is not checked w
ith the m
icrobial 
etiology. Therefore the true indication of antibiotics 
cannot be verified.
A com
parison betw
een PCT per-protocol and 
intention-to-treat analysis w
ould provide insight 
in PCT protocol adherence. Only an intention-to-
treat analysis is provided, so non-adherence 
cannot be evaluated.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
Reference standard w
as physician 
assessm
ent in the ED, and m
icrobial 
laboratory investigations for final 
diagnosis.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
The review
 question is PCT guided therapy in the 
initiation of antibiotics in the ED. Because all 
patients received antibiotics initially, this study 
does not answ
er the prim
ary review
 question.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
The study reports low
 adherence to Lab score 
recom
m
endations. No reasons for 
nonadherence w
ere reported. 
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
The index test had a three-point-scale, either low
, 
m
oderate or high risk of bacaterial infection. No 
antibiotic advice w
as given. Advice on antibiotics m
ay 
have altered the results of antibiotic prescription or 
hospital adm
ittance.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
Reference standard w
as physician 
assessm
ent in the ED, based on clinical 
guidelines.
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DOM
AIN 1: Patient selection
A. Risk of bias
B. Concerns regarding applicability
W
as a case-control design avoided?  (off 
white = yes, black = no, gray = unclear)
Did the study avoid inappropriate 
exclusions  (off white = yes, black = no, 
gray = unclear)
Could the selection of patients have 
introduced bias? (RISK: off w
hite = low
, black 
= high, gray = unclear)
Describe included patients (prior testing, presentation, intended use of index test and 
setting):
Concern that included patients do not 
m
atch review
 question? (RISK: off 
w
hite = low
, black = high, gray = 
unclear)
Describe the index test and how it was conducted and interpreted:
W
ere the index test results interpreted 
w
ithout know
ledge of the reference 
standard? (off w
hite = yes, black = no, 
gray = unclear)
Included pediatric patients all had fever (38.0 and up), with one additional sym
ptom
 
(tachypnea, dyspnoea, wheezing, late inspiratory crackles, bronchial breathing, pleural 
rub), and were without severe im
m
unesuppression (HIC with low cd4+, 
im
m
unesuppressive treatm
ent, neutropenia, CF, acute croup, hospital stay within 14 
days, or other severe infection.  the index test determ
ined if they would receive 
antibiotics.
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, with 
predefined protocol violations, i.e. severe co-m
orbidity, ICU need, 
hem
odynam
ic or respiratory instability
Not applicable, the reference standard 
is physician assessm
ent
47 patients were excluded because of "other" 
reasons, not specified, of the total of 597 
eligible patients.
Included patients had cough and/or dyspnoea, and were without specific 
exclusioncriteria, chf, "other pulm
onary disease, m
alignancy, im
m
unocom
prom
ised 
status, or other types of infection.  The index test determ
ines if they will receive 
antibiotics.
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, 
protocol violations were allowed on physician discretion without 
predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
Random
isation by envelopes, a m
ethod prone 
for random
isation bias.
Patients with suspected CAP present in the ED, the index test determ
ines if they will 
receive antibiotics.
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, 
protocol violations were allowed on physician discretion without 
predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
Random
isation by envelopes, a m
ethod prone 
for random
isation bias.
Im
m
unocom
petent patients visiting the ED, were divided in adm
itted and outpatient 
groups, and in sim
ple/com
plicated UTI groups, the PCT level was used for the duration 
of treatm
ent.
Because all patients received 
antibiotics initially, this study does not 
answer the research question.
PCT testing was perform
ed in the lab.  A previously described 
algorithm
 was used for interpretation, protocol violations were 
allowed on physician discretion without predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
Tem
peratures taken at hom
e were used as 
inclusion criteria, these m
ay not be reliable 
because there is no standard m
easurem
ent 
technique.
Patients between 7 days and 3 years of age, who had fever of 38.0, m
easured either at 
hom
e or in the ED, with no identified source of infection after history and physical 
exam
ination, were eligible, parents gave inform
ed consent. The Lab score was used to 
reduce antibiotics prescription.
The index test com
prised of a PCT level (m
easured using VIDAS 
Brahm
s assay), CRP level, and urinary dipstick. Specific results 
determ
ine a 9-points score.
Not applicable, the reference standard 
is physician assessm
ent
115 were excluded, but the reason for 
exclusion is not specified.
CAP patients who were treated as outpatient were included after ED visit.  The index 
test determ
ined if they would receive antibiotics.
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, 
protocol violations were allowed on physician discretion without 
predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
Random
isation by envelopes, a m
ethod prone 
for random
isation bias.
Patients visiting a tertiary pediatric ED, who presented with history of a rectal 
tem
perature and where the physician required additional laboratory investigation 
(defined as fever without source after history and physical exam
ination).
Fever based on history m
ay not as 
reliable as an objective m
easurem
ent.
PCT testing was perform
ed using sem
iquantative PCT-Q test.
Not applicable, the reference standard 
is physician assessm
ent
Patients with suspected LRTIs of unknown etiology, the index test is to discrim
inate 
bacterial from
 non-bacterial origin
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, 
protocol violations were allowed based on predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
Patients in whom
 there was found an 
alternative explanation other than 
AECOPD were excluded, also patients 
with psychiatric com
orbidities were 
excluded. 
By excluding patients with another explanation, 
the effect of the intervention will be exagerated. 
Psychiatric com
orbidity m
ay be associated with 
increased nonadherence to therapy. By excluding 
these patients, the effect also m
ay be 
exaggerated.
Patients, older than 39 years, with ECOPD with specific spirom
etric criteria, without 
any other explanation of com
plaints, without psychiatric com
orbidity or 
im
m
unosuppression, asthm
a, CF or infiltrates on chest X-rays on adm
ission. The index 
test determ
ined if patients would receive antibiotics.
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, 
protocol violations were allowed on physician discretion without 
predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
Random
isation by envelopes, a m
ethod prone 
for random
isation bias.
Adult asthm
a patients, following international asthm
a guidelines, without bacterial 
infection in other parts of body, confirm
ed pneum
onia on chest X ray, other chronic 
respiratory diseases, or suffering from
 severe organ disfunction. The index test 
determ
ined if patients would receive antibiotics.
PCT testing was perform
ed in the lab using a Kryptor device. A 
previously described algorithm
 was used for interpretation, 
protocol violations were allowed on physician discretion without 
predefined criteria.
Not applicable, the reference standard 
is physician assessm
ent
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Dom
ain 3: Reference standard
A. Risk of Bias
B. Concerns regarding applicability
W
ere the reference standard results 
interpreted without knowledge of the 
results of the index test? (off white = 
yes, black = no, gray = unclear)
Could the reference standard, its 
conduct, or its interpretation have 
introduced bias? (RISK: off w
hite = low
, 
black = high, gray = unclear)
Is there concern that the target 
condition as defined by the 
reference standard does not m
atch 
the review
 question? (RISK: off 
w
hite = low
, black = high, gray = 
unclear)
Describe any patients who did not 
receive the index test(s) and/or 
reference standard or who were 
excluded from
 the 2x2 table (refer to 
flow diagram
):
Describe the tim
e interval and 
any interventions between 
index test(s) and reference 
standard:
In the control group, the index test 
results were unknown.
Reference standard was physician 
assessm
ent in determ
ining initiation of 
antibiotics. The num
ber of protocol 
violations in the PCT-guided group (low 
PCT, still antibiotics, based on physician 
assessm
ent) are not described.
14 eligible patients who were excluded, 
were unable to give consent because of 
language problem
s with parents, 13 
because of "other" reasons that were 
not specified.
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
Patients with chf, other pulm
onary 
disease, hyperventilation, cerebral, URTI, 
allergy, throm
boem
bolic event, 
carcinom
a, im
m
unocom
prom
ised, no-
respiratory infection, and " others"  were 
not deem
ed eligible
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
Excluded patients: did not m
eet CAP 
criteria, im
m
unocom
prom
ised, TB, CF, 
HAP, not confirm
ed infiltrate by 
radiologist, died before random
isation, 
no inform
ed consent
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
All included patients were analysed in 
the intention-to-treat analysis. They 
were excluded in the per-protocol 
analysis, the reasons of exclusion were 
described.
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
This study has not included m
ore than 
75% of eligible patients, because of 
either lack of tim
e for logistics, and 
physician unwillingness to proceed in 
diagnostic tests in well appearing 
patients. 
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
ED CAP patients who were not eligible 
for outpatient treatm
ent were excluded, 
this is not specified
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
Patients whose parents did not consent 
were excluded. Also, in case of 
insufficient blood sam
pling, patients 
were exlcuded.
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the indext test 
results were unknown.
237 patients were not eligible after 
screening, 12 eligible patients were 
screened because of "other" reasons, 
not specified
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
62 patients were excluded for analysis, 7 
psychiatric patients, 7 with other not 
specified com
orbidities, 3 with chest 
pain
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
In the control group, the index test 
results were unknown.
22 patients were excluded on exclusion 
criteria, not specified, 2 died before 
inclusion, 4 did not give inform
ed 
consent
tests were conducted 
sim
ultaneously in the 
em
ergency departm
ent
DOM
AIN 4: Flow
 and tim
ing
A. Risk of Bias
W
as there an appropriate interval 
betw
een index test(s) and reference 
standard? (off w
hite = yes, black = no, 
gray = unclear)
Did all patients receive a reference 
standard? (off w
hite = yes, black = no, 
gray = unclear)
Did patients receive the sam
e reference 
standard? (off w
hite = yes, black = no, 
gray = unclear)
W
ere all patients included in the analysis? 
(off w
hite = yes, black = no, gray = 
unclear)
Could the patient flow
 have introduced 
bias? (RISK: off w
hite = low
, black = high, 
gray = unclear)
M
ore than 75%
 of m
issed inclusions, 
w
ithout reporting of individual reasons.
There is a selection bias due to exclusion 
criteria. 
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ABSTRACT
Introduction 
In the emergency department (ED), patients with fever often receive antibiotics, be-
cause physicians have difficulties in determining the etiology of fever. Procalcitonin 
is a novel biomarker for bacterial infections. We investigated if PCT-guided antibiot-
ic therapy reduced the antibiotic prescription rate in febrile emergency department 
(ED) patients. 
Methods 
Undifferentiated febrile ED patients were randomized to either PCT-guided therapy 
or standard-of-care. In the PCT-guided group, a single PCT measurement was added 
to standard laboratory results. In the PCT-guided therapy group, antibiotic treat-
ment was recommended when PCT was ≥0.5μg/L. 
The primary outcome was number of patients who received antibiotics in the ED. 
Results 
107 Patients were included. Fewer antibiotics were prescribed in the PCT-guided 
therapy group (80% vs 92% (p= 0.08)). Differences were observed in ICU admission 
(14(24%) vs 4 (8%) (p=0.03)); mortality (0 (0%) vs 2 (4%) (p=0.12)); temperature 
(median 38.8 (IQR 38.2 – 39.2) vs median 39.0 (IQR 38.7 – 39.5)) (p=0.03)) and CRP 
level (mean 138 mg/L (SD 120) vs 179 mg/L (SD 146) (p=0.02)) between PCT-guid-
ed therapy and standard-of-care. Mean length of hospital stay was 8 days in both 
groups. In multivariate regression analysis, PCT-guided therapy resulted in a trend 
towards reduction of the proportion of patients who received antibiotics (OR 0.47 
(95%CI 0.13 – 1.66)). 
Discussion  
Although no statistically significant reduction in number of patients who received 
was found, the findings in this study suggest that PCT-guided therapy may reduce 
antibiotics prescriptions in febrile patients from an undifferentiated adult ED popu-
lation. PCT-guided therapy may be an important tool in antimicrobial stewardship. 
Larger trials are needed to validate the value of PCT in the ED. 
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INTRODUCTION
Antibiotics are the mainstay of treatment of bacterial disease. With the increasing 
use of antibiotics, resistance of microorganisms is on the rise1. The surviving sep-
sis campaign states that, when patients have a suspected infection with systemic 
inflammatory response syndrome (SIRS), broad-spectrum antibiotics have to be ad-
ministered within one hour2. This increases the rate of antibiotic prescriptions in 
the emergency department (ED)3,4, and may also contribute to further resistance for 
antibiotics. Antimicrobial stewardship stands for targeted and effective antibacteri-
al therapy, with special attention for the initiation and timely ending of antibiotics 
use. The goal of antimicrobial stewardship is to contain the increasing resistance 
of microorganisms5,6. Procalcitonin (PCT) is a novel biomarker, which has a higher 
sensitivity and specificity in the diagnosis of bacterial infection compared to the 
current standard diagnostic tests available in the ED7-10. PCT is a precursor protein 
of calcitonin. Unlike calcitonin, which is only produced in the C-cells of the thyroid 
gland, procalcitonin can be produced ubiquitously throughout the human body. The 
production of PCT is upregulated by pro-inflammatory cytokines like interleukin -1 
(IL-1), IL-2, IL-6 and tumor necrosis factor alpha, and directly by bacterial endotoxins 
and lipopolysaccharide. Interferon gamma, a cytokine associated with viral infec-
tions, reduces the upregulation of PCT.  Furthermore, an increase in PCT levels can 
be monitored within 4 to 6 hours after start of infection11-13. CRP is an acute phase 
protein, synthesized exclusively in the liver. CRP levels increase during inflammatory 
states, but are not specific for bacterial infections and take more time, 6 to 48 hours 
after start of infection, to be detectable compared to PCT12,14. These characteristics 
give PCT a theoretical advantage over CRP. Previously, we showed that the addition 
of PCT to the current diagnostic workup of patients presenting with fever helps to 
discriminate between infectious and non-infectious causes15. 
Moreover, recent primary care and ED based interventional PCT-guided therapy 
studies reported a reduction in antibiotics use in patients suspected of lower re-
spiratory tract infections9,16,17. However, since these studies were limited to specific 
patient populations, the results are not generalizable to febrile patients without a 
strong suspicion of a specific infection.  Therefore, this study addresses all febrile ED 
patients, a heterogeneous and more challenging group, in order to determine the 
value of PCT-guided therapy in this emergency department clinical setting.
The objective of this study was to investigate if PCT-guided therapy reduced unnec-
essary antibiotics prescription in an undifferentiated febrile ED population.
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METHODS
Design
Single center, randomised controlled trial of patients visiting the ED of the Sloter-
vaart Hospital in Amsterdam, the Netherlands. The hospital board of medical ethics 
approved the study protocol. All patients gave written informed consent.
Setting
The Slotervaart hospital in Amsterdam is a general teaching hospital with 410 beds.
Population
All non-pregnant patients, between 18 and 85 years of age, who presented at the 
ED with fever and gave written informed consent, were eligible for inclusion. 
Design
All eligible patients were asked to participate in the study. After inclusion, patients 
were randomized to either a PCT-guided therapy arm or a standard-of-care arm, 
using a computer program. In all patients, blood samples and two sets of blood 
cultures were obtained. Samples for bacterial and viral cultures and polymerase 
chain reaction (PCR) were taken from the suspected focus of infection, as judged by 
the treating physician. In both groups, PCT was determined. PCT results were only 
available to the physician in the ED in the PCT-guided therapy group. With all avail-
able laboratory results, physicians filled out a standard case report form on which 
was reported whether antibiotics were indicated and whether antibiotics were pre-
scribed. The PCT treatment algorithm recommended withholding antibiotics when 
PCT was <0.5 μg/L, and recommended prescribing antibiotics with PCT levels ≥0.5 
μg/L. This treatment algorithm was described Bouadma et al18. Physicians were al-
lowed to prescribe antibiotics in case of low PCT levels if this was according to their 
clinical judgement. There were no predetermined criteria for disregarding the treat-
ment algorithm. 
Outcomes
The primary outcome was the number of patients who received antibiotics. Sec-
ondary outcomes were hospital and intensive care unit (ICU) admission and length 
of stay, and mortality. A definite diagnosis of all patients was reported retrospec-
tively, both by an independent physician and by the primary investigator, blinded 
for PCT results, and was based on culture results and all diagnostic tests available.
Data analysis
We determined differences in variables between the standard-of-care group and 
the PCT-guided group using Chi-squared tests for dichotomous variables and Stu-
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PCT guided Standard-of-care Total p-value*
n 59 48 107
Temperature, 
median ˚C(IQR) 38.8 (38.2 – 39.2) 39.0 (38.7 – 39.5) 38.9 (38.4 – 39.3) p = 0.03
ICU admission, n 
(%) 14 (24%) 4 (8%) 18 (17%) p = 0.03
CRP, median 
mg/mL (SD) 108 (120) 165 (146) 127 (133) p = 0.02
* Students’ T-test for continuous variables, Chi-squared test for dichotomous variables.
p = 0.7038 (35%)18 (38%)20 (34%)Female sex, n (%)
Abbrevations list: N: number.  SD: standard deviation. IQR: Inter quartile range. ICU: intensive care 
unit. 
p = 0.122 (2%)2 (4%)0 (0%)Mortality, n (%)
p = 0.55603 (18)60 (17)60 (20)Age, median year (SD)
p = 0.5323 (22%)9 (19%)14 (24%)Diabetes Mellitus, n (%)
p = 0.3197 (91%)42 (88%)55 (93%)Hospitalization, n (%)
p = 0.5216 (15%)6 (13%)10 (17%)Malignancy, n (%)
p = 0.7012 (11%)6 (13%)6 (10%)Immunocompromised, n (%)
p = 0.830.38 (4.7)0.39 (5.0)0.33 (4.6)PCT, median μg/L (SD)
p = 0.766 (3 – 9)7 (3 – 9)6 (3 – 9)Length of stay, median days (IQR)
Table 1: Baseline characteristics and calculated differences of the study population
p = 0.7038 (36%)18 (38%)20 (34%)Bacterial infection confirmed
p = 0.8490 (84%)40 (83%)50 (85%)Antibiotics indicated
p = 0.0891(85%)44 (92%)47 (80%)Antibiotics prescribed
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dent’s T-tests for continuous variables. Variables age and gender, together with 
variables with significant differences between groups (p<0.1) were included in mul-
tivariate binominal logistic regression analysis. 
 
RESULTS
Patients were included from May 2010 to May 2012. A total of 342 patients were el-
igible for inclusion; A total number of 107 patients were included and randomised, 
14 patients were excluded because data were incomplete and irretrievable. Of the 
eligible patients, 221 were not included due to logistical problems.
Primary outcome
In the PCT-guided group, significantly fewer antibiotics were prescribed compared 
to the standard-of-care group (80% vs. 92%, respectively; p=0.08; 13% reduction). 
The groups did not differ by number of confirmed bacterial infections. A total of 15 
patients (25%) in the PCT-guided group received antibiotics despite of their low PCT 
measurement (PCT <0.5 μg/L). 
Secondary outcomes
There was no difference in length of hospital stay or mortality. Yet, significantly 
more patients in the PCT-guided group were admitted to the intensive care unit, 
(24% vs. 8%, respectively). Furthermore, the patients in the standard-of-care group 
had a measured temperature and CRP level that were significantly higher. Conse-
quently, standard therapy was compared to PCT-guided therapy in multivariate lo-
gistic regression analysis. The determinants ICU admission, temperature and CRP 
level had a significant effect in univariate logistic regression and were corrected for 
in multivariate binomial logistic regression analysis. PCT-guided therapy reduced 
the rate of antibiotics prescribed, OR 0.47 (95%CI 0.13 – 1.66). 
There were 73 (68%) patients with bacterial infections, 22 (21%) patients with viral 
infections, 1 (1%) patient with a parasitic infection, and 14 (13%) patients with a 
non-infectious cause of fever. 
The types of infections were: respiratory infections in 49 (46%) patients, urinary 
tract infections in 19 (18%) patients, skin and soft tissue infections in 10 (9%) pa-
tients, bloodstream infections in 6 (6%) patients, digestive tract infections in 4 (4%) 
patients, meningo-encephalic infections in 2 (2%) patients, and other febrile dis-
ease, including thyrotoxicosis, malignant neuroleptic syndrome and polymyalgia 
rheumatic in 17 (15%) patients. 
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Infection Total of patients (n, %) Specified infection (n)
Clinical diagnosis 
only (n)
Proven by culture 
(n)
Most common 
identified 
pathogens*
(n)
Streptococcus sp. 4
E. Coli 2
M. Mycoplasma 2
H. Influenzae 2
Influenza A virus 5
Human rhinovirus 5
Para-influenza virus 2
E. Coli 8
P. Aegurinosa 4
K. pneumoniae 3
Streptococcus sp. 2
S. Aureus 1
P. Aegurinosa 1
E. Coli (ESBL), 
K. Pneumoniae 
(ESBL), 
P. Aegurinosa
 S. Aureus 1
Streptococcus sp. 1
P. Aegurinosa 1
Influenza A virus, 
M. Pneumoniae
Influenza A virus, S. 
Aureus 1
Para-influenza 
virus, S. 
Pneumoniae
1
1
Streptococcus sp. 
(meningitis) 1
(CT-confirmed 
cerebral abscess) 1
No specific 
suspected infection 5 (5%) - - - - - -
Tumor fever 3
Thyreotoxicosis 1
Malignant 
neuroleptic 
syndrome
Appendicitis 1
Urea crystal 
arthritis (gout) 1
Diverticulitis 1
Polymyalgia 
rheumatica 1
1
Bacterial 73 42 31
Viral 22 5 17
Parasitic 1 - 1
Other 14
Table 2. Types of infection and most common identified pathogens
107 (100%)Total* of infections
----9 (9%)Other
Viral respiratory 
infection with 
bacterial 
superinfection
112Bacterial2 (2%)
Meningo-
encephalic 
infections
3---3 (3%)
10 (9%)Skin and soft tissue infection
1Herpes Simplex1-1Viral
33Viral
369Bacterial
Gastro-intestinal 
infection
1P. Falciparum1-1Parasitic
11-1Bacterial
4 (4%)
---
1Dengue virus1-1
Bacterial19 (18%)Urinary tract infection
4-4Bacterial
6 (6%)Bloodborne infection Viral
49 (46%)Pneumonia/respiratory infection
*In some cultures, multiple microorganisms were present.  
Abbrevations: E. Coli : Escherichia Coli, M.Mycoplasma: Mycobacterium Mycoplasma, H. Influenzae: Haemophilus Influenzae, P. Aegurinosa: Pseudomonas 
Aegurinosa, K.Pneumoniae: Klebshiella Pneumoniae, P. Falciparum: Plasmodium Falciparum, S. Aureus: Staphylococcus Aureus.
N: number. Sp: Species. ESBL: extend spectrum beta-lacatamase. CT: computer tomography.
12214Viral
132235Bacterial
61319
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DISCUSSION
In this randomized clinical trial, we showed that PCT-guided antibiotic therapy for 
undifferentiated febrile patients in the ED did not result in a significant reduction in 
prescription of antibiotics, but did show a trend towards reduction of the initiation 
of unnecessary antibiotic therapy. A recent review of literature7 shows that the PCT 
intervention studies in primary care, ED and ICU settings use only subgroups of 
patients. These studies mainly focus on respiratory tract infections and sepsis. Our 
study is the first study that included an adult ED population with fever, irrelevant 
of suspected underlying pathology. Because no selection of patients was made, be-
sides fever, the use of PCT-guided therapy may be expanded beyond patients with 
specific suspected pathology in the ED. 
We demonstrated a trend towards reduction of the initiation of unnecessary anti-
biotic therapy. Reduction in number of antibiotic prescriptions has been reported 
for specific patient populations in the ED17,19-24. Also, antibiotic reduction in patients 
with suspected respiratory tract infections and fever has been reported in general 
practice when PCT-guided antibiotic therapy is used9. In the proHOSP study16 the 
authors reported a significant reduction in the prescription of antibiotics in patients 
with lower respiratory tract infections. Furthermore, there were similar rates for 
adverse events in mortality and ICU admittance. 
This is the first PCT-guided therapy study carried out in adult ED patients in the Neth-
erlands, a country known for its restrictive antibiotics prescription policy25,26. Other 
ED based studies were performed in Switzerland16,20,23, Denmark24, China22, and one 
international multicenter trial in Switzerland, France and the United States17. The 
lower rate of reduction of antibiotic prescription in the current study may be partly 
explained by the higher threshold of Dutch physicians to prescribe antibiotics.
In the ICU setting, PCT is used as a marker to discontinue antibiotic treatment18,27,28. 
In PCT-guided therapy trials based in the ICU, researchers had access to serial mea-
surements of PCT. However, in this ED based study, a single measurement was used 
to either start or not to start antimicrobial therapy. Although this resulted in a lower 
rate of reduction of antibiotic use compared to ICU-based studies, it is nonetheless 
an interesting result, because PCT can change antibiotic policy in a real-life ED set-
ting in a safe and timely manner. 
The study population consisted mainly of patients with respiratory and urinary tract 
infections. This is in accordance with other ED-based studies, both in the Neth-
erlands and internationally10,29,30. As the type of infection in febrile patients is not 
always clear to the ED physician, the use of fever as sole inclusion criterion reflects 
the real-life clinical situation. 
In the PCT-guided therapy group, there were significantly more ICU admissions, and 
patients had a higher temperature. Because the patients were randomized, these 
differences were due to chance. However, this means that the PCT-guided therapy 
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group may have consisted of generally sicker patients. We performed a statistical 
correction for this difference; however, the differences between groups may have 
influenced the results. In a similar population, PCT-guided therapy could therefore 
reduce the proportion of antibiotic prescriptions even more. 
Limitations
There were some limitations in this study. First of all, the sample size was small. A 
number of 221 patients were not included because of logistical problems in the ED. 
Patients were not included due to unfamiliarity of the physicians with the study, 
despite several hospital-wide information sessions. This was because all specialties 
in the Slotervaart hospital had their own ED consultants. Therefore, eligible patients 
were not always asked to participate. After inclusion, 14 patients had to be excluded 
because of incomplete data. In the PCT-guided therapy group, there was a 25% rate 
of antibiotic prescription with a low PCT level. Patients with a low PCT result were 
still prescribed antibiotics. This may be attributable to either the unfamiliarity of 
PCT as an accurate diagnostic marker, or a lack of confidence in the new diagnostic 
instrument31.   
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CONCLUSION
Although no statistically significant reduction in number of patients who received 
antibiotics was found, the findings in this study suggest that PCT-guided therapy 
may reduce antibiotics prescriptions in febrile patients from an undifferentiated 
adult ED population. PCT-guided therapy may be an important tool in antimicrobial 
stewardship. Larger trials are needed to validate the value of PCT in the ED. 
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ABSTRACT
Background
Fever is a common symptom in the emergency department(ED). Fever can be 
caused by bacterial infections, which are treated with antibiotics. Often, bacterial 
infections cannot be ruled out in the ED using standard diagnostics, and empiric 
antibiotic treatment is started. Procalcitonin(PCT) is a biomarker for bacterial infec-
tions, but its role in an undifferentiated ED population remains unclear. We hypoth-
esize that PCT-guided therapy may reduce antibiotics prescription in undifferentiat-
ed febrile ED patients. The primary objectives of this study are to determine a) the 
efficacy, b) the safety of PCT-guided therapy, and c) the accuracy of the biomarker 
PCT for bacterial infections. The secondary objective is to study the cost-effective-
ness of PCT-guided therapy.
Methods and design
This is a multicenter noninferiority randomized controlled trial. All adult ED patients 
with fever(≥ 38.2°C) are randomized between standard care with and without the 
addition of a PCT level, after written informed consent. 
a) For efficacy, the reduction of patients receiving antibiotics is calculated, using a 
superiority analysis: differences between the PCT-guided group and control group 
are assessed using a Fisher’s exact test, and a multivariable logistic regression anal-
ysis to account for the effects of demographic and medical variables on the percent-
age of febrile patients receiving antibiotics. 
b) Safety consists of a composite endpoint, defined as mortality, intensive care ad-
mission and ED return visit within 14 days. Noninferiority of PCT will be tested us-
ing a one-sided 95%confidence interval for the difference in the composite safety 
endpoint between the PCT-guided and control groups using a noninferiority margin 
of 7.5%.  
c)Accuracy of PCT and CRP for the diagnosis of bacterial infections will be reported, 
using the sensitivity, specificity, and the area under the receiver-operating-charac-
teristic curve in the definitive diagnosis of bacterial infections. 
The sample size is 550 patients, which was calculated using a power analysis for all 
primary objectives. Enrollment of patients started in august 2014 and will last two 
years.
Discussion
PCT may offer a more tailor-made treatment to the individual ED patient with fever. 
Prospective costs analyses will reveal the economic consequences of implementing 
PCT-guided therapy in the ED.
This trial is registered in the Dutch trial register: NTR4949.
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BACKGROUND
Fever is one of the most common symptoms of patients visiting the emergency 
department (ED). The etiology of fever is diverse, ranging from infectious diseases 
to neoplasms and trauma1. Specific etiologies of fever, such as severe bacterial in-
fections, have to be treated within one hour after ED presentation with adequate 
antibiotic therapy, according to the surviving sepsis guidelines2.
Because time is of the essence in the initiation of therapy, physicians in the ED have 
a limited time window for diagnosing the etiology of fever. This results in a “better 
safe than sorry” approach, in which broad-spectrum antibiotics are administered to 
febrile patients, only based on history and physical examination, and readily avail-
able diagnostic entities.
On the other hand, antibiotic resistance is becoming an increasing problem world-
wide. Antimicrobial stewardship advocates thoughtful initiation of antibiotic thera-
py. Thus, in treatment of bacterial infections, both under-treatment and overtreat-
ment are undesirable. Therefore, it is vital to increase the accuracy of diagnostics 
of febrile illness. 
The mainstay of diagnosing the etiology of fever in the ED consists of history, physi-
cal examination and laboratory analysis of serum and other bodily fluids, and chest 
X-ray examinations. Cultures and viral throat swabs are obtained, but are of no use 
in the ED, because results take several hours to days and treatment has to be start-
ed early after ED presentation2. Currently, leukocyte count, with or without leuko-
cyte differentiation, and C-reactive protein (CRP) are the laboratory discriminators 
of choice in the initial approach in the diagnostic process of febrile diseases.
A higher accuracy of ruling in or ruling out bacterial infections using biomarkers may 
result in more accurate antimicrobial therapy. On the individual patient level, few-
er patients would be treated empirically with antibiotics. Adverse events and drug 
interactions would be reduced. Also, a more accurate diagnosis could save hospital 
expenses and result in cost reductions. On a population level, antibiotics resistance 
could be countered. For patient safety, this should obviously be without an added 
risk of under-treatment. 
Procalcitonin (PCT) is a promising biomarker for bacterial infections. PCT is a precur-
sor protein of calcitonin. Unlike calcitonin, which is only produced in the C-cells of 
the thyroid gland, PCT can be produced ubiquitously throughout the human body. 
The production of PCT is upregulated by proinflammatory cytokines like interleukin 
-1 (IL-1), IL-2, IL-6 and tumor necrosis factor alpha, and directly by bacterial endo-
toxins and lipopolysaccharide. Interferon gamma, a cytokine associated with viral 
infections, reduces the upregulation of PCT.  It has been shown that PCT levels in 
non-infectious febrile conditions, such as autoimmune diseases or fever caused by 
malignant disorders stay low, whereas CRP levels often rise significantly3. Further-
more, an increase in PCT levels can be monitored within 4 to 6 hours after start of 
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infection4-6. In comparison, CRP is an acute phase protein synthesized exclusively 
in the liver. CRP levels increase during inflammatory states, but are not specific for 
bacterial infections and take more time, 6 to 48 hours after start of infection, to be 
detectable compared to PCT5,7. These characteristics give PCT a theoretical advan-
tage over CRP. 
Recently, clinical studies have focused on PCT as a biomarker of bacterial infections, 
showing better diagnostic properties than commonly used markers such as CRP3,8-14. 
Studies have shown that PCT-guided antibiotic therapy- i.e. starting or withholding 
antibiotics, based on the PCT-level - is safe and reduces prescription of antibiotics in 
several distinct patient groups: savings of more than 23% in the intensive care unit 
(ICU) and up to 78% in the general practice setting8,11,15. However, evidence of the 
effectiveness of PCT-guided antibiotic therapy in an undifferentiated ED population 
is scarce. 
The ED is the gateway of hospital healthcare. Patients enter with symptoms and 
leave with a diagnosis. Either they are admitted, or are sent home. For almost every 
diagnosis, there are numerous medical tests and interventions available that can 
be utilized in the ED. However, budgets are limited and should therefore be used 
in the most efficient manner possible. ED based cost-effectiveness studies are used 
to estimate the value for money offered by new technologies. These studies serve 
as a tool for hospital administrators and decision makers who are responsible for 
prioritizing interventions under economic constraints16. 
 
Estimated yearly costs associated with antibiotic resistance in Europe are in the 
range of 1.5 billion euros, comprising extra healthcare costs and productivity loss-
es caused by infections due to antibiotic-resistant bacteria17. PCT-guided therapy 
may contribute to a reduction of these enormous costs. It may lead to a reduction 
in costs of antibiotics and additional diagnostics tests, such as blood cultures in 
non-bacterial disease. Costs of hospital admissions could be reduced as admission 
for observation may become obsolete. As an added effect, there may be a reduction 
of productivity losses, related to paid and unpaid work. Patients may be able to re-
turn to their daily activities faster.
The current evidence on the cost-effectiveness of PCT-guided therapy consists of 
retrospective hypothetical models. One study analyzed the cost-effectiveness of 
PCT testing in patients hospitalized for community-acquired pneumonia with a 
mathematical model18. The authors showed that a PCT-guided protocol would cost 
less and would be more effective than usual care18. Recently, a model-based study 
from the US assessed the economic impact of PCT testing in patients with acute 
respiratory tract infections. The authors documented that PCT-guided care was cost 
saving in inpatient, ICU and outpatient settings, mainly due to a reduction in antibi-
otic costs. Total yearly savings at the US national level were calculated at 1.6 billion 
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dollars19.
These estimates only included costs of PCT testing and savings on costs of hospi-
talization, excluding savings from other care consumption and productivity losses, 
which cannot be estimated at this stage. There is a need to broaden the evidence 
base to promote the efficient use of PCT-guided therapy in patients with fever pre-
senting at EDs.
The primary objectives of this study are to determine a) the efficacy and b) the 
safety of PCT-guided therapy, and c) the accuracy of the biomarker PCT for bacterial 
infections. The secondary objective is to study the cost-effectiveness of PCT-guided 
therapy.
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METHODS AND DESIGN
The HiTEMP study is designed as a multicenter noninferiority randomized controlled 
trial on PCT-guided therapy. The study will be performed in both academic and 
non-academic teaching hospital settings. Patients will be asked for written informed 
consent. Patients who consent are randomized using an online computer program, 
to either the standard-of-care diagnostic workup of febrile patients (control group), 
or the standard-of-care workup with the addition of the diagnostic biomarker PCT.
Primary outcome measures
a) The efficacy of PCT-guided therapy is defined as the percentage of patients who 
are prescribed antibiotics in the ED. b) The safety outcome measure consists of a 
composite endpoint of 30 days mortality, intensive care unit (ICU) admission within 
30 days, or a return visit to the ED within 14 days. c) The accuracy of the definitive 
diagnosis is reported for PCT and CRP using the sensitivity, specificity, and the AUC 
of the diagnosis of bacterial infections. The definitive diagnosis is defined in two 
ways. 1. As “confirmed bacterial infection”, in which culture – and PCR results that 
fit the clinical case presentation are used to report presence of bacterial infections. 
2. As “suspected bacterial infection”, in which two independent physicians will give 
their expert opinion on the presence of a bacterial infection using culture results, 
image modalities and clinical course, in case of discrepancy, a third physician will 
decide. 
Secondary outcome measures
Secondary outcome measures for cost-effectiveness are hospital treatment costs, 
related medical consumption during follow-up, costs of absenteeism and reduced 
productivity while at work. 
The adherence to PCT advice is reported, including the percentage of antibiotic pre-
scriptions with low PCT result, and withholding of antibiotics in patients with high 
PCT result. The percentage of patients who received antibiotics without suspected 
bacterial infection is reported. Outcome measures are reported for the total patient 
population, and are stratified by source of infection: respiratory tract infections, 
urinary tract infections, skin and soft tissue infections, central nervous system infec-
tions, abdominal infections, non-infectious fever, fever without source, and other 
causes of fever. 
Inclusion and exclusion criteria
Inclusion criteria: All patients of 18 years and older visiting the ED, with a tem-
perature of ≥ 38.20C (100.80F) are eligible. Temperature is measured using an ear 
thermometer, in triage. Eligible patients need to provide written informed consent. 
Exclusion criteria:  Patients with specific immunocompromised status, defined 
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as neutropenia with absolute neutrophil count less than 0.5x109/L, current che-
motherapy, or post-organ transplantation are excluded. Furthermore, pregnant 
patients, moribund patients and patients with a diagnosis that requires primary 
surgical intervention, or within 72 hours after surgery are excluded.  Patients are 
randomized using a minimization procedure20. The factors for minimization are im-
balance in randomization result and study site. The randomization result is allocat-
ed at patient enrolment by a computer-generated algorithm. 
Sample size calculation and statistical analyses
Sample size and power analysis: For the three primary objectives, the following 
analyses are used: a) a superiority analysis for the reduction in the percentage of 
febrile patients receiving antibiotics. b) a noninferiority analysis for safety, and c) an 
analysis of the test characteristics (sensitivity and specificity) of the biomarker PCT 
and CRP. The total sample size calculation is based on a power analysis for each of 
these three primary outcome measures; the total sample size is the maximum of 
the required sample sizes for the different primary outcome measures. 
a) For the superiority analysis of the reduction in the prescription of antibiotics, we 
assumed that antibiotics are initially prescribed at the ED to 73% of the patients 
in the control arm, and that the intervention will reduce this percentage to 53%, 
based on a careful estimate using recent literature14. To obtain 80% power to detect 
a significant difference between the two groups using a two-sided Fisher’s exact test 
with a significance level of 5%, the required sample size is 101 patients per group.
b) The noninferiority analysis for the safety objective uses a composite endpoint 
consisting of ICU admittance, 30-days mortality or second ED visit within 14 days. 
For an accurate sample size calculation, we first analyzed ED data from the Eras-
mus MC from January 2011 until May 2012. In this data set, the prevalence of the 
composite safety endpoint was 12.7% (102 cases out of 809 patients). We used 
this percentage as the expected rate in the control group. Using a noninferiority 
margin of 7.5%, a noninferiority analysis comparing the rates in the control and the 
intervention groups requires 244 patients in each group to obtain 80% power with a 
one-sided alpha of 5%. To account for 10% expected dropout, the total sample size 
must be 550 patients.
c) The third sample size calculation is based on a comparison of sensitivity and spec-
ificity of PCT and CRP in patients with infection. We used data from a meta-anal-
ysis21,22 to estimate the accuracy of PCT and CRP for bacterial infection. We con-
servatively assumed zero correlation between the test results of PCT and CRP for 
the diagnosis of bacterial infection. For the prevalence of bacterial infections, we 
used data from our pilot study3 to obtain a representative estimate of the preva-
lence of bacterial infections, which led to an estimated prevalence of 68%. Based 
on the results of the meta-analysis, the sensitivity of PCT was 0.83 and for CRP 
0.73; the specificity was 0.88 for PCT and 0.60 for CRP. Using McNemar’s test, 340 
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patients with a bacterial infection (340/0.68=500 patients in total) are required to 
obtain 80% power for detecting a difference in sensitivity between PCT and CRP. 
Forty-one patients without a bacterial infection (41/(1-0.68)=129 patients in total) 
are required to obtain 80% power for detecting a difference in specificity between 
PCT and CRP. To ensure sufficient power for all three primary outcome measures, 
we thus use a sample size of 275 patients per group (550 patients in total).
Statistical analyses for the primary study parameters 
a) Antibiotics use. The percentage of patients that are prescribed antibiotics is com-
pared between the PCT-guided group and control group using a Fisher’s exact test. 
Demographic parameters (age, sex, mortality), medical parameters (medication 
use, comorbidity, temperature, CRP and PCT measurements), hospital admission 
related parameters (hospital admittance, hospital length of stay, ICU admittance, 
ICU length of stay) are compared between the PCT-guided group and control group 
using Fisher’s exact tests for dichotomous variables, chi-square tests for categorical 
variables with more than two categories, t-tests for continuous variables that are 
normally distributed, and Kruskal-Wallis tests for continuous variables that are not 
normally distributed. A logistic regression analysis will be used to determine the 
influence of these parameters on the proportion of antibiotics prescriptions in the 
control group and the PCT-guided therapy group. To select the independent vari-
ables in this logistic regression model, we will use a stepwise backward approach in 
which only the independent variables are retained that have a significant effect us-
ing a significance level of 5%; however, the variable group (PCT-guided group versus 
control group) will be included in the model irrespective of the results. In the event 
of missing values in possible confounding data, like intoxications and prescription 
drugs use, we will use multiple imputation. Both an intention to treat analysis and 
a per protocol analysis will be performed. Physician adherence to the PCT guidance 
will be determined.
b) Safety. Significant differences between the PCT-guided group and control group 
in the composite safety endpoint are determined using a one-sided upper 95% con-
fidence limit for the difference in proportion between the PCT-guided group and the 
control group. This confidence interval will be calculated using the method of Agres-
ti and Caffo23. Noninferiority of the intervention will be established if the 95% confi-
dence interval excludes 7.5%, i.e. if PCT-guided prescription of antibiotics does not 
increase the rate of the composite endpoint by more than 7.5 percentage points. 
Differences in hospital length of stay will be assessed using the Kruskal-Wallis test.
c) Accuracy of PCT and CRP.  In all patients, the final diagnosis of the etiology of 
fever will be determined. Also, it will be determined if there is a bacterial infection. 
The variables “confirmed bacterial infection” and “suspected bacterial infection” 
will serve as gold standards for the evaluation of the accuracy of the biomarkers 
CRP and PCT. These will be determined retrospectively, using culture results and all 
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diagnostic tests available.  In all patients, both PCT and CRP levels will be available 
for statistical analysis. The ability to predict bacterial infection of both PCT and CRP 
will be evaluated using receiver operating characteristic curves, and the area under 
the curve will be calculated. In addition, logistic regression will be performed to 
analyze the effects of PCT and CRP levels on the probability of a bacterial infection. 
The independent variables in this analysis are age, sex, PCT, CRP, temperature, co-
morbidity, and other variables that have a p<0.1 for the difference between groups. 
We will account for possible non-linear effects of age, PCT, CRP and temperature by 
using appropriate transformations of these variables.
Statistical analyses for the secondary study parameters 
The study will involve an economic evaluation from the societal perspective com-
paring PCT-guided therapy with usual care. The economic evaluation will use the 
technique of cost-minimization analysis, which compares two interventions of iden-
tical effectiveness to find out which is less costly. Total treatment costs will be com-
pared between the PCT-guided therapy arm and the control arm, including costs 
for PCT testing (intervention group only), other diagnostic tests, ED visits, antibiot-
ics and other medications, adverse effects of antibiotics, hospital admissions, re-
turn visits to the general practitioner (GP) and other related medical consumption. 
These costs will be taken into account during the one-month follow-up period. Unit 
prices will be calculated using real economic cost prices or using standard cost-pric-
es for health economic evaluations24. Unit prices will be multiplied by the quantities 
for each resource used, and then summed over the separate types of resource to 
give a total cost per patient. In addition, differences in labor productivity losses will 
be evaluated by comparing costs of absence from work (absenteeism) and reduced 
productivity while at work (presenteeism). Moreover, productivity losses related to 
unpaid work (e.g., household work, shopping, odd jobs, and voluntary work) will be 
included. Productivity losses will be evaluated using the Productivity Costs Ques-
tionnaire25. Mean total costs will be calculated for patients in each treatment group. 
Laboratory examinations
Blood samples will be obtained at inclusion. Samples will be centrifuged (3000 N 
Relative centrifugal force (Rcf) at room temperature for 5 minutes). The serum will 
be measured on the routine analyzer of the clinical chemistry laboratory (Roche Co-
bas 8000 system, Roche Diagnostics Netherlands). PCT-measurements will be per-
formed by using an electro-chemiluminiscent immunoassay (ECLIA)(Roche diagnos-
tics, Brahms, Henningsdorf, Germany). All samples will be measured and reported 
without knowledge of the clinical status of the subjects.
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PCT-guided therapy
PCT-guided therapy is defined as the initiation of antibiotics, based on all available 
diagnostics with the addition of PCT-levels. The PCT results are appraised using a 
two-point scale, in which bacterial infections are respectively deemed unlikely (PCT 
< 0.5 μg/L) and likely (PCT ≥ 0.5 μg/L).  These cut-off values are used in other tri-
als26-28. 
Follow-up
One month after inclusion, patients will be contacted by telephone by one of the 
investigators. Course of the disease, including medicine use, related GP hospital vis-
its (and diagnostics/prescriptions), and labor productivity losses, will be evaluated. 
Three months after inclusion, one of the investigators will contact patient’s GP in 
order to evaluate the final outcome of the febrile episode. Patients are allowed to 
participate only once. 
Adverse events
The composite safety endpoint is continually monitored during the trial. Also, ad-
verse events, not in the composite safety endpoint - death after 30 days, life threat-
ening events or any other important medical event that may jeopardize patients in 
any way - are monitored by the data safety monitoring board of the study.
Ethics approval and trial registration
The ethics committee of the Erasmus University Medical Center, in Rotterdam, the 
Netherlands, approved this trial. It is conducted according to the principles of the 
Declaration of Helsinki, version March 1, 2013 and in accordance with the Dutch 
Medical Research Involving Human Subjects Act (Wet Medisch wetenschappelijk 
Onderzoek met mensen, WMO). The CONSORT statements and its revised exten-
sion for reporting noninferiority trials were consulted and taken into account when 
designing and writing this protocol29,30. The trial has been registered in the Dutch 
trial registry, NTR4949.
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DISCUSSION
Although observational studies have shown that PCT is more sensitive and specific 
for bacterial infections in comparison to CRP14,31, and prospective trials have inves-
tigated the reduction of antibiotics in patients with respiratory complaints32,33,  the 
role of PCT in the ED remains unclear. This study is designed to answer the question 
whether PCT can aid in improving the accuracy of diagnosing bacterial infections 
in an ED setting.  The real-life clinical ED setting differs from a research setting in 
which patients have very specific symptoms. Consequently, the value of PCT for ED 
patients without specific complaints has not been determined. 
Because of this clinical problem, we used an objective measurement of tempera-
ture of 38.2oC or higher as sole inclusion criterion. As a result, we have a more het-
erogeneous population compared to other trials32,33, allowing us to extrapolate the 
results to the majority of the adult ED patient population. Furthermore, we will be 
able to identify cases where physicians disregard the PCT level, and investigate the 
causes. These are urgent questions in emergency medicine. 
The costs of PCT-guided therapy may be of influence in implementation in clinical 
practice. In the Netherlands alone, 94.2 billion euros was spent on healthcare in 
2013, and the costs are rising34. Therefore, there is much interest in healthcare ini-
tiatives that benefit patients’ health and are not associated with additional costs. 
Currently, there are no prospective cost-effectiveness studies on PCT-guided ther-
apy. Two economic evaluation studies18,19 report that a PCT-guided antibiotic algo-
rithm may reduce costs. However, physician adherence to the PCT-guided therapy 
protocol could not be accurately estimated, and productivity losses are not ana-
lyzed. Therefore, these studies do not provide concrete evidence. In the HiTEMP 
study, costs are analyzed prospectively to provide a more accurate recommenda-
tion. 
To reduce the risk of harming patients who receive PCT-guided therapy, we de-
signed a noninferiority study protocol for the primary safety objective. Our study 
is in its design largely similar to the ProHOSP trial33. This ED based noninferiority 
trial, which investigates the start of antibiotic therapy using PCT in patients with 
suspected respiratory tract infections, uses a composite endpoint with a noninferi-
ority margin of 7.5%. Moreover, in the Cochrane review on PCT-guided therapy, no 
differences in mortality or treatment failure were found35. We therefore consider 
the noninferiority margin of 7.5% of the composite endpoint ethically acceptable. 
We use a composite endpoint, consisting of patient centered outcomes. These out-
comes, i.e. mortality, ICU admittance <30 days or return to ED within two weeks, 
are a potential sign of treatment failure.
There are logistical issues that may arise during the course of the study. One of the 
most important issues may be physician protocol adherence. Physicians need to 
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learn how they should interpret the value of the PCT level, and develop a certain 
clinical ’feel’ towards it. The investigators will facilitate adoption of PCT, by informing 
every physician prior and during the study. Possibly, a ‘learning curve’ can be seen in 
the treatment according to PCT guidance. However, the physician motivates every 
choice of treatment that is not in accordance with the treatment advice based on 
the PCT result. Moreover, the accuracy of PCT will be calculated using the definitive 
diagnosis. Physician adherence to PCT guidance will also be investigated. 
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CONCLUSION
The HiTEMP trial addresses critical clinical questions in emergency medicine. PCT 
may offer a more tailor-made treatment to the individual ED patient with fever. The 
study will also shed light on the cost consequences of implementing PCT-guided 
therapy in the ED. 
Prospective
The HiTEMP study is open for inclusion. Results are expected at the end of 2016.
This study protocol is approved by the medical ethics committee (Medisch ethische 
toetsingscommissie, METC) of the Erasmus University Medical Center, in Rotter-
dam, the Netherlands. Reference number MEC 2013-149.
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ABSTRACT
Introduction
Importance: Procalcitonin(PCT)-guided therapy may reduce the number of antibi-
otics prescribed, but the effect in a general emergency department(ED) population 
is unclear.
Objective: To determine efficacy, safety, accuracy and economic consequences of 
PCT-guided therapy in ED patients with fever. 
Methods
Design: Noninferiority randomized multicenter clinical trial of PCT-guided therapy 
versus standard care. 
Setting: Two Dutch hospitals. 
Participants: Adult patients with fever(≥38.2°C/100.8°F) in triage. Exclusion criteria: 
no written informed consent, specific immunocompromised conditions, pregnancy, 
moribund patients, patients who were within 72 hours after surgery or who re-
quired primary surgical intervention.
Intervention: Randomization between PCT-guided therapy and standard care. In the 
PCT-guided group, a single PCT value was available to the treating physician in the 
ED. The treatment protocol advised antibiotics when PCT level was ≥0.5μg/L.
Main Outcomes and Measures: Primary outcomes. Efficacy: number of patients 
who were prescribed antibiotics. Safety: composite safety outcome. Accuracy: AUC 
of PCT and CRP in diagnosing suspected and confirmed bacterial infections. Second-
ary outcome. Economic consequences: medical and non-medical costs.
Results
A total of 551 patients were included. Efficacy(n=551): PCT-guided therapy did not 
reduce the number of patients who received antibiotics compared to the control 
group, 200(73%) versus 212(77%) of patients received antibiotics(p=0.28). Multi-
variable logistic regression analysis: OR 0.83(95% CI0.53–1.30) for prescription of 
antibiotics using PCT-guided therapy. Safety(n=526): No statistically significant dif-
ference in composite safety outcome between groups (p=0.12). PCT-guided therapy 
was noninferior to standard care, upper limit of the one-sided 95% CI was 0.46.
Accuracy(n=529): PCT ≥0.5μg/L for confirmed bacterial infections: sensitivity 
0.52(95% CI0.45–0.60), specificity 0.74(95% CI0.68–0.78). AUC of confirmed bacte-
rial infections: PCT 0.681(95% CI0.633–0.730), CRP 0.619(95% CI0.569–0.669). AUC 
of suspected and confirmed bacterial infections: PCT 0.683(95% CI0.635–0.731), 
CRP 0.695(95% CI0.646–0.744). 
Economic consequences: The total average costs per person: € 5386 for patients in 
the control group, € 4853 for patients in the PCT-guided group, mean difference was 
-€533(95% CI -€1570-€505). 
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Conclusion 
PCT-guided therapy did not reduce antibiotics in a general ED population with fever. 
PCT-guided therapy was noninferior to standard care by means of safety. Although 
the accuracy of PCT for bacterial infections was higher than CRP, it was still poor. 
Future studies should focus on more accurate diagnostic modalities of bacterial in-
fections.
Trial Registration Dutch trial register: NTR4949. 
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4949  
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INTRODUCTION
In patients with bacterial infections, the treatment goal is to provide optimal anti-
microbial therapy in accordance with antibiotic stewardship guidelines1. However, 
in the emergency department(ED), antimicrobial treatment is often initiated before 
a definitive diagnosis is made, since bacterial infections cannot always be ruled out 
using routine biomarkers such as C-reactive protein(CRP)2.
When considering antibiotic treatment in patients with a suspected bacterial in-
fection, ED physicians face a dilemma: On the one hand, antibiotics have to be pre-
scribed sparingly, because overuse of antibiotics increases antibiotic resistance and 
raises healthcare costs3,4. On the other hand, withholding antibiotics from patients 
with bacterial infections and sepsis increases mortality5,6. Consequently, patients 
with suspected infections are often given antibiotics in the ED – a decision based on 
empirical grounds, rather than on a definitive diagnosis2,7-9.
For the correct diagnosis of bacterial infection, accurate diagnostic modalities are 
crucial. Procalcitonin(PCT) is a biomarker with a higher diagnostic accuracy than 
CRP for bacterial infections in specific adult patient populations10-12. PCT can be ap-
plied in an algorithm that determines whether antibiotic treatment is necessary, a 
strategy known as PCT-guided therapy13. PCT-guided therapy reduces antibiotics in 
various clinical settings, such as in primary care and intensive care units(ICU)13,14. In 
the ED, PCT-guided therapy reduces antibiotics in subpopulations of patients with 
respiratory complaints and patients with suspected community acquired pneumo-
nia(CAP), without increase in adverse events12,15,16. However, the effect of PCT-guid-
ed therapy in a general ED population remains unclear, because previous ED studies 
either used specific patient groups, or lacked statistical power12,15-17. Furthermore, 
current evidence on the economic consequences of PCT-guided therapy is incom-
plete, as studies so far have mainly been retrospective model-based studies, limited 
to hospital costs18-21. 
The aim of this study was to determine if PCT-guided therapy can be used for a 
general ED population of patients with fever, by determining the efficacy, safety, 
diagnostic accuracy, and economic consequences of this strategy.
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METHODS
Study design
The HiTEMP study(Higher diagnostic accuracy and cost-effectiveness using pro-
calcitonin in the treatment of emergency medicine patients with fever) was per-
formed in a tertiary referral hospital, Erasmus University Medical Center(EMC) in 
Rotterdam, and in the Jeroen Bosch hospital(JBZ) in ‘s-Hertogenbosch, both in the 
Netherlands. The study was a multicenter, randomized clinical trial with a noninfe-
riority design. The study design has been published previously22. In brief, patients 
were randomized in ED triage between standard care(control group) and PCT-guid-
ed therapy(PCT-guided group) and were followed up for 90 days, by ways of med-
ical database review, telephone interviews and general practitioner(GP) inquiry. 
This study was approved by the Erasmus University Medical Center ethics review 
board(NL44227.078.13).
Study population
ED patients with a temperature of ≥38.2°C(100.8°F) were eligible. The temperature 
of 38.2°C was based on the epidemiology of fever in ED patients23. Patients were 
excluded if they had specific immunocompromised conditions, defined as neutro-
penia with absolute neutrophil count of <0.5x109cells/L, current chemotherapy, 
or post-solid organ transplantation. Furthermore, pregnant patients, moribund pa-
tients and patients with a diagnosis that required primary surgical intervention, or 
who were within 72 hours after surgery were excluded.  
Intervention
PCT levels were determined in all patients. However, only PCT levels of patients 
in the PCT-guided group were available to the ED physician. A bacterial infection 
was deemed unlikely when PCT was <0.5μg/L, and antibiotics were discouraged. 
When PCT was ≥0.5μg/L, a bacterial infection was likely and antibiotics were en-
couraged. All treating physicians were trained in interpreting PCT values. Following 
institutional guidelines, patients with suspected infections and systemic inflamma-
tory response syndrome(SIRS) received a single dose of broad-spectrum antibiotics 
within one hour after ED arrival. This was no main outcome measure, because this 
treatment took place before laboratory results were available. 
Primary outcomes
The efficacy of PCT-guided therapy was defined as the reduction in percentage of 
patients who were prescribed antibiotic therapy in the ED. 
Safety was assessed with a composite safety endpoint(CSE) consisting of 30-days 
mortality, ICU admission within 30 days after ED visit, and return visits to the ED 
within 14 days as indication of treatment failure. 
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Accuracy was defined as the accuracy of PCT and CRP in diagnosing confirmed bac-
terial infections only, and confirmed and suspected bacterial infections combined. 
Confirmed bacterial infections were defined as clinically significant positive blood 
cultures and focus cultures. Suspected bacterial infections were determined by 
chart review with predefined clinical criteria, by two independent physicians(sup-
plement 1). In case of disagreement, a third physician was referee. 
Secondary outcomes
Efficacy of PCT-guided therapy for patients with respiratory sources of infections 
was assessed in a subgroup analysis, in order to compare results with studies on 
PCT-guided therapy in this specific subgroup. Secondary safety outcome measures 
were hospital admission, length-of-hospital-stay and length-of-ICU-stay. We calcu-
lated the percentage of protocol nonadherence. Secondary accuracy outcome was 
accuracy of PCT and CRP in diagnosing bacteremia.
The economic analysis with cost-minimization design included hospital and socie-
tal costs. Medical costs included ED visits, PCT testing, antibiotics administered in 
ED and first three days of antibiotic treatment, hospital and ICU admissions, and 
general practitioner(GP)consultations. Non-medical costs were defined as produc-
tivity losses, which comprised costs of absence from work(absenteeism), reduced 
productivity while at work(presenteeism), and productivity losses related to unpaid 
work. Costs of productivity losses were assessed using the iMTA Productivity Cost 
Questionnaire(iPCQ)24. The time horizon for this analysis was 30 days, except for the 
out-of-hospital medical costs, which was 90 days.  
Statistical analysis 
Efficacy was determined using multivariable logistic regression analysis with step-
wise backward selection of variables, with a p-value cut-off of 0.05. Age, sex, tem-
perature, medication use, comorbidity, PCT and CRP levels and other variables were 
considered as independent variables in this analysis. This analysis was performed 
according the intention-to-treat principle. PCT-guided therapy was deemed non-
inferior if the upper limit of the one-sided 95 confidence interval(95% CI) for the 
difference in the CSE between the PCT-guided group and the control group was 
not higher than 7.5 percentage points. The 95% CI was calculated according to the 
method described by Agresti and Caffo25. The study was powered for the CSE, based 
on the noninferiority margin of 7.5%. The calculated sample size was 550 patients. 
Accuracy was reported in three ways. First, as sensitivity and specificity, with bi-
nomial proportion CIs calculated using the Clopper-Pearson method. Second, as a 
receiver operator characteristic curve(ROC) curve. Third, using multivariable logistic 
regression, corrected for the independent variables age, sex, PCT and CRP levels, 
temperature, comorbidity, and other variables with p < 0.1 for the difference be-
tween groups. We accounted for non-linear effects of PCT with logarithmic transfor-
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mation. Differences in secondary outcomes were analyzed with Fisher’s exact test 
for dichotomous variables, the independent samples T-test for normally distributed 
variables, and the Mann-Whitney U test for continuous variables that were not nor-
mally distributed. We calculated the optimal cut-off of PCT for confirmed bacterial 
infections with the Youden’s index26. Cost-minimization: Costs were derived from 
the Dutch guidelines for economic evaluations in healthcare27. For medical costs, 
the quantities for each resource used were multiplied by standard unit prices. 
Non-medical costs were calculated by multiplying the number of hours of produc-
tivity losses by an average hourly wage, for patients who were employed, and by 
multiplying the number of hours of inability to do unpaid work by standard house-
keeper replacement costs for all patients. We calculated mean values for all cost 
categories and for total costs for both the PCT-guided and control groups. Mean 
differences between the groups and, using nonparametric bootstrapping, 95% CIs 
were calculated. All costs were reported in Euros(€). Unless otherwise specified, all 
statistical tests were two-sided with a significance level of 0.05. Statistical analyses 
were performed with the statistical package for the social sciences(SPSS v.23), IBM 
corporation, and Excel, Microsoft corporation.  
RESULTS
Between August 2014 and January 2017, 2117 patients were screened for inclusion. 
Of these 2117 patients, 551 patients were included, of whom 449 in EMC and 102 
in JBZ(figure 1). There were 372 missed inclusions in EMC, and 184 in JBZ. Missed 
inclusions were eligible patients who were not randomized because physicians 
were unable to perform the randomization procedure due to time constraints. All 
551 cases were included in the intention-to-treat analysis for efficacy. There were 
25(5%) patients lost-to-follow-up after 30 days, making the number of patients for 
the safety analysis 526. Patients who were lost-to-follow-up could not be contacted 
by telephone, and there was no response from their GP. PCT results were unavail-
able for 19 patients, of whom 8 in the PCT-guided group. This was due to failure to 
obtain blood samples in the ED. For three additional patients, no CRP result was 
available, making the number of cases for the accuracy analyses 529. Baseline char-
acteristics are reported in table 1.
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2 pt Figure 1. Flowchart 
Total eligible patients 
(n = 2117) 
Jeroen Bosch hospital 
(n = 511) 
Erasmus University Medical Center 
(n = 1606) 
Excluded patients 
(n = 1157)  
Immunocompromised 366 
Surgical fever    94 
Pregnancy                4 
Moribund      4 
Unable to give IC 281 
Unwilling to participate   35 
Other reasons      1 
 
Missed inclusions 372 
 
Excluded patients 
(n = 409)  
Immunocompromised   71 
Surgical fever    11 
Pregnancy                1 
Moribund      1 
Unable to give IC 133 
Unwilling to participate     3 
Other reasons      5 
 
Missed inclusions 184 
 
Included patients 
(n = 449) 
Included patients 
(n = 102) 
 
PCT-guided 
therapy 
(n = 225) 
Total included patients 
(n = 551) 
 
PCT-guided therapy (n = 275) 
 
Lost to follow-up (n = 13) 
 
Patients for safety analysis (n = 262) 
 
Complete 90-days follow-up for 
economic analysis (n = 177) 
 
Control  
group 
(n =224) 
PCT-guided 
therapy 
(n = 50) 
 
Control  
group 
(n = 52) 
 
 
Control group (n = 276) 
 
Lost to follow-up (n = 12) 
 
Patients for safety analysis (n = 264) 
 
Complete 90-days follow-up for 
economic analysis (n = 192) 
 
IC: informed consent, N: number of patients, PCT: procalcitonin 
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Primary outcomes
Efficacy: 200(73%) of patients in the PCT-guided group received antibiotics, com-
pared to 212(77%) of patients in the control group (p = 0.28)(table 2). PCT-guided 
therapy did not reduce the probability of antibiotics prescription, odds ratio(OR) 
0.83(95% CI 0.53–1.30) when corrected for age, sex, temperature, medication use, 
comorbidity and PCT and CRP levels. No other independent variables had signifi-
cant effect(table 3). 
Safety: There was no significant difference in the CSE between groups(table 2). 
The upper limit of the one-sided 95% CI for the difference in the CSE between the 
PCT-guided group and the control group was 0.46, which was below the defined 
noninferiority margin of 7.5, making PCT-guided therapy noninferior to standard 
care by means of safety. 
Table 1. Baseline characteristics
All (n = 551) Control group (n= 276) PCT-guided group (n = 275)
Demographic characteristics
Age median [IQR] 63 [43 - 71] 62 [44 - 73] 61 [43 - 70]
Female sex n (%) 253 (46) 122 (44) 131 (48)
Vital signs at presentation
Temperature median [IQR] 38.8 [38.4 - 39.2] 38.8 [38.4 - 39.2] 38.8 [38.4 - 39.3]
Heart rate median [IQR] n = 550 105 [92 - 119] 105 [92 - 119] 105 [90 - 118]
Systolic bloodpressure median [IQR] n = 549 130 [118 - 145] 130 [118 - 145] 130 [117 - 145]
Diastolic bloodpressure median [IQR] n = 549 75 [67 - 85] 75 [67 - 85] 75 [67 - 85]
Respiratory rate median [IQR] n = 410 20 [17 - 25] 22 [18 - 25] 20 [16 - 25]
Comorbidity
Diabetes n (%) 97 (18) 51 (19) 46 (17)
Malignancy n (%) 106 (19) 44 (16) 62 (23)
HIV n (%) 17 (3) 10 (4) 7 (3)
Current medication use
Current antibiotics use (before ED visit)n (%) 88 (16) 40 (15) 48 (18)
Steroids n (%) 78 (14) 37 (13) 41 (15)
Oral anticoagulants n (%) 64 (12) 31 (11) 33 (12)
Acetylsalicylic acid n (%) 67 (12) 33 (12) 34 (12)
Biomarkers
PCT in mcg/L median [IQR] n = 532 0.26 [0.10 - 0.96] 0.26 [0.10 - 1.00] 0.28 [0.10 - 0.93]
CRP in mg/L median [IQR] n = 548 62 [19 - 150] 67 [21 - 159] 57 [17 - 132]
Leukocytes in count*10^9 cells/L median [IQR] 12.0 [8.5 - 15.6] 11.7 [8.6 - 14.9] 11.6 [8.3 - 16.0]
Diagnosis
Confirmed bacterial infections n (%) 198 (36) 103 (37) 95 (35)
Confirmed viral infections n (%) 41 (7) 20 (7) 21 (41)
Confirmed fungal infections n (%) 1 (0) 0 (0) 1 (0)
Confirmed parasite infections n (%) 1 (0) 0 (0) 1 (0)
Confirmed non-infectious fever n (%) 37 (7) 14 (3) 23 (4)
Bacteremia n (%) 99 (18) 57 (21) 42 (15)
Categories of fever by focus
-          Skin and soft tissue n (%) 47 (9) 27 (10) 20 (7)
-          Respiratory tract n (%) 212 (39) 102 (37) 110 (40)
-          Urogenital tract n (%) 108 (20) 54 (20) 54 (20)
-          Abdominal n (%) 69 (13) 36 (13) 33 (12)
-          Central nervous system n (%) 4 (1) 1 (0) 3 (1)
-          Other source n (%) 13 (2) 9 (3) 4 (2)
-          Fever without source n (%) 60 (11) 33 (12) 27 (10)
-          Non infectious fever n (%) 37 (7) 15 (5) 22 (8)
Initial ED treatment
Antibiotics in ED because of SIRS n (%) 283 (51) 148 (54) 135 (49)
CRP: C-reactive protein, ED: emergency department, HIV: human immunodeficiency virus, IQR: interquartile range, PCT: procalcitonin
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Figure 2. ROC curves 
 
ROC curve of PCT and CRP for confirmed bacterial infection (n = 529) 
 
 
 
PCT AUC 0.681 (95%CI 0.633 – 0.730) 
CRP AUC 0.619 (95%CI 0.569 – 0.669) 
 
 
 
 
 
 
 
 
 
ROC curve of PCT and CRP for confirmed and suspected bacterial infection (n = 529) 
 
 
 
PCT AUC 0.683 (95%CI 0.635 – 0.731) 
CRP AUC 0.695 (95%CI 0.646 – 0.744) 
 
 
 
 
 
 
 
 
 
ROC curve of PCT and CRP for bacteremia (n = 529) 
 
 
 
PCT AUC 0.736 (95%CI 0.681 – 0.790) 
CRP AUC 0.585 (95%CI 0.523 – 0.646) 
 
AUC: Area under curve, CRP: C- reactive protein, PCT: Procalcitonin, ROC curve: Receiver 
operator characteristic curve 
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Accuracy: For confirmed bacterial infections only, sensitivity of PCT ≥0.5μg/L was 
0.52(95% CI 0.45–0.60), and specificity 0.73(95% CI 0.68–0.78). The ROC curve of 
PCT yielded an AUC of 0.681(95% CI 0.633–0.730), which was higher than the AUC 
of CRP, 0.619(95% CI 0.569–0.669) (figure 2). 
Multivariable logistic regression analysis showed an OR of PCT of 1.37(95% CI 1.20–
1.56), corrected for age, sex, temperature, comorbidity, CRP level and leukocyte 
count (table 3). This OR showed that a 1% relative increase in PCT level increases 
the odds for a patient having a bacterial infection 0.37.
For confirmed and suspected infections combined, sensitivity of PCT ≥0.5μg/L was 
0.43(95% CI 0.38–0.48), and specificity 0.85(95% CI 0.77–0.89). The AUC of PCT 
was 0.683(95% CI 0.635–0.731), and was lower than the AUC of CRP, 0.695(95% 
CI 0.646–0.744). The OR of PCT of 1.29(95% CI 1.09–1.53), corrected for age, sex, 
temperature, comorbidity, CRP level and leukocyte count. 
Table 3. Multivariable analysis of prescription of antibiotics and confirmed and suspected bacterial infections
All patients (n = 551)* Subgroup analysis of patients suspected and 
Dependent variable: Antibiotics prescribed Antibiotics prescribed
Odds ratio (95% CI) Odds ratio (95% CI)
Randomisation (PCT-guided group) 0.83 (0.53 - 1.30) 1.29 (0.59 - 2.82)
Age (years) 1.04 (1.02 - 1.05) 1.04 (1.02 - 1.06)
Female 0.99 (0.63 - 1.56) 1.14 (0.51 - 2.55)
Temperature (degrees Celcius) 2.37 (1.50 - 3.75) 2.11 (0.94 - 4.74) 
Comorbidity: malignancy 1.74 (0.88 - 3.45) 3.81 (0.75 - 19.35)
Comorbidity: diabetes 0.96 (0.48 - 1.91) 0.98 (0.29 - 3.38)
Comorbidity: HIV 1.76 (0.46 - 6.85) 2.31 (0.35 - 15.24)
Medication use: previous antibiotics 3.12 (1.45 - 6.71) 2.31 (0.74 - 7.19)
Medication use: steroids 1.07 (0.55 - 2.10) 3.48 (1.11 - 10.88)
Medication use: oral anticoagulants 1.09 (0.50 - 2.37) 2.69 (0.60 - 11.94)
Medication use: acetylsalicyl acid 2.05 (0.86 - 4.88) 2.86 (0.60 - 13.65)
PCT level (µg/L) 1.18 (1.00 - 1.38) 1.19 (0.74 - 1.90)
CRP level (mg/L) 1.01 (1.00 - 1.01) 1.01 (1.00 - 1.02)
Accuracy outcomes: multivariable logistic regression analysis
All patients (n = 529)** All patients (n = 529)**
Dependent variable: Confirmed bacterial infections Confirmed and suspected bacterial infections
Odds ratio (95% CI) Odds ratio (95% CI)
Logarithmic PCT level 1.37 (1.20 - 1.56) 1.29 (1.08 - 1.52)
CRP level (mg/L) 1.00 (1.00 - 1.01) 1.01 (1.00 - 1.01)
Age (years) 1.01 (1.00 - 1.03) 1.03 (1.02 - 1.04)
Female 0.77 (0.52 - 1.14) 0.59 (0.38 - 0.92)
Temperature (degrees Celcius) 1.67 (1.17 - 2.37) 2.18 (1.41 - 3.36)
Comorbidity: malignancy 1.62 (1.00 - 2.64) 2.06 (1.06 - 4.00)
Comorbidity: diabetes 1.00 (0.59 - 1.70) 1.65 (0.85 - 3.22)
Comorbidity: HIV 0.70 (0.21 - 2.36) 0.70 (0.21 - 2.25)
Leukocyte count (10^9 cells/L) 1.00 (0.99 - 1.02) 1.02 (0.99 - 1.05)
**Multivariable logistic regression analysis with predefined variables, with the addition of leukocyte count.
CI: confidence interval, CRP: C-reactive protein, n: number, PCT: procalcitonin. 
* Multivariable logistic regression analysis with predefined variables. No additional baseline variables met criteria for 
Efficacy outcome: multivariable logistic regression analysis
84
Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a 
multicenter noninferiority randomized clinical trial (HiTEMP study)
Secondary outcomes
In the subgroup analysis of patients with respiratory sources of infections(n = 212), 
83(75%) of patients in the PCT-group received antibiotics, compared to 73(72%) 
patients in the control group (p=0.76). The OR for prescription of antibiotics was 
1.29(95% CI 0.59–2.82) (table 3). 
In the total population, there were no statistically significant differences in individ-
ual endpoints of the CSE (n=526), second ED visit within 14 days (p=0.20), ICU ad-
mission within 30 days after ED visit(p=1.00) and 30-days mortality (p=0.11), nor in 
endpoints hospital admission(p=0.10), length-of-hospital-stay(p=0.25) and length-
of-ICU-stay(p=0.32)(table 2). 
Protocol nonadherence was 49%(n=529), which consisted of 232 patients who re-
ceived antibiotics with PCT<0.5μg/L, and 26 patients who did not receive antibiotics 
with PCT≥0.5μg/L (supplement 2). 
A total of 89(48%) of patients with a confirmed bacterial infection(n=186) had 
PCT<0.5μg/L (supplement 2). Of these 89 patients, 12 patients did not receive anti-
biotics. Of these 12 patients, two patients suffered adverse events, one return visit 
to the ED, and one ICU admission. The AUC of PCT for bacteremia was 0.736(95% CI 
0.681–0.790), the AUC of CRP for bacteremia was 0.585(95% CI 0.523–0.646). The 
OR of PCT for bacteremia was 1.37(95% CI 1.20–1.56), corrected for age, sex, tem-
perature, comorbidity, CRP level. No additional variables met criteria for inclusion 
(supplement 3). 
The calculated optimal cut-off of PCT for confirmed bacterial infection was 0.25μg/L. 
Sensitivity of PCT ≥0.25μg/L was 0.70(95% CI 0.63–0.77), and specificity 0.58(95% 
CI 0.52–0.63). 
A total of 369 patients had a complete follow-up for the cost-minimization analysis, 
177(64%) in the control group and 192(70%) in the PCT-guided group. The total av-
erage costs per person were €4853 for patients in the PCT-guided group and €5386 
for patients in the control group, with a mean difference of -€533 (95% CI -€1570 
to €505). 
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Table 4: Econom
ic analysis
M
ean
Standard deviation
M
ean
Standard deviation
M
ean
95%
 CI
Hospital costs
3899
€                                                   
4704
€                                                   
4162
€                                                   
4680
€                                                   
263-
€                                                     
-€ 1225 to € 698
PCT testing
56
€                                                       
-
€                                                      
-
€                                                      
-
€                                                      
56
€                                                       
€ 56 to € 56
Antibiotics adm
inistered in ED
7
€                                                         
12
€                                                       
8
€                                                         
15
€                                                       
1-
€                                                         
-€ 3 to € 2
Antibiotics first three days
82
€                                                       
136
€                                                     
73
€                                                       
135
€                                                     
9
€                                                         
-€ 18 to € 37
ED adm
ission
275
€                                                     
63
€                                                       
278
€                                                     
68
€                                                       
3-
€                                                         
-€ 16 to € 11
Adm
ission university hospital
2966
€                                                   
3714
€                                                   
3330
€                                                   
4087
€                                                   
364-
€                                                     
-€ 1162 to € 435
Adm
ission non-university hospital
261
€                                                     
885
€                                                     
235
€                                                     
911
€                                                     
25
€                                                       
-€ 158 to € 209
ICU adm
ission
252
€                                                     
1838
€                                                   
239
€                                                     
1762
€                                                   
13
€                                                       
-€ 356 to € 382
Costs of extram
ural care
89
€                                                       
117
€                                                     
109
€                                                     
144
€                                                     
20-
€                                                       
-€ 47 to € 6
General practitioner visit
54
€                                                       
75
€                                                       
74
€                                                       
102
€                                                     
20-
€                                                       
-€ 38 to -€ 1
General practitioner house call
34
€                                                       
91
€                                                       
35
€                                                       
98
€                                                       
1-
€                                                         
-€ 20 to € 18
Productivity costs
866
€                                                     
1742
€                                                   
1115
€                                                   
2118
€                                                   
249-
€                                                     
-€ 644 to € 147
Costs of absenteeism
 from
 w
ork
632
€                                                     
1628
€                                                   
830
€                                                     
1875
€                                                   
198-
€                                                     
-€ 557 to € 160
Costs of productivity loss w
hile at w
ork
28
€                                                       
142
€                                                     
42
€                                                       
223
€                                                     
14-
€                                                       
-€ 52 to € 24
Replacem
ent for unpaid w
ork
206
€                                                     
521
€                                                     
243
€                                                     
694
€                                                     
37-
€                                                       
-€ 162 to € 88
Total costs
4853
€                                                   
4969
€                                                   
5386
€                                                   
5168
€                                                   
533-
€                                                     
-€ 1570 to € 505
ED: Em
ergency departm
ent, ICU: intensive care unit, PCT: procalcitonin
Difference
PCT-guided group (n = 192)
Control group (n = 177)
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DISCUSSION
Our study showed that PCT-guided therapy did not reduce the number of febrile pa-
tients who were prescribed antibiotics in the ED. PCT-guided therapy was noninferi-
or to standard therapy regarding the CSE. PCT was more accurate in the diagnosis of 
confirmed bacterial infections than CRP, but the accuracy was poor. For confirmed 
and suspected infections, the accuracy of PCT was lower than the accuracy of CRP, 
which suggests that, in patients with suspected infections, PCT results can be incon-
gruent with clinical judgement. PCT-guided therapy did not result in a statistically 
significant costs reduction. 
Our findings are in contrast with other studies on PCT-guided therapy in the 
ED10,12,15,16,28,29. These studies reported antibiotic reductions of 13 to 39 with 
PCT-guided therapy, in adult patient populations of patients with lower respiratory 
tract infections, CAP and COPD. However, in our study, we found no difference in 
the number of antibiotics prescriptions; not in the total cohort, nor in the subgroup 
analysis of patients with respiratory infections. We speculate that physicians based 
treatment decisions on clinical judgement and other diagnostic modalities instead 
of PCT advice in conflicting situations. 
The essence of PCT-guided therapy is to reduce antibiotics in patients without bac-
terial infections. For this strategy to work, PCT levels have to identify patients with-
out bacterial infections accurately, and on top of that, physicians have to trust the 
results. In the ProHOSP study, Schuetz et al.12 reported that PCT-guided therapy 
significantly reduced antibiotics prescriptions in ED patients with suspected CAP. 
The authors suggested that Swiss physicians’ experience with PCT resulted in an 
increased adherence to PCT advice in the ProHOSP study, because physicians in 
Switzerland were used to working with PCT. Physicians in Dutch EDs did not have 
extensive previous clinical experience with the PCT biomarker before this study 
started. However, we hypothesize that this lack of previous clinical experience, and 
possible concomitant lack of trust in the accuracy of PCT results, cannot be the 
only explanation for our findings. Following the 49% PCT-guided therapy protocol 
nonadherence, we presume that, in a general ED population, PCT is insufficient as a 
single biomarker in the diagnosis of bacterial infections, and that clinical judgement 
and other diagnostic modalities are crucical for physicians in order to prevent un-
dertreatment. This was also suggested by Kristoffersen et al., who found a PCT-guid-
ed therapy protocol nonadherence of 41% 30. 
Although PCT was more accurate for confirmed bacterial infections than CRP and 
although an increase in PCT level made the presence of a patient having a con-
firmed infection more likely, a single cut-off of PCT ≥0.5μg/L resulted in an errone-
ous treatment advice to withhold antibiotics in 89(49%) patients with a confirmed 
bacterial infection. This cut-off value was higher than in other ED and primary care 
studies12,14,15. The calculated optimal cut-off of PCT for confirmed bacterial infec-
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tions, ≥0.25µg/L, had a sensitivity of 0.70, and coincidentally corresponded with 
the cut-off used in these studies. Out of 253 patients with PCT levels of ≥0.25µg/L, 
55 patients(28%) had a confirmed bacterial infection. PCT levels, both with the cut-
off of ≥0.5µg/L and with the calculated optimal cut-off of ≥0.25µg/L for confirmed 
bacterial infections resulted in false negative outcomes in respectively 89(17%) and 
55(10%) patients(supplement 2). From these findings we conclude that a single PCT 
result gave inaccurate treatment advice and should not be used as only criterion to 
start or withhold antibiotics in a general ED population. 
The accuracy of PCT for bacterial infections in our study is lower than in two recent 
meta-analyses on the accuracy of PCT in the ED (e.g. an AUC of PCT for bacteremia 
of 0.736 in our study versus 0.84 reported by Jones et al.)31,32. This may be due to 
the fact that our patient population was designed to resemble a general ED pop-
ulation, thereby making it a heterogeneous group with only 36 of patients with a 
confirmed bacterial infection. Studies with highly selected populations such as the 
ProHOSP study, consisted of higher percentages of bacterial infections, with 68 of 
patients having a CAP12.
In the PCT-guided group, patients were admitted to the hospital less often, and had 
a lower absolute 30-days mortality. Although both findings did not meet the criteria 
for statistical significance, we speculate that physicians may have used PCT as a bio-
marker for disease severity. On the one hand, low PCT results may have influenced 
physicians not to admit patients to the hospital. On the other hand, high PCT results 
may have prompted physicians to treat patients more aggressively, resulting in a 
reduction in 30-days mortality. Shehabi et al.33 described that a single PCT level at 
ICU admission was predictive of sepsis severity. The value of PCT in disease severity 
in a general ED patient population has not yet been determined. 
The economic analysis demonstrated that there was no statistically significant dif-
ference in costs between groups. This was contrary to our hypothesis that PCT-guid-
ed therapy reduced overall costs. Hospital admissions and consequent productivity 
losses account for the highest expenses. Future biomarker strategies that can re-
duce hospital admissions may reduce healthcare costs.
Limitations
We used body temperature as sole inclusion criterion. This was both a strength and 
a weakness of the study. A strength, because it was an objective measurement and 
makes the results generalizable to all ED patients with fever. A weakness, because 
fever is not a perfect marker of infectious disease. The use of this inclusion criterion 
resulted in a selection bias, where patients with infectious diseases and normother-
mia or hypothermia were not eligible for inclusion. Patients with altered mental 
status and severely ill patients were de facto excluded, because these patients were 
unable to give written informed consent. Therefore, the results are not generaliz-
able for the entire adult ED patient population. 
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CONCLUSION
PCT-guided therapy was noninferior to standard care by means of safety, but did 
not reduce the prescription of antibiotics in patients with fever in a general ED pop-
ulation. In this heterogeneous patient population, PCT was more accurate in the 
diagnosis of confirmed bacterial infections than CRP, but the accuracy of PCT for 
bacterial infections was poor. 
Future studies should focus on more accurate diagnostic modalities of bacterial 
infections to reduce antibiotics prescriptions in the ED. Furthermore, PCT-guided 
therapy may be used for assessing disease severity. 
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Supplement 1. Criteria for confirmed and suspected infections
Confirmed infections
Confirmed bacterial infections:
Positive culture result for bacteria (from an otherwise sterile location), positive Legionella or pneumococcus urine test. *
(Coagulase negative Staphylococcus bacteremia is considered as contamination and not as infection.)
Confirmed viral infections: 
Positive viral PCR or serology. *
Confirmed fungal infections: 
Positive blood culture or PCR.
Confirmed parasitical infections: 
Positive blood culture or PCR, positive blood smear for malaria.
Suspected infections
Suspected bacterial infections:
Negative findings in cultures and PCR. 
Positive infiltrate on chest x-ray with as at least 1 respiratory symptom (cough, sputum, dyspnea, tachypnea, pleuritic pain), plus 
either  rales or crepitation on auscultation, shivering, leukocytosis. Positive image modality: infiltrate, abscess. Positive urine 
nitrite, with positive leukocytes in urine and leukocytosis, or with dysuria complaints in history.  Skin: local red and painfull 
swelling. Abscess found on endoscopy. CSF analysis one of the following criteria: high opening pressure (>18cm H2O), pleiocytosis 
(> 5.109/L), elevated protein level (>0.4 g/L), low glucose (<2.5 mmol/L), low glucose CSF/blood ratio (< 0.4), high lactate (>4.2 
mmol/L). ERCP findings suggestive of cholangitis. Clinical improvement with antibiotics treatment, when no highly suspected other 
cause is present. 
Suspected viral infections:
Negative findings in cultures and PCR. 
History mentions flu-like symptoms. Dry cough. Pathognomic findings of viral infections, such as, but not limited to Koplik spots. 
Improvement without antibiotics.
Noninfectious fever:
Negative findings in cultures and PCR. 
Negative image modality findings suspected for infection. Confirmed or highly likely other diagnosis. Improvement without 
antibiotics.
Unknown:
Negative findings in cultures and PCR. 
Insufficient clinical data in medical chart to determine suspected infection category.
*when a patient has both a confirmed bacterial and viral infection, it is considered a bacterial infection because this has treatment 
consequences.
CSF: cerebrospinal fluid. ERCP: endoscopic retrograde cholangiopancreatoscopy. PCR: polymerase chain reaction diagnostics.
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Supplement 3: Multivariable analysis of bacteremia
Multivariable logistic regression analysis
All patients (n = 529)*
Dependent variable: Bacteremia
Odds ratio (95% CI)
Logaritmic PCT level 1.37 (1.20 - 1.56)
CRP level (mg/L) 1.00 (1.00 - 1.01)
Age (years) 1.01 (1.00 - 1.03)
Female 0.77 (0.52 - 1.14)
Temperature (degrees Celcius) 1.67 (1.17 - 2.37)
Comorbidity: malignancy 1.62 (1.00 - 2.64)
Comorbidity: diabetes 1.00 (0.59 - 1.70)
Comorbidity: HIV 0.70 (0.21 - 2.36)
Multivariable logistic regression analysis with predefined variables. No additional 
baseline variables met criteria for inclusion in analysis.
CI: confidence interval, CRP: C-reactive protein, n: number, OR : Odds ratio, PCT: 
procalcitonin. 
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ABSTRACT
Introduction 
Fever is a common symptom in the Emergency department (ED). If viral infections can 
be identified more accurately, the overuse of antibiotics, attributed adverse events 
and antibiotics resistance may be reduced. TNF-related apoptosis-inducing ligand 
(TRAIL) and interferon-gamma-inducible protein 10 (IP-10) are described as novel 
biomarkers for viral disease. We investigated if TRAIL and IP-10 can differentiate eti-
ologies of fever in the ED, both as a single biomarker, and in combination with procal-
citonin (PCT).
Methods
Adult patients with fever in the ED were included. TRAIL and IP-10 levels were de-
termined in patient cases of confirmed viral, bacterial and non-infectious fever. Con-
firmed viral and confirmed bacterial infection were defined as laboratory evidence 
of presence of disease and clinical signs, confirmed non-infectious as absence of lab-
oratory evidence and strong alternative diagnosis. A Kruskal-Wallis test was utilized 
to determine difference between etiologies of fever for TRAIL and IP-10 levels, and 
confirmed viral infections were compared with other etiologies of fever using Mann 
Whitney U tests. The area-under-the-curve (AUC) was calculated for TRAIL and IP-10 
and optimal cut-off values were derived. In binary logistic regression analysis, a com-
bined biomarker model including PCT, TRAIL and IP-10 was created and the AUC was 
calculated.
Results
A total of 54 patients were included, of whom 13 with a confirmed viral disease, 33 
with a confirmed bacterial disease and 8 patients with confirmed non-infectious dis-
ease. TRAIL levels were significantly higher in patients with confirmed viral infections, 
compared to patients with a confirmed bacterial infection and non-infectious disease, 
(p < 0.001). IP-10 levels were not significantly different (p = 0.052). For the discrimi-
nation of confirmed viral infections from other febrile etiologies, levels of both TRAIL 
(p = 0.016) and IP-10 (p = 0.017) were significantly higher in confirmed viral disease. 
AUCs were 0.72 (95%CI 0.56 – 0.88) for TRAIL and 0.72 (95%CI 0.59 – 0.86) for IP-10. 
The combined biomarker model showed an AUC of 0.84 (95%CI 0.72 – 0.97) for dis-
crimination between confirmed viral and non-viral disease.
Discussion
Levels of TRAIL and IP-10 were significantly elevated in viral infections, compared to 
bacterial and non-infectious febrile disease in an undifferentiated ED patient cohort. 
A combined biomarker model with PCT resulted in an even higher diagnostic accura-
cy of viral disease than single biomarkers individually. The cut-off values of the novel 
biomarkers require validation, but the results of this study are a proof of principle.
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INTRODUCTION
Diagnosing the cause of fever in a patient in the emergency department (ED) is 
difficult. Fever is a common presenting symptom in both viral and bacterial disease. 
Also, many non-infectious diseases may cause fever1-3. 
There is a dilemma in the treatment of febrile illness in the ED. On the one hand, 
patients with a severe bacterial infection have to be treated with antibiotics as soon 
as possible. Delay is associated with a rise in morbidity and mortality4. On the other 
hand, particularly in this time of antimicrobial stewardship, it is good clinical prac-
tice to use antibiotics for treatment of bacterial disease as efficient as possible5,6. 
Antibiotic overtreatment of patients may result in an increase of antibiotic resis-
tance5,6. 
Bacterial cultures and specific viral assays are obtained in the ED, but results often 
take several days to become available. Due to time restraints, it is not possible to 
wait for these results in daily ED practice. Treatment has to be started before the 
definitive diagnosis is available. New strategies for appropriate use of antimicrobial 
therapy are needed7,8.
In the standard diagnostic workup of febrile patients, biomarkers are used to focus 
on predicting the presence of bacteria2,9,10. In current practice, C-reactive protein 
(CRP) and to a lesser extent procalcitonin (PCT) are used as clinical biomarkers for 
identification of bacterial infection. Although the use of these markers reduces an-
tibiotics in selected populations, diagnostic uncertainty remains9,10.
Recently, TNF-related apoptosis-inducing ligand (TRAIL) and interferon-gamma-in-
ducible protein 10 (IP-10) were described as novel biomarkers for viral disease11. 
TRAIL is expressed in various cells of the adaptive immune system, and plays a role 
in the response to viral infections12. IP-10 has a role in the inflammation cascade in 
viral and bacterial disease13. 
Biomarkers focusing on both bacterial and viral disease can be combined.  Low lev-
els of PCT have been associated with the absence of bacteria. Therefore, a combi-
nation of PCT, which is TRAIL and IP-10 may be valuable for the additional diagnostic 
accuracy diagnosis of viral infection.
The novel biomarkers for the differentiation of viral disease may be of clinical sig-
nificance. Therefore, we investigated if TRAIL and IP-10 can differentiate viral and 
bacterial or non-infectious causes of fever in the ED. Furthermore, we combined 
the results of TRAIL and IP-10 with PCT in a combined biomarker model.
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METHODS
This was was a substudy of a previous study on PCT-guided therapy for febrile pa-
tients in the ED at the Slotervaart Hospital, Amsterdam, the Netherlands14. The local 
ethics committee approved the study. From May 2010 to May 2012, a total of 107 
adult febrile patients (T > 38.0 °C) were included after written informed consent 
was obtained.  From the cohort of this study, patients with a confirmed diagnosis 
of bacterial infection, viral infection, or non-infectious disease were selected. The 
patients were confined to one of the following groups. 1)Confirmed bacterial in-
fection, defined as a positive culture result in concordance with clinical findings. 2) 
Confirmed viral infection, defined as positive viral PCR in concordance with clinical 
findings. 3) Non-infectious disease, no evidence of infectious fever despite exten-
sive supplementary diagnostics, and a strong alternative diagnosis. Patients with 
both a confirmed bacterial and viral infection were excluded. In all patients, levels 
of TRAIL and IP-10 were determined, using Human TRAIL/TNFSF10 Quantikine ELISA 
Kit and Human CXCL10/IP-10 Quantikine ELISA Kit of R&D Systems according to the 
manufacturer’s manual. 
Data-analysis
A Kruskal-Wallis test was used to determine differences of levels of TRAIL and IP-10 
between the three defined groups of patients. Additionally, patients with confirmed 
viral disease were compared with patients with confirmed non-viral disease (groups 
of confirmed bacterial infection and non-infectious combined). Furthermore, pa-
tients with non-infectious disease and infectious disease (groups confirmed bacte-
rial infection and confirmed viral disease combined), using Mann-Whitney U tests. 
P-values of <0,05 were considered significant. The area under the ROC for TRAIL and 
IP-10 was calculated for confirmed viral disease versus non-viral disease. Using the 
ROC curves, optimal cut-offs of both TRAIL and IP-10 were determined. The value of 
the square of distance between point (0,1) and the ROC curve (d2) was calculated 
using d2 = (1-sensitivity)2 + ((1-specificity)2. The lowest value indicated the optimal 
cut-off. PCT, TRAIL and IP-10 results were combined in a binary logistic regression 
model. This combined biomarker model for discriminating viral disease used a cut-
off of <0.5 µg/L for PCT, and the optimal cut-off values for TRAIL and IP-10. The 
area under the curve was calculated for the model of the combined biomarkers 
for confirmed viral disease versus non-viral disease.  Data-analysis was performed 
using statistical package for the social sciences (SPSS) version 21, IBM corporation.  
 
99
PrTRAIL and IP-10 as biomarkers of viral infection in the emergency department
RESULTS
A total of 54 patients were selected; 13 patients had a confirmed viral infection, 33 
a confirmed bacterial infection and 8 patients had confirmed non-infectious dis-
ease. Respiratory infection was present in 11 patients with viral disease, and in 12 
patients with bacterial disease. Baseline characteristics are reported in table 1, spe-
cific pathogens of the defined groups are reported in table 2. 
Confirmed viral Confirmed bacterial Confirmed non-infectious p-value (one-way ANOVA)
N 13 33 8
Female n (%) 6 (46) 14 (42) 2 (25) p = 0.616
Age in years n (%) 53 (36) 65 (30) 56 (37) p = 0.349
Temperature in ˚C median [IQR] 38.5 (1.1) 39.0 (0.8) 38.8 (1.7) p = 0.320
Hospitalization n (%) 12 (93) 31 (94) 6 (75) p = 0.257
Hospital length of stay median [IQR] 6 (5) 7 (9) 7 (15) p = 0.338
ICU admission n (%) 2 (15) 6 (18) 1 (11) p = 0.923
Mortality n (%) 0 (0) 2 (6) 0 (0) p = 0.532
Diabetes Mellitus n (%) 4 (31) 7 (21) 0 (0) p = 0.241
Immunocompromised n (%) 1 (8) 5 (12) 1 (13) p = 0.908
Malignancy n (%) 1 (8) 5 (15) 4 (50) p = 0.038
HIV n (%) 0 (0) 2 (6) 1 (13) p = 0.484
Steroids n (%) 2 (15) 7 (21) 2 (25) p = 0.860
CRP, median mg/mL median [IQR] 107 (98) 202 (249) 96 (105) p = 0.060
PCT, median µg/mL median [IQR] 0.21 (0.38) 1.26 (2.55) 0.30 (0.40) p = 0.102
TRAIL, median pg/mL median [IQR] 51 (21) 34 (35) 8 (14) p = 0.078
IP-10, median pg/mL median [IQR] 1295 (611) 585 (963) 466 (1234) p = 0.036
Leukocyte count 109 cells/L median [IQR] 9.7 (5.7) 14.2 (7.0) 6.6 (7.1) p = 0.002
Respiratory infection n (%) 11 (85) 12 (36)
Urinary tract infection n (%) 0 (0) 13 (39)
Skin infection n (%) 1 (8) 3 (9)
Viremia / bacteriemia only n (%) 1 (8) 3 (9)
Cholangitis n (%) none 1 (3)
Meningitis n (%) none 1 (3)
Table 1: Baseline characteristics of study population
Abbrevations list: N: number. IQR: Inter quartile range. ICU: intensive care unit. HIV: human immunodeficiency virus. CRP: C-reactive protein. PCT: Procalcitonin. 
TRAIL: TNF-related apoptosis-inducing ligand. IP-10: interferon-γ-inducible protein 10
Confirmed viral disease Confirmed bacterial disease Confirmed non-infectious disease
Pathogen N* Pathogen N** Cause N
Adenovirus 1 E. Coli 11 Fever without known cause, confirmed non-
infectious
2
Dengue 1 H. influenzae 2 Gout 1
Herpes simplex virus 1 K. Pneumoniae 4 Hyperthyroidism 1
Influenza A virus 4 M. pneumoniae 2 Malignant neuroleptic syndrome 1
parainfluenza virus 2 P.aegurinosa 8 Tumor fever 3
Rhinovirus 5 S. agalactiae 1
S. aureus 2
S. pneumoniae 2
Enterococcus sp 1
Legionella sp 1
Micrococcus sp 1
Streptococcus sp 3
Total 14 Total 38 Total 8
Table 2: Pathogens in the confirmed viral, confirmed bacterial and confirmed non-infectious disease group 
N: number. * One patient had both a confirmed adenovirus and rhinovirus infection ** Three patients had confirmed infections with two different bacterial 
pathogens, one patient had confirmed infection with three different bacterial pathogens.
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Figure 1.  
Concentration of TRAIL in pg/ml in confirmed viral, bacterial and non-infectious disease 
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Figure 2.  
Concentration of IP-10 in pg/ml in confirmed viral, bacterial and non-infectious disease 
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The levels of TRAIL were significantly higher in patients with a confirmed viral in-
fection, compared to patients with a confirmed bacterial infection and confirmed 
non-infectious fever (p > 0.001). IP-10 did not show a significant difference (p = 
0.052).  Results are shown in figure 1 and 2. TRAIL levels were not significantly dif-
ferent between patients with confirmed viral and confirmed bacterial infections (p 
= 0.100). IP-10 levels were significantly elevated (p = 0.022) in confirmed viral versus 
confirmed bacterial infections. 
1 
 
 
Figure 3.  
Receiver-Operator-Curve of TRAIL and IP-10 in differentiation between confirmed viral disease versus 
non-viral disease 
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When compared between confirmed viral and confirmed non-viral disease, levels 
of both TRAIL and IP-10 were significantly higher in confirmed viral disease, (p = 
0.016, and p = 0.017, respectively). TRAIL levels were significantly elevated in pa-
tients with confirmed infections, compared to patients with confirmed non-infec-
tious fever, (p <0.000), no significant difference between IP-10 levels was observed 
(p = 0.319). ROC for TRAIL and for IP-10 (figure 3) showed an area under the curve 
of 0.72 (95%CI 0.56 – 0.88) for TRAIL and 0.72 (95%CI 0.59 – 0.86) for IP-10 re-
spectively, in the discrimination of confirmed viral disease from confirmed non-viral 
disease (figure 3). The optimal cut-off in differentiating confirmed viral disease from 
confirmed non-viral disease of TRAIL was 93.83 pg/ml, and 911.43pg/ml for IP-10. 
Binary logistic regression analysis for PCT <0.5 µg/L for confirmed viral disease re-
sulted in an odds ratio (OR) of 3.18 (95%CI 0.76 – 13.24). The AUC of PCT <0.5 µg/L 
for confirmed viral disease was 0.629 (95%CI 0.46 – 0.80). The combined biomark-
er model for confirmed viral disease versus confirmed non-viral disease consisted 
of a PCT level of <0.5 µg/L, a TRAIL level of >93.83 pg/ml and an IP-10 level of 
> 911.43pg/ml. The binary logistic regression analysis of the combined biomarker 
model resulted in an OR of 5.10 (95%CI 0.96 – 27.04). The AUC of the combined 
biomarker model was 0.84 (95%CI 0.72 – 0.97). AUC is shown in figure 4.
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Figure 4.  
Receiver-Operator-Curve of the combined biomarker model, consisting of optimal cut-off values of 
TRAIL (≥93.83 pg/ml), IP-10 (≥911.49 pg/ml) and procalcitonin (<0.5 µg/L) in differentiation between 
Confirmed viral disease versus non-viral disease 
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DISCUSSION
In this study of febrile ED patients, there was a strong association between elevated 
levels of TRAIL and IP-10 and the presence of viral infection. The combination of 
TRAIL and IP-10 with PCT resulted in an even higher accuracy in discriminating con-
firmed viral disease from confirmed non-viral disease.
Oved et al.11 reported TRAIL levels to be lower in patients with bacterial infections. 
In our study, we demonstrated that this finding is reproducible in an undifferenti-
ated cohort of ED patients. This result further strengthens the evidence that TRAIL 
may be utilized as a biomarker for viral disease in clinical practice. Although a sig-
nificant difference in IP-10 levels between groups in our population could not be 
observed, a trend towards significance was shown. Larger validation studies may 
show the discriminative value of IP-10 in more detail.
This is the first study to report on biological markers for differentiating between 
confirmed viral and confirmed non-viral infection in an ED setting. These biomark-
ers may be helpful in ED treatment decision-making. Currently, the initiation of an-
tibiotics in the ED is based on the rule-out of bacterial infections2,3. Additional viral 
rule-in or rule-out may further reduce the over-prescription of antibiotics in the ED. 
However, the clinical significance of TRAIL and IP-10 in the treatment of febrile pa-
tients is still unclear. There is a need for larger validation studies of these novel bio-
markers; a larger follow-up study is currently being set-up at our institution. Most 
importantly, the cut-off values have to be clinically validated in order to use TRAIL 
and IP-10 to guide antibiotic therapy. 
The findings of this study are in line with theoretically favorable characteristics of 
TRAIL and IP-10. The interferon-gamma (IFN-γ) pathway is activated in reaction to 
viral infections15. TRAIL is in turn upregulated by IFN alpha (IFN-α) and beta (IFN-β), 
and by IFN-γ, produced autocrinely by T-helper cells. TRAIL binds to the TRAIL re-
ceptor and induces apoptosis of the infected cells12,16-18. 
IP-10 is also upregulated by IFN-γ, and less elevated in bacterial infections com-
pared to viral infections11,19. This in line with our findings.  IP-10 is a CXC chemokine 
secreted by several cell types including macrophages and is induced in response to 
diverse stimuli, such as IFN α, β and γ ,but also directly by viruses20. IP10 has been 
shown to play an important role in the recruiting of virus-specific T-cells and viral 
clearance in simian varicella virus infection21 and during acute hepatitis C infection22.
Limitations
A selection of patients of a cohort with undifferentiated febrile patients was used. 
Of a total of 107 patients, there was a definitive diagnosis in 54 patients. The cut-off 
values found in our analyses were derived from a small sample size. The cut-off val-
ues used in this study show additional accuracy in the diagnosis of confirmed viral 
disease in a combined biomarker model, and thereby suggest that both TRAIL and 
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IP-10 are of discriminatory value. However, these cut-off values are not validated in 
a sufficiently large cohort and can therefore not be utilized in clinical practice yet. 
Notwithstanding, these findings are a proof of principle for the use of TRAIL and 
IP-10 in the ED. In this study, patients with either a confirmed bacterial infection, a 
confirmed viral infection, or confirmed non-infectious disease were included. We 
excluded patients with both confirmed bacterial and viral infections. In clinical prac-
tice, it may be difficult to distinguish a community-acquired pneumonia from a viral 
upper respiratory infection with bacterial superinfection. Our cohort was a sample 
of an ED population, consisting of a variety of viral and bacterial pathogens. The pa-
tients in the confirmed viral infections group mainly had respiratory tract infections, 
whereas the patients in the confirmed bacterial infections group had more diverse 
sites of infection. Besides respiratory tract infections, they also had urinary tract 
and skin infections. It could well be possible that different inflammatory cascades 
are activated in different sites of infection. This may account for the differences in 
TRAIL and IP-10 levels between confirmed viral and confirmed bacterial infections. 
However, in this clinical study, a difference between markers is shown nonetheless, 
and these findings advocate further research. At the moment, TRAIL and IP10 are 
only available as Enzyme Linked Immunosorbent Assay (ELISA), making them less 
suitable for clinical use in the ED. Further studies in larger ED cohorts are necessary 
to establish the added value of these viral infection markers in order to motivate 
diagnostic companies to develop immunoassays on automated immunochemistry 
platforms with more favorable turn-around times (i.e. < 60 minutes) making these 
markers more suitable for ED use.
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CONCLUSION
Measurement of TRAIL and IP-10 in febrile patients in the ED may be of added value 
in the diagnostic process, with elevated levels indicating the presence of confirmed 
viral infection. The addition of TRAIL and IP-10 to PCT in differentiating between 
confirmed viral and confirmed non-viral disease in a combined biomarker model 
results in a higher discriminating value than the single biomarkers on their own. 
These results are a proof of principle. Validation in a larger cohort may determine 
the clinical value of TRAIL and IP-10 in the ED. 
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ABSTRACT 
Background 
To effectively reduce the unnecessary use of broad spectrum antibiotics in the 
emergency department(ED), patients with bacterial infections need to be identified 
accurately. We investigate the diagnostic value of a combination of biomarkers for 
bacterial infections CRP and PCT, together with biomarkers for viral infections, TRAIL 
and IP-10, in identifying bacterial infections in a general ED population with fever.
Methods 
This is a sub-study in the HiTEMP cohort. Patients with fever were included during 
ED triage, and blood samples were obtained. Using both diagnostics and expert 
panel analysis, all patients were classified as having either (suspected or confirmed) 
bacterial, or non-bacterial disease. Using multivariable logistic regression analy-
sis, three biomarker models were calculated, model 1:(CRP,TRAIL,IP-10), model 
2:(PCT,TRAIL,IP-10) and model 3:(CRP, PCT, TRAIL,IP-10).
Results 
A total of 315 patients were included, of whom 228 patients had a bacterial in-
fection. The areas under the curve for the combined models were, for model 1: 
0.730(95%CI 0.665–0.795), for model 2: 0.748 (95%CI 0.685–0.811), and for model 
3: 0.767(95%CI 0.704–0.829).
  
Discussion 
These findings show that a combination of CRP, PCT, TRAIL and IP-10 can identify 
bacterial infections with higher accuracy than single biomarkers and combinations 
of a single bacterial biomarkers combined with TRAIL and IP-10.  
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INTRODUCTION
Antibiotic resistance is a threat to global health1,2. The widespread use of broad 
spectrum antibiotics contributes to the selection pressure of antibiotic resistant 
bacteria3,4. 
Patients with suspected infections in the emergency department (ED) are often 
treated with broad spectrum antibiotics, because bacterial infections cannot be 
ruled out5. Currently, the diagnostic workup in EDs consists of clinical assessment 
and laboratory investigations such as C-reactive protein (CRP) and procalcitonin 
(PCT). PCT-guided therapy has successfully reduced antibiotics in selected popula-
tions of patients with respiratory complaints in the ED6-8. However, in a general ED 
population, PCT-guided therapy proved to be ineffective, due to inaccuracy of PCT 
in differentiating between bacterial and non-bacterial disease9. In order to reduce 
antibiotics prescriptions in a general ED population, the discrimination of bacteri-
al from non-bacterial disease has to be as accurate as possible. Recently, studies 
have shown that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 
and interferon-gamma induced protein-10 (IP-10), two immune response derived 
biomarkers, can accurately differentiate between viral and bacterial infections in 
the ED, both as single markers and in combination with CRP or PCT10-12. These study 
populations consisted either of young children, or had highly selected patient pop-
ulations. Moreover, the combination of both CRP and PCT, together with TRAIL and 
IP-10, has not been investigated in an adult ED population. Furthermore, the clinical 
value of the combination of these biomarkers has not been fully elucidated.
The aim of this study is to investigate the predictive value of a combination of CRP, 
PCT, TRAIL and IP-10 in diagnosing bacterial infections in a general ED population. 
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METHODS
This was a sub-study of the HiTEMP study cohort, which is described previously9,13. 
In brief, the cohort of this study consisted of adult patients who visited the ED of 
the Erasmus University Medical Center between August 2014 and June 2016 with a 
temperature of ≥38.2 ˚C/ ≥100.7 ˚F in ED triage. 
Study population
All adult febrile patients were eligible for inclusion. All patients gave written in-
formed consent. Pregnant patients, patients with a solid organ transplant, severe 
neutropenia, or active chemotherapy, post-operative patients (up to 72 hours), and 
patients with a confirmed surgical diagnosis before ED triage and patients with a life 
expectancy of less than 24 hours were excluded. Patients who opted out of partici-
pating in additional studies after the HiTEMP study, were excluded. 
Study design 
In the ED, blood samples were obtained for clinical use and for additional research 
purposes. In all patients, CRP, PCT, TRAIL and IP-10 were determined. In this study, 
predictive values of three combined models of multiple biomarkers were investi-
gated, for differentiating between bacterial and non-bacterial disease. All models 
contained optimal cut-off values of TRAIL and IP-10. Model 1 further included CRP, 
model 2 included PCT, and model 3 included both CRP and PCT.
 
Primary outcome
The primary outcome was the presence of either a confirmed or suspected bacte-
rial infection, and defined as “bacterial infection”. Patients were classified in either 
the confirmed and suspected bacterial infections group, or the non-bacterial infec-
tions group, consisting of patients with confirmed and suspected viral infections, 
patients with non-infectious fever, and patients with undetermined disease, but not 
suspected of bacterial infection. 
Confirmed infections were defined as clinically significant cultures. The presence 
of a coagulase negative staphylococcus (CNS) in a blood culture was deemed as 
contamination. Suspected bacterial infections were determined by an expert panel 
analysis, a structured medical chart review by two independent physicians, using 
predefined criteria (suppl 1). In case of disagreement, a third expert physician acted 
as referee. In case of the presence of both a confirmed viral and bacterial infection, 
the patient was classified in the bacterial infections group, because a bacterial in-
fection was considered clinically relevant. 
Data analysis
Differences in baseline characteristics were compared between patients with bac-
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terial infections and patients with non-bacterial disease using Fisher’s exact test for 
dichotomous variables and independent samples T-test for continuous variables, 
and Mann Whitney U test for not normally distributed continuous variables. 
Accuracy of CRP, PCT, TRAIL and IP-10 for bacterial infections was reported as sen-
sitivity and specificity and area under receiver operating characteristic curve (AUC) 
for optimal cut-offs of individual biomarkers. We calculated the optimal cut-off of 
CRP, PCT, TRAIL and IP-10 using Youden’s index. For CRP and PCT, the optimal cut-off 
was defined as the lowest value that predicted the presence of a bacterial infection. 
TRAIL and IP-10 were used as a rule-out of bacterial infections. The optimal cut-off 
was defined as the highest value that still predicted the presence of a bacterial 
infection. Higher values of TRAIL and IP-10 predicted an absence of a bacterial in-
fection. Sensitivity and specificity for CRP, PCT, TRAIL and IP-10 in diagnosing bacte-
rial infections were reported with binominal proportion confidence intervals (CIs), 
using the Clopper-Pearson method. We created three multivariable binary logistic 
regression models to predict combined accuracy of bacterial infections. The models 
included the optimal cut-offs of the following biomarkers, model 1: CRP, TRAIL, IP-
10, model 2: PCT, TRAIL, IP-10, and model 3: CRP, PCT, TRAIL, IP-10. An AUC for each 
of the models was reported. All statistical tests were two-sided with a significance 
level of 0.05. Data-analysis was performed with the statistical package for the social 
sciences (SPSS), version 23, IBM cooperation.
 
RESULTS
In the HiTEMP study, a total of 449 patients were included in the Erasmus Universi-
ty Medical Center. In this analysis, the total number of patients 315. Nine patients 
did not consent for additional studies other than the HiTEMP study, and in 125 
patients, insufficient additional material for analysis of TRAIL and IP-10 was avail-
able. Of these 315 patients, there was no respiratory rate available in 95 patients, 
and in two patients no blood pressure was available because these variables were 
not measured in ED triage. Of all patients included in the study, 228 had either 
a suspected or confirmed bacterial infection. Of these 228 patients, 7 (3%) had a 
concomitant confirmed viral infection. Another 87 patients were not suspected of 
having a bacterial infection. Of these 87 patients, 10 (12%) had a confirmed viral 
infection, 48 (55%) had a suspected viral infection, 23 (26%) had confirmed non-in-
fectious fever, and in 6 (7%) patients the cause of fever was unknown (Table 1). 
There were statistically significant differences baseline characteristics between pa-
tients with bacterial and non-bacterial disease in age (p = 0.00), temperature (p = 
0.02), malignancy as comorbidity (p = 0.01) and diabetes mellitus as comorbidity (p 
= 0.00). The AUC for bacterial infections for CRP was 0.679(95% CI 0.613 – 0.746), 
for PCT 0.680 (95% CI 0.619 – 0.742), and the ROC for ruling out bacterial infections 
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was 0.607 (95% CI 0.532 – 0.683) for TRAIL and 0.665 (0.597 – 0.734) for IP-10. 
The ROCs are reported in figure 1. 
The optimal cut-offs, Youden’s index, sensitivity and specificity were reported in 
table 2. In multivariable logistic regression analysis, the odds ratios (OR) of the op-
timal cut-offs for biomarkers for bacterial infections in model 1 were: for CRP, OR 
3.07 (95% CI 1.78 – 5.31), for TRAIL OR 1.94 (95% CI 1.05 – 3.58) and IP-10 OR 2.58 
Table 1. Baseline characteristics
All (n = 315) Non-bacterial infections (n = 87) Bacterial infections (n = 228) P-value
Demographic characteristics
Age median [IQR] 58 [39 - 69] 47 [27 - 63] 61 [45 - 70] p < 0.001
Female sex n (%) 149 (47) 40 (46) 109 (48) p = 0.80
Vital signs at presentation
Temperature median [IQR] 38.7 [38.5 - 39.2] 38.6 [38.4 - 39.1] 38.8 [38.5 - 39.3] p = 0.15
Heart rate median [IQR] 105 [95 - 120] 107 [90 - 120] 105 [95 - 120] n = 229 p = 0.96
Systolic bloodpressure median [IQR] n = 313 130 [118 - 145] 128 [117 - 140] n = 85 130 [119 - 146] p = 0.18
Diastolic bloodpressure median [IQR] n = 313 75 [67 - 85] 75 [69 - 85] n = 85 75 [66 - 85] p = 0.42
Respiratory rate median [IQR] n = 220 20 [16 - 25] 24 [16 - 24] n = 63 20 [16 - 25] n = 159 p = 0.11
Comorbidity
Diabetes n (%) 50 (16) 5 (6) 45 (20) p = 0.00
Malignancy n (%) 69 (22) 10 (12) 59 (26) p = 0.01
HIV n (%) 16 (5) 6 (7) 10 (4) p = 0.39
Current medication use
Current antibiotics use (before ED visit)n (%) 42 (13) 7 (8) 35 (15) p = 0.10
Corticosteroids n (%) 45 (14) 16 (18) 29 (13) p = 0.21
Oral anticoagulants n (%) 37 (12) 6 (7) 31 (14) p = 0.12
Acetylsalicylic acid n (%) 32 (10) 6 (7) 26 (11) p = 0.30
Biomarkers
CRP in mg/L median [IQR] 62 [19 - 142] 24 [13 - 82] 71 [ 28 - 161] p < 0.001*
PCT in mcg/L median [IQR] 0.22 [0.10 - 0.65] 0.13 [0.07 - 0.27] 0.31 [0.11 - 1.12] p < 0.001*
TRAIL in pg/ml median [IQR] 28.0 [0.0 - 74.5] 37.6 [0.0 - 145.0] 24.8 [0.0 - 62.4] p = 0.00*
IP-10 in pg/mL median [IQR] 470 [197 - 825] 774 [340 - 825] 351 [183 - 723] p < 0.001
Clinical syndrome at presentation
Skin n (%) 31 (10) 1 (1) 30 (13)
Respiratory n (%) 120 (38) 45 (52) 75 (33)
Urogenital n (%) 65 (21) 0 (0) 65 (28)
Abdominal n (%) 35 (11) 4 (5) 31 (14)
Central nervous system n (%) 3(1) 0 (0) 3 (1)
Other n (%) 4 (1) 0 (0) 4(2)
Noninfectious n (%) 25 (8) 24(28) 1(0)
Unknown n (%) 34 (11) 13 (15) 21 (9)
Final diagnosis after expert review
Suspected bacterial infections n (%) 113 (36) 0 (0) 113 (50)
Confirmed bacterial infections n (%) 115 (37) 0 (0) 115 (50)
Suspected viral infections n (%) 48 (15) 48 (55) 0 (0)
Confirmed viral infections n (%) 17 (5) 10 (12) 7 (3)
Confirmed non-infectious fever n (%) 23 (7) 23 (26) 0 (0)
Fever of unknown etiology n (%) 6 (2) 6 (7) 0 (0)
Additional diagnostics
Bacteremia n (%) 58 (18) 1 (1) 57 (18)
* P-values were calculated with Fisher's exact test for dichotomous variables, and independent samples T-test for continuous variables. Continuous variables 
that were not normally distributed, were calculated using the Mann-Whitney U test with an *. ** This posititive blood culture was a coagulase negative 
staphylococcus, and was considered contamination. CRP: C-reactive protein, ED: emergency department, HIV: human immunodeficiency virus, IQR: 
interquartile range,  IP-10: interferon-gamma induced protein-10, PCT: procalcitonin
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 Figure 1. ROC curves of CRP, PCT, TRAIL and IP10 for suspected and confirmed bacterial infections 
 
AUC of CRP and PCT for suspected and confirmed bacterial infections 
 
CRP: AUC 0.679 (95% CI 0.613 – 0.746) 
PCT: AUC 0.680 (95% CI 0.619 – 0.742) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUC of TRAIL and IP-10 for ruling out suspected and confirmed bacterial infections 
 
TRAIL: AUC 0.607 (95% CI 0.532 – 0.683) 
IP-10: AUC 0.665 (95% CI 0.597 – 0.734) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUC: Area under curve, CRP: C- reactive protein, IP-10: interferon-gamma induced protein-10 PCT: Procalcitonin, ROC curve: 
Receiver operator characteristic curve, TRAIL:  tumor necrosis factor-related apoptosis-inducing ligand 
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(95% CI 1.48 – 4.51). 
The ORs for model 2 were: for PCT, OR 4.10 (95% CI 2.22 – 7.63), for TRAIL, OR 1.79 
(95% CI 0.97 – 3.33) and IP-10, OR 3.45 (95% CI 1.94 – 6.12). The ORs for model 3 
were: for CRP, OR 2.33 (95% CI 1.31 – 4.13), for PCT OR 3.30 (95% CI 1.74 -6.28), for 
TRAIL OR 1.56 (95% CI 0.82 – 2.95) and IP-10 OR 3.09 (95% CI 1.72 – 5.55).
The AUCs of the combined optimal cut-offs of biomarkers models for bacterial in-
fections were, for model 1: AUC of 0.730 (95% CI 0.665 – 0.795), for model 2: 0.748 
(95% CI 0.685 – 0.811), and for model 3:  0.767 (95% CI 0.704 – 0.829). The ROCs 
were reported in figure 2.
 
 
Figure 2. ROC curves of combined biomarker models for suspected and confirmed bacterial infections 
 
Model 1: AUC 0.730 (95% CI 0.665 – 0.795) 
Model 2: AUC 0.748 (95% CI 0.685 – 0.811) 
Model 3: AUC 0.767 (95% CI 0.704 – 0.829) 
 
AUC: Area under curve, CRP: C- reactive protein, IP-10: interferon-gamma induced protein-10 PCT: Procalcitonin, ROC curve: 
Receiver operator characteristic curve, TRAIL:  tumor necrosis factor-related apoptosis-inducing ligand 
118
Identifying patients with bacterial infections using a combination of biomarkers in the emergency department
DISCUSSION
The results of this study showed that a combined model containing optimal cut-
offs of CRP, PCT, TRAIL and IP-10 predicted the presence of bacterial infections with 
higher probability than individual measurements of the currently used biomarkers 
CRP and PCT. Moreover, the model combining both CRP and PCT, together with 
TRAIL and IP-10, was more accurate than models with either CRP or PCT as a single 
marker. 
A previous study by van Houten et al. showed that a combination of CRP, TRAIL and 
IP-10 was superior in diagnosing bacterial infections compared to PCT in young chil-
dren11. Another study, in adult ED patients, showed that PCT in combination both 
TRAIL and IP-10 was more accurate in ruling in viral infections in patients with con-
firmed infections than individual measurements of these biomarkers. Our results 
are in line with these findings. Furthermore, by comparing three combined models, 
we showed that a combination of both CRP and PCT with TRAIL and IP-10 is superior 
than either individual biomarker.
In our results, we found a lower AUC than other studies that used a combination 
of biomarkers in differentiating between bacterial and non-bacterial disease11,14. 
These studies both used a previously described combination, called the “signature 
test” or “index test”10. This test is a logistic regression formula with predefined cut-
off levels of CRP (40mg/l), TRAIL (70pg/ml) and IP-10 (500 pg/ml). Furthermore, in 
the index test, patients were divided into three groups, classified as either having 
a viral, or equivocal, or bacterial infection. The results presented in these studies 
showed the accuracy in differentiating bacterial from viral infections, with exclusion 
of the equivocal group, such as in the study by van Houten et al., who reported a 
AUC of 0.90 (95% CI 0.86 – 0.95). To effectively reduce antibiotics in patients with 
infectious diseases in the ED, bacterial infections have to be ruled-out unequivo-
cally. When diagnostic uncertainty remains, biomarker-guided therapy is not effec-
tive9. Therefore, future prospective interventional studies should investigate if this 
approach, with a classification with three categories, or a category which consists 
of patients with a very low probability of having a bacterial infection, may reduce 
prescription of antibiotics in patients in this category. 
An additional explanation of the differences in diagnostic accuracy between previ-
ous studies and our results, is the selection of study populations. Van Houten et al. 
only included children between 2 and 60 months of age, with either a suspected 
respiratory tract infection, or fever without source11. In pediatric patients, fever is 
most commonly the result of respiratory infections15. In this study, only 38% of pa-
tients had respiratory focus of fever. Differences in etiology of fever may account for 
a lower accuracy in our population.
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Limitations
In this study, we used a cohort of the HiTEMP study9. The main inclusion criterion 
was fever. Although this is an objectively measurable variable, it created a selec-
tion bias, because patients with suspected infections without fever were excluded 
from participation. As in similar studies on differentiating between bacterial and 
non-bacterial disease, the reference standard of suspected and confirmed bacterial 
infections we used in our study is no gold standard11,16. In the structured medical 
chart review, one of the criteria was “clinical improvement under antibiotics”. Some 
of the patients who were classified using this criterion, may also have improved 
without antibiotics. Therefore, there may have been overestimation of the number 
of patients in the group of suspected bacterial infections, resulting in a lower accu-
racy of the combination of biomarkers. The multivariable logistic regression model 
with a combination of biomarkers was calculated using optimal cut-offs. The use 
of these binary cut-offs made the model user-friendly, at the cost of accuracy. Fur-
thermore, this model was not validated. Therefore, we suggest a validation study 
of a multivariable model including biomarkers CRP, PCT, TRAIL and IP-10, with the 
incorporation of a group with intermediate probability of bacterial infections. 
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CONCLUSION
Using a combination of biomarkers CRP, PCT, TRAIL and IP-10, bacterial infections 
could be diagnosed with higher accuracy compared to single biomarkers or a com-
bination of either CRP or PCT with TRAIL and IP-10, in adult patients with fever in a 
general ED. Interventional studies may determine the clinical value of the combina-
tion of these biomarkers. 
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ABSTRACT
Objective 
In the emergency department(ED), it is important to identify patients with sepsis 
early, in order to start optimal treatment. Risk stratification in the ED is performed 
with clinical scores SIRS and qSOFA. The objective of this study is to compare the 
predictive values of SIRS and qSOFA with biomarkers C-reactive protein(CRP), pro-
calcitonin(PCT), proadrenomedullin(proADM), pro-endothelin-1(proET-1) and solu-
ble urokinase-type plasminogen activator receptor(suPAR) for prediction of inten-
sive care unit(ICU) admission and 30-days and 90-days mortality.
Methods 
Post-hoc analysis of the HiTEMP study, a multicenter study in a general ED popula-
tion with fever. Patients were followed-up for 90 days. In all patients, blood samples 
for biomarker analysis were obtained in the ED. Single-center study, Erasmus Uni-
versity Medical Center, Rotterdam, the Netherlands. All adult patients who visited 
the ED with fever were eligible. Exclusion criteria were: no written informed con-
sent, pregnancy, solid organ transplant, severe neutropenia, or current chemother-
apy, post-operative patients, and moribund patients. Only patients with complete 
90-days follow-up were included in analysis.
Results 
A total of 353 patients were included in the study. Nine patients were admitted to 
the ICU, 9 patients died within 30 days, and a total of 13 within 90 days. For ICU ad-
mission, clinical scores had similar predictive values as biomarkers, (AUC(95%CI) of 
SIRS 0.727 (0.542-0.912), qSOFA 0.688 (0.499-0.876), CRP 0.528 (0.322-0.734),PCT 
0.570 (0.352 - 0.788), proADM 0.730 (0.614-0.846), proET-1 0.773 (0.660-0.886), 
suPAR 0.672( 0.488-0.857), respectively). For both 30-days and 90-days mortality, 
biomarkers outperformed clinical scores, (AUC(95%CI) for 30-days mortality: SIRS 
0.522 (0.317-0.726), qSOFA 0.518 (0.312-0.723), CRP 0.742 (0.610-0.873), PCT 
0.668 (0.481-0.855), proADM 0.836 (0.743-0.930), proET-1 0.945 (0.896-0.993), 
suPAR 0.842( 0.685-1.000), respectively). 
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Conclusion 
Biomarkers proADM, proET-1 and suPAR, and to a lesser extent CRP and PCT were 
more accurate in predicting mortality than clinical scores SIRS and qSOFA. ProADM, 
proET-1 and suPAR and clinical scores predicted ICU admission with comparable 
accuracy. Biomarkers can be used for timely diagnosis of a severe course of disease 
in sepsis. 
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INTRODUCTION
Sepsis is a global health problem causing high rates of intensive care unit (ICU) ad-
missions and mortality1,2. 
In the emergency department (ED), patients who are at risk for developing a severe 
course of disease need to be identified early, so timely treatment can be initiated, 
and patients will receive optimal sepsis care3,4. 
Sepsis is a multi-system disease, with involvement of different inflammatory path-
ways, the coagulation system and the endothelial system5,6. Currently, physicians 
in the ED classify disease severity with clinical scores, such as the systemic inflam-
matory response syndrome (SIRS) criteria and with the quickSOFA (qSOFA) score3,7. 
These clinical scores have fair accuracy for adverse outcome prediction8. However, 
these clinical scores mainly include vital signs, and have limited predictive value in 
specific patient groups, such as the elderly9.
Biomarkers can predict disease severity by indicating the state of activation of path-
ways in different systems, even before patients have abnormal vital parameters. 
Procalcitonin (PCT) can be used as a prognostic marker for severity of sepsis in 
the ED and ICU10,11. Indicators of activation of the microvascular system and endo-
thelial dysfunction, mid-regional proadrenomedullin (proADM), pro-endothelin-1 
(proET-1) and soluble urokinase-type plasminogen activator receptor (suPAR), a 
biomarker for activation of inflammatory systems, can predict mortality in patients 
with community acquired pneumonia and in patients with sepsis12-16. 
Despite the multi-system involvement in sepsis, a comparison of the predictive val-
ue of clinical scores and biomarkers of both inflammatory activity and endothelial 
dysfunction has not been studied extensively in a general ED population. 
The aim of this study is to determine and compare the predictive value of clini-
cal scores with single measurements of biomarkers CRP, PCT, proADM, proET-1 and 
suPAR on ICU admission and all-cause 30-days and 90-days mortality in a general 
ED population. 
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METHODS
This study was a post-hoc study of the HiTEMP (Higher diagnostic accuracy and 
cost-effectiveness using procalcitonin in the treatment of emergency medicine pa-
tients with fever) study cohort, which has been described previously11,17. In brief, 
the cohort of this study consists of adult patients who visited the ED of the Erasmus 
University Medical Center between August 2014 and June 2016 with a temperature 
of ≥38.2 ˚C/ ≥100.7 ˚F in ED triage. 
Study population
All adult febrile patients were eligible for inclusion. All patients gave written in-
formed consent. Pregnant patients, patients with a solid organ transplant, severe 
neutropenia, or current chemotherapy, post-operative patients (up to 72 hours), 
and patients with a confirmed surgical diagnosis before ED triage and patients with 
a life expectancy of less than 24 hours were excluded. In this post-hoc analysis only 
patients with a complete follow-up were included, to ensure validity of data on 
mortality.
Study design 
In the ED, blood samples were obtained for clinical use and for additional research 
purposes. Patients were followed up after 30 days by a telephone interview, after 90 
days by contacting their general practitioner and with medical chart review. 
Outcomes
The primary outcomes of the study were ICU admission within 30 days after ED 
visit, and mortality within 30 and 90 days after ED visit. 
Measurements
In all patients, we calculated a SIRS and qSOFA score. In case of missing values in 
vital parameters, we set the missing values to a non-divergent value, so the pa-
tients would not score an extra point on the clinical score. The assumption was 
that the triage nurse would have reported all vital parameters if an abnormal value 
was expected. Furthermore, in all patients, CRP, PCT, proADM, proET-1 and suPAR 
levels were measured from blood samples obtained in the ED. CRP and PCT mea-
surements were performed on the routine analyzer of the clinical chemistry lab-
oratory (using an electro-chemiluminiscent immunoassay (ECLIA) (Roche diagnos-
tics, Brahms, Henningsdorf, Germany). ProADM and proET-1 measurements were 
performed on a Kryptor Compact Plus in Thermofisher laboratories, Henningsdorf, 
Germany. ELISA SuPAR measurements (Virogates, Denmark) were performed in NU-
TOPI laboratories, Poznan, Poland.
128
Early identification of disease severity using biomarkers in the emergency department
Data analysis
Using vital parameters measured at ED admission, we calculated the SIRS and qSO-
FA clinical scores. For the primary outcomes, baseline differences and differences 
in qSOFA, SIRS and biomarkers were analyzed using the Fisher’s exact test for di-
chotomous variables, with the independent T-test for normally distributed contin-
uous variables, and with the Mann-Whitney U test for non-normally distributed 
variables. For the outcomes ICU admission and 30-days and 90-days mortality, re-
ceiver operator characteristic (ROC) curves were used to calculate the area under 
the curve (AUC) for each biomarker and the SIRS and qSOFA severity scores. We cal-
culated the optimal cut-off for each biomarker with Youden’s index18. The optimal 
cut-offs were used to calculate sensitivity and specificity for the primary outcomes, 
binomial proportion confidence intervals (CIs) were calculated using the using the 
Clopper-Pearson method. All statistical tests were two-sided with a significance lev-
el of 0.05, unless otherwise specified. Data-analysis was performed with the statis-
tical package for the social sciences (SPSS), version 23, IBM cooperation. 
 
RESULTS
Of a total of 449 patients who were included, 9 patients did not give consent for 
additional studies, there were insufficient additional blood samples to determine 
all biomarkers from 68 patients, and 19 patients did not have complete 90-days 
follow-up. This resulted in a total number of 353 patients who were included in the 
analysis. Of the total cohort, 9 (3%) patients were admitted to the ICU within 30 
days, of whom 8 within 72 hours after ED visit. Nine patients (3%) died within 30 
days of their ED visit. Four patients died within the period of 31 and 90 days after ED 
visit, making the total of patients who died within 90 days 13(4%). 
Baseline characteristics
Baseline characteristics are reported in table 1. In 108 patients, no respiratory rate 
was available, and in 2 patients no blood pressure was available because these data 
were not recorded in ED triage. Between patients who were admitted to the ICU, 
there were statistically significant differences in baseline characteristics for age (p = 
0.03), diabetes as comorbidity (p = 0.05) and respiratory rate (n = 237) (p <0.001). 
Between 30-days survivors and non-survivors, there were statistically significant dif-
ferences in age, (p = 0.01), sex (p = 0.04), malignancy as comorbidity (p = 0.02) and 
respiratory rate (n = 237) (p = 0.00). Between 90-days survivors and non-survivors, 
there were statistically significant differences in age (p = 0.01), sex (p = 0.03) and 
malignancy as comorbidity (p = 0.01) (supplement 1).
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Biomarkers
Patients who were admitted to the ICU had significantly higher levels of proADM, 
proET-1, SIRS score, and a qSOFA score in the ED than patients who were not admit-
ted to the ICU (proADM (p = 0.02), proET-1 (p = 0.02), SIRS (0.01), qSOFA (p = 0.01)). 
Patients who died within 30 days after ED visit, had significantly higher levels of 
CRP, proADM, proET-1 and suPAR than survivors (CRP (p = 0.02), proADM (p = 0.01), 
proET-1 (p <0.001), suPAR (p <0.001)). 
Patients who died within 90 days after ED visit, had significantly higher levels of PCT, 
proADM, proET-1 and suPAR than survivors (CRP (p = 0.05), PCT (p = 0.01), proADM 
(p < 0.001), proET-1 (p <0.001), suPAR (p <0.001) (supplement 1)). The ROC curves 
of the primary endpoints are reported in figure 1. For ICU admission, proADM, pro-
ET-1, and SIRS and qSOFA scores had statistically significant predictive values. For 
both 30-days and 90-days mortality, CRP, PCT, proADM, proET-1 and suPAR had sta-
tistically significant predictive values. The AUCs of biomarkers and clinical scores are 
reported in table 2.
Table 1. Baseline characteristics
All (n = 353) ICU admissions (n = 9) 30-days non-survivors (n = 9) 90-days non-survivors (n = 13)
Demographic characteristics
Age median [IQR] 59 [41 - 69] 68 [60 - 76] 75 [61 - 77] 72 [54 - 77]
Female sex n (%) 163 (46) 6 (67) 1 (11) 2 (15)
Vital signs at presentation
Temperature median [IQR] 38.8 [38.4 - 39.2] 38.8 [38.4 - 39.5] 38.6 [ 38.5 - 39.0] 38.6 [38.4 - 38.9]
Heart rate median [IQR] 105 [92 - 120] 113 [98 - 122] 110 [89 - 126] 110 [95 - 126]
Systolic bloodpressure median [IQR] n = 351 130 [119 - 145] 127 [107 - 146] 121 [114 - 126] 121 [113 - 139]
Diastolic bloodpressure median [IQR] n = 351 76 [67 - 85] 85 [60 - 94] 80 [72 - 86] 78 [64 - 84]
Respiratory rate median [IQR] n = 245 20 [16 - 25] 28 [23 - 40] (n = 8) 32 [21 - 40] (n = 5) 25 [19 - 38](n = 8)
Comorbidity
Malignancy n (%) 73 (21) 3 (33) 5 (56) 7 (54)
Diabetes mellitus n (%) 59 (17) 4 (44) 2 (22) 2 (15)
HIV n (%) 11 (3) 0 (0) 0 (0) 0 (0)
Clinical scores
SIRS median [IQR] 3 [2 -3] 3 [3 - 4] 3 [2 - 3] 3 [2 - 3]
qSOFA median [IQR] 0 [0-1] 1 [0 - 1] 0 [0 - 1] 0 [0 - 1]
Biomarkers
CRP in mg/L median [IQR] 61 [18 - 143] 101 [17 - 155] 129 [96 - 229] 122 [79 - 198]
PCT in mcg/L median [IQR] 0.23 [0.09 - 0.82] 0.31 [0.08 - 10.09] 1.21 [0.25 - 1.76] 1.21 [0.47 - 2.33]
ProADM in nmol/L median [IQR] 0.99 [0.70 - 1.49] 1.41 [1.20 - 2.00] 2.04 [1.42 - 3.26] 2.21 [1.65 - 3.26]
ProET-1 in pmol/L median [IQR] 90.6 [63.6 - 127.4] 139.2 [100.5 - 239.3] 301.9 [ 179.1 - 573.0] 255.1 [177.0 - 485.9]
suPAR in ng/mL median [IQR] 3.73 [2.91 - 5.46] 5.02 [ 3.21 - 10.39] 9.77 [5.96 - 13.69] 9.77 [5.04 - 13.69]
Etiology of fever
Confirmed bacterial infection n (%) 122 (35) 4 (44) 3 (33) 6 (46)
Confirmed viral infection n (%) 28 (8) 1 (11) 0 (0) 0 (0)
Confirmed bacteremia n (%) 64 (18) 3 (33) 1 (11) 3 (23)
Initial ED treatment
Antibiotics in ED because of SIRS n (%) 167 (47) 7 (78) 6 (67) 8 (62)
Antibiotic therapy started n (%) 252 (72) 7 (78) 8 (89) 12 (92)
Disposition
Hospital admission n (%) 259 (73) 9 (100) 8 (89) 12 (92)
ICU admission n (%) 9 (3) 9 (100) 3 (33) 3 (23)
30-days mortality n (%) 9 (3) 3 (33) 9 (100) 9 (69)
90-days mortality n (%) 13 (4) 3 (33) 9 (100) 13 (100)
CRP: C-reactive protein, ED: emergency department, HIV: human immunodeficiency virus, ICU: intensive care unit, IQR: interquartile range, PCT: procalcitonin, proADM: proadrenomedullin, 
proET-1: pro-endothelin-1, qSOFA: quick SOFA, SIRS: systemic inflammatory response syndrome, suPAR: soluble urokinase-type plasminogen activator receptor.
130
Early identification of disease severity using biomarkers in the emergency department
Figure 1. ROC curves of clinical scores and biomarkers for primary outcomes 
 
 
a. ROC curve of clinical scores and biomarkers for intensive care unit admission 
 
 b. ROC curve of clinical scores and biomarkers for 30-days mortality 
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Optimal cut-offs and Youden’s index for ICU admission, 30-days and 90-days mortal-
ity of CRP, PCT, proADM, proET-1, suPAR and SIRS and qSOFA criteria are reported 
in table 2. 
Sensitivity and specificity of clinical scores and biomarkers for primary outcomes 
are reported in table 2. For ICU admission within 30 days after ED visit, clinical 
scores had predictive values that were comparable to the predictive values of bio-
markers proADM, proET-1 and suPAR, and to a lesser extent CRP and PCT. For both 
30-days and 90-days mortality, all biomarkers had higher predictive values than clin-
ical scores.
c. ROC curve of clinical scores and biomarkers for 90-days mortality 
 
 
Areas under curve are reported in table 2. 
 
qSOFA: quick SOFA, ROC: Receiver operator curve, SIRS: systemic inflammatory response syndrome, ROC 
curve: Receiver operator characteristic curve, suPAR: soluble urokinase-type plasminogen activator 
receptor.  
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DISCUSSION
The results of our study show that biomarkers proADM, proET-1 and suPAR predict-
ed ICU admission, 30-days and 90-days mortality with good to excellent accuracy in 
a general ED population of patients with fever, and outperformed clinical scores in 
predicting mortality. 
Our findings are in line with several studies on the biomarkers PCT, proADM, pro-
ET-1 and suPAR, that showed fair prognostic accuracy for ICU admission and in-hos-
pital or 30-days mortality10,12,16. A meta-analysis of the predictive value of proADM 
in ED patients with community acquired pneumonia yielded a combined AUC of 
0.76 (95 % CI, 0.72-0.80)19. 
For both clinical scores SIRS and qSOFA, we found a lower predictive value for both 
30-days and 90-days mortality than a recent study by Seymour et al. In the study 
by Seymour et al., the qSOFA score and SIRS score identified in-hospital mortality in 
patients with a suspected infection with an AUC of 0.76 (0.75 – 0.77) for SIRS and 
0.81 (95% CI 0.80 – 0.82) for qSOFA, respectively8. Singer et al reported an AUC 
of qSOFA for in-hospital mortality of 0.76 (95% CI 0.73 – 0.78), in a retrospective 
study of a general ED population20. Contrary to these studies, our results showed 
that SIRS and qSOFA did not predict mortality, with a AUC for 30-days mortality for 
SIRS of 0.522 (95% CI 0.317 – 0.726) and for qSOFA of 0.518 (95% CI 0.312 – 0.723). 
These differences may be attributable to a selection bias in our study; severely ill 
patients who could not give written informed consent were not included. Yet, low-
er accuracy of qSOFA was also found in geriatric patients with suspected fever9. In 
our study, the accuracy of both SIRS and qSOFA for ICU admission was higher than 
the accuracy for 30-days and 90-days mortality. However, abnormal clinical scores 
may have prompted physicians to admit specific patients to the ICU. Because this 
potential influence on clinical decision making, clinical scores may have had a con-
founding role in the prediction of ICU admission in this study.  
The difference between clinical scores and biomarkers is that biomarkers are indica-
tors of specific activated systems and inflammatory pathways in sepsis, contrary to 
clinical scores, which only represent the combined end-organ effects of all activated 
systems in sepsis. End-organ effects, such as increased respiratory rate, tachycardia 
and hypotension are compensatory mechanisms, which are activated to counter or-
gan dysfunction. Patients with sepsis who still have normal vital parameters cannot 
be identified using a clinical score. However, because activation of specific activated 
systems and inflammatory pathways can be measured using biomarkers, patients 
with severe course of disease can be detected earlier. In short, clinical scores are 
lagging behind in identifying critically ill patients. This is a crucial difference. When 
patients with severe disease are identified earlier, interventions can be started ear-
lier, and end-organ failure and subsequent adverse events may be prevented.  
Sepsis is a complex syndrome, and has no uniform manifestation7. Therefore, bio-
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marker guided treatment in sepsis can be effective in selected groups of patients, 
but inaccurate and ineffective in a general, real-life population. In cardiology, myo-
cardial infarction is ruled out based on measurements of a single biomarker, high 
sensitive troponin T, with an accuracy of >99%21. Consequently, troponin guided risk 
assessment and treatment is incorporated in international treatment guidelines22,23. 
Likewise, using the biomarkers in this study, the activity of specific pathophysiologic 
pathways can be identified with high accuracy. To effectively treat patients based 
on risk stratification tools, the accuracy of these tools needs to be unequivocal. The 
findings in this study are based on a small number of patients with adverse events. 
Hence, these findings have to be validated in a larger cohort in order to start bio-
marker-guided interventions. 
We hypothesize that combining both biomarkers for severity of disease with clinical 
scores in a combined prediction model will yield a higher accuracy for predicting 
disease severity than individual biomarkers or clinical scores. Therefore, we suggest 
a combined prediction model of both the qSOFA clinical score and biomarkers CRP, 
PCT, proADM, proET-1 and suPAR for identifying patients who are at risk for both 
ICU admission and 30-days and 90-days mortality. This model needs to be validated 
in larger populations to determine if interventional studies are feasible. If feasible, 
implementation of this strategy can result in timely and accurate identification of 
patients who are at risk for adverse events. Consequently, end-organ failure and 
subsequent adverse events can be prevented, unnecessary hospital admissions and 
ICU admissions can be reduced, and critically ill patients receive optimal care.
Limitations
Fever as inclusion criterion was used to select patients with a suspected infection 
objectively, and to make the results generalizable for a real-life ED population. 
However, not all patients with suspected infectious diseases who visit the ED have 
fever. Additionally, patients in this study were required to give written informed 
consent in the ED. Severely ill patients with reduced consciousness were therefore 
not included. Hence, these factors created a selection bias in our cohort, and conse-
quently, results of this study cannot be generalized to all ED patients with suspected 
infections. The respiratory rate was not reported in several patients. Because this 
variable is part of both the qSOFA and SIRS scores, we made the assumption that 
these parameters were non-divergent in the patients with missing values. If there 
were abnormal variables in these patients, the accuracy of the clinical scores could 
deviate from our results. Our population had a low number of patients who were 
admitted to the ICU and who had 30-days and 90-days mortality. Therefore, our 
results may be an overestimation of the predictive value due to the small number 
of patients. This study is therefore intended as a proof of concept that biomarkers 
can be used as early predictive indicators for mortality in a general ED population. 
Validation of the accuracy of the proposed model is required.   
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CONCLUSION
In our study, we showed that in a general ED population, biomarkers proADM, pro-
ET-1 and suPAR, and to a lesser extent CRP and PCT were more accurate in predict-
ing 30-days and 90-days mortality than clinical scores SIRS and qSOFA. ProADM, 
proET-1 and suPAR and clinical scores predicted ICU admission with comparable 
accuracy. Biomarkers can be used for timely diagnosis of a severe course of disease 
in sepsis. 
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Aims of this thesis
The overall aims of this thesis were to investigate if biomarkers can improve early 
identification of bacterial infections and provide early estimation of severity of dis-
ease, and if biomarkers can be used to effectively reduce the prescription of antibi-
otics for febrile patients without bacterial infections in the ED.
Main results
In the emergency department (ED), biomarker-guided treatment with procalcitonin 
(PCT) did not result in a reduction of prescription of antibiotics to patients with 
fever. However, combinations of biomarkers for both viral and bacterial infections 
(CRP, PCT, TRAIL and IP-10) could discriminate between bacterial and non-bacteri-
al disease with higher accuracy than individual markers and previously described 
combinations of biomarkers. Biomarkers (CRP, PCT, proADM, proET-1 and suPAR) 
could identify patients who were at risk for a severe course of illness and mortality. 
PCT-guided therapy
In part I of this thesis we focused on PCT-guided therapy, a biomarker strategy to 
reduce antibiotic prescriptions in the ED. Because PCT-levels are generally elevated 
in case of bacterial infections, PCT can be theoretically used as a biomarker to dis-
criminate between bacterial and non-bacterial disease1. The diagnostic value of PCT 
has been studied extensively, and PCT has been found to be more accurate than the 
conventional biomarker C-reactive protein (CRP)2. With antimicrobial stewardship 
in mind, several distinct PCT-guided therapies were designed, with different goals. 
In one strategy, PCT-guided therapy is used to reduce the length of antibiotic treat-
ment. This strategy has been studied mostly in the intensive care unit (ICU), and 
was shown to be safe, and effective in reducing the overall exposure to antibiotics 
in ICU patients3. Another strategy of PCT-guided therapy is the guidance of initiation 
of antibiotics. 
Initiation of antibiotics
In this thesis, we focused on initiation of antibiotics using PCT-guided therapy. Ac-
curacy of a biomarker is only one part of a biomarker-guided therapy. Physicians 
make the decision to start antibiotics. Therefore, the adherence to the treatment 
algorithm is another important factor in the efficacy of biomarker-guided therapy. 
To assess the previously reported clinical value and efficacy of PCT-guided therapy, 
we performed a systematic review on studies that prospectively investigated effi-
cacy. We limited the setting of the studies to the ED. Patients only spend a limited 
amount of time in the ED. Physicians have to make critical decisions on initiation of 
treatment under time constraints, with limited information of the patients’ medical 
history and with limited availability of diagnostic modalities4. Because these con-
ditions may influence treatment decisions, and because these conditions are sig-
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nificantly different from primary care, medical wards and ICUs, we only compared 
studies from ED settings.
In our systematic review, a common finding of all studies was that PCT-guided ther-
apy did not result in an increase in adverse events5. Furthermore, we found that 
PCT-guided therapy did reduce antibiotic prescriptions in adult patients with respi-
ratory infections. However, in young children PCT-guided therapy did not reduce 
antibiotics. Additionally, several of the studies included in the systematic review 
reported nonadherence to study protocols. Nonadherence was not limited to ED 
settings, and is also reported in PCT-guided therapy studies in primary care, medical 
wards and ICUs5. Nonadherence was defined as the discrepancy between the treat-
ment advice based on the PCT-guided advice, and the actual antibiotic treatment 
physicians initiated. Nonadherence could be either withholding antibiotics despite 
the advice to start treatment, or by starting treatment in spite of the advice to with-
hold antibiotics. 
The practice of emergency medicine
None of the studies on PCT-guided therapy addressed a general ED population. In-
stead, populations were classified by age (pediatric patients) or specific complaints 
(respiratory complaints). Therefore, findings of these studies are not applicable to 
daily practice in the ED, because 1. Most patients who visit the ED are adults. 2. 
Most patients who have suspected infections do not have specific classified find-
ings, such as unilateral rales on auscultation of the lungs, or a lobar infiltrate on a 
chest x-ray. Moreover, the incidence of bacterial infections was higher in selected 
populations than in a general ED population. For example, the incidence of commu-
nity acquired pneumonia in the proHosp study was 68%, whereas in the study by 
Limper et al. the incidence of CAP in a general ED population was only 27%6,7. In the 
later study, 39% of patients did not have a confirmed diagnosis. Physicians in the ED 
need adequate decision-making support tools to treat all patients with suspected 
infections, not only patients with clearly identifiable symptoms, but also, or maybe 
even more so, patients with vague or indeterminate complaints. With this rationale, 
we started a pilot study on PCT-guided therapy in the ED. 
PCT-guided therapy in a general ED population
To select patients with a suspected infection in an objective manner, we used fe-
ver as single inclusion criterion. Fever is an objectively and easily measurable vital 
parameter, and a fair indicator of infections6,8. With this criterion, we could include 
a heterogeneous population of patients with infectious diseases without the risk 
of selection of specific classes of patients, making the results generalizable to the 
general ED population. In the pilot study, we did not find a statistically significant 
reduction of antibiotic treatment with the use of PCT-guided therapy, although a 
trend towards reduction was observered9. Based on the findings in the pilot study, 
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we designed a larger study with a similar research question, with the acronym Hi-
TEMP, for fever, or hyperthermia, which was an abbreviation of “Higher diagnostic 
accuracy and cost-effectiveness using procalcitonin in the treatment of emergency 
medicine patients with fever”10. In addition to the outcomes of the pilot study, we 
added a healthcare costs analysis, including hospital costs and societal costs. Fur-
thermore, this was a multicenter study, in both a tertiary care academic hospital, 
and a non-academic hospital11. 
Based on the results of the largest ED study on PCT-guided therapy, the proHosp 
study, and our pilot study, our hypothesis was to find a significant reduction of pre-
scription of antibiotics. However, to our surprise, we did not. Results of the study 
showed no significant difference in antibiotic prescriptions between patients who 
received standard care and patients who received PCT-guided therapy12. In our 
view, the explanation of this finding was attributable to another unexpected find-
ing, namely the low accuracy of PCT for both confirmed and suspected bacterial 
infections compared to previous studies on PCT2. 
In the HITEMP study, our goal was to design a study in which all patients with sus-
pected infections in the ED were included, using objective inclusion criteria. Al-
though selection bias occurred in our population on several areas, (patients with 
severe disease were not included because they could not give written informed 
consent in the ED, patients with mild disease without fever were not included be-
cause they did not meet the inclusion criterion of fever), the population of the Hi-
TEMP study approximated the heterogeneity of a general ED population to a higher 
extend than the previous studies on PCT-guided therapy5. We found that the AUC 
of the predictive value of PCT for bacterial infections in a general ED population 
was 0.681 (95%CI 0.633–0.730), which was lower than AUCs of PCT for bacterial 
infections in previously reported in studies on specific patient groups. There was 
nonadherence to PCT-guided treatment advice in 49% of cases in our study12. We 
expect that physicians who were in a conflicting situation, in other words, when 
their clinical judgement was in contrast with the PCT advice, would trust on their 
own clinical judgement and disregard the PCT-guided treatment advice. This means 
that physicians implicitly compared the diagnostic value of PCT with the diagnostic 
value of clinical judgement. Additionally, in subsequent encounters with PCT results 
after a conflicting situation, physicians may have had a biased attitude, an anchor, 
towards PCT results. With a previous negative experience with PCT values in mind, 
physicians could have been even more inclined to disregard treatment advice4,13. 
Additional biomarker strategies
Our main conclusion of the HITEMP study was that PCT-guided therapy was not ef-
fective in reducing antibiotics in a general ED population. The antibiotic treatment 
advice, based on a single PCT measurement with a cut-off of ≥0.5μg/l, was disre-
garded by physicians due to conflicts of PCT-guided treatment advice with clinical 
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judgement. To reduce antibiotics in the ED, bacterial infections needed to be deter-
mined with higher accuracy. With this idea, we performed two studies combining 
PCT with TRAIL and IP-10. We hypothesized that if a patient was diagnosed with a 
viral infection, it was less likely that a bacterial infection was present. In the pilot 
study on viral biomarkers, we showed that TRAIL and IP-10 could differentiate pa-
tients with confirmed viral infections from patients with confirmed bacterial infec-
tions and non-infectious fever. However, this was a selected sample of patients with 
a single confirmed infection. In real-life, patients can have both a viral and bacterial 
infection simultaneously. Moreover, by selecting only patients with confirmed infec-
tions, there was a possibility of an overestimation of accuracy. Therefore, we deter-
mined the accuracy of a combination of biomarkers for viral and bacterial infections 
in the HiTEMP cohort, to approximate a general ED population. In this subsequent 
study, we found that the combination of CRP, PCT, TRAIL and IP-10 could differen-
tiate between bacterial and non-bacterial disease with higher accuracy than indi-
vidual biomarkers. The classification “suspected infections” was performed by two 
independent physicians, with a systematic approach. However, expert panel review 
is no gold standard for diagnosing bacterial infections. To determine the true value 
of this combination of biomarkers, an interventional study is needed. Before an in-
terventional study can be initiated, the accuracy of the combination of biomarkers 
needs to be validated in prospective studies. 
Severity of disease
In the last study in this thesis, we focused on a different outcome, severity of disease. 
We defined severe disease as either need for intensive care unit (ICU) admission, or 
mortality. In this study, we showed that an increase of biomarkers for activation of 
different systems in sepsis predicted ICU admission with comparable accuracy as 
validated clinical scores, and predicted mortality with even higher accuracy than 
clinical scores14. Because of the low number of patients who had severe disease, we 
could not calculate a combined prediction model with both biomarkers and clini-
cal scores. Theoretically, a combination of multiple biomarkers for different systems 
that are activated in sepsis, together with clinical scores that indicate the effects of 
sepsis, could yield a detailed indication of disease severity of sepsis. Although an in-
dication of disease severity in patients with suspected infections does not determine 
if patients have bacterial infections or not, an indication of disease severity may help 
physicians in treatment decisions. Clinical guidelines advise to treat patients with 
suspected sepsis with broad spectrum antibiotics, in order to reduce mortality15,16. 
If patients who are at risk for a severe course of illness could be identified in the ED, 
these patients could receive optimal treatment in an early stage. On the other hand, 
if patients are not at risk for a severe course of illness, antibiotic treatment could 
be avoided, and a watchful waiting approach could be initiated in specific patient 
groups. For example, such an approach has been previously proposed for pediatric 
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patients with uncomplicated otitis media17. Additionally, even hospital admissions 
could be reduced, if patients are not severely ill, and hence do not require clinical 
observation. This will eventually reduce overall healthcare costs. Although the pre-
dictive value of biomarkers for disease severity should first be validated in prospec-
tive studies before an interventional study can be performed, withholding antibiot-
ics for not severely ill patients may be an option to reduce antibiotic prescriptions 
in the ED. Of course, careful consideration of inclusion criteria and acceptable con-
sequences should be part of the study design. 
Next steps
Based on the results of the studies in this thesis, we expect that combinations or 
sets of biomarkers are a key step to increase diagnostic accuracy in differentiation 
between bacterial and non-bacterial disease. In our study on the combination of 
biomarkers for viral and bacterial infections, we have used a single cut-off for all 
biomarkers in the model. However, there may be other approaches that may be 
more effective in ruling out bacterial infections and consequently reducing the use 
of antibiotics. Recent studies in pediatric patients have used the combination of 
CRP, TRAIL and IP-10 using the so-called “index test”18,19. In this test, patients have 
a high, low or equivocal probability for bacterial infections. This approach can be 
used to effectively rule-out bacterial infections in patients with low probability, and 
antibiotic treatment can be avoided. One of our next projects will be the design and 
validation of a clinical decision support tool to differentiate between bacterial and 
non-bacterial disease in adult ED patients, with a combination of CRP, PCT, TRAIL 
and IP-10. Although PCT-guided therapy was shown to be ineffective in the HiTEMP 
study, a combination of several biomarkers can be more accurate in differentiating 
between bacterial and non-bacterial disease12,20. In this project, we will explore dif-
ferent approaches, a “classical” dichotomous outcome, an approach with an equiv-
ocal group, and a numerical scoring system which indicates probability of bacterial 
disease. This project is the logical next step after the HiTEMP study, by a refinement 
of diagnostic means. The goal of this project is to reduce unnecessary prescription 
of antibiotics. 
The second project is a further study into severity of disease. In sepsis, multiple 
systems eventually cause organ failure. Our hypothesis is that if we can measure 
activity in all these systems, together with measurement of clinical parameters, we 
can identify those patients who are at risk for a severe course of illness in an earlier 
stage, and intervene earlier. Furthermore, patients with a predicted mild course of 
disease may be exempt from unnecessary treatment and observation. One of the 
first steps of the project will be an observational study of the biomarkers proADM, 
proET-1 and suPAR for hospital admission, ICU admission and mortality in the ED. 
To specifically assess disease severity in patients with sepsis, we plan to investigate 
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multiple systems, such as activation of the immune system and the microvascu-
lar system, with the addition of the activation of the coagulation system. A study 
on ICU patients will be initiated where we will measure biomarkers before, during 
and after ICU admission. With this approach, we expect to gain more insight in the 
pathophysiology of sepsis, and to be able to quantify disease severity in an ob-
jective way. In the future, these insights may lead to early interventions that may 
optimize critical care, reduce healthcare costs by reducing hospital admissions, and 
possibly, reduce antibiotics. 
Future diagnostic modalities
In this thesis, and in our newly proposed projects, the goal was, and remains, to 
determine the diagnostic value of indicators that can differentiate between patho-
gens, and can assess activity of different physiological systems. The indicators we 
studied were protein-based biomarkers and clinical scores. Clinical scores contain 
vital parameters, such as respiratory rate and blood pressure. In sepsis, abnormal 
vital parameters can be seen as a compensation mechanism for failing underlying 
systems, such as the vascular system and endothelium. Likewise, abnormal pro-
tein-based biomarkers represent a reaction to pathogen-initiated activation of spe-
cific genes that encode for these biomarkers. The so-called “omics” diagnostics (ge-
nomics, transcriptomics, proteomics and metabolomics) are diagnostic tests that 
utilize the human genome, and provide information on activation and inhibition of a 
multitude of (patho)physiological systems, on a deeper level than ever before. The 
omics diagnostics are part of the upcoming field of systems biology21,22. The transla-
tion of systems biology from laboratories to clinical practice is one of the challenges 
for the future. 
Future treatments
Antibiotics are most common treatment for bacterial infections. However, due to 
the threat of antibiotic resistance and the looming post-antibiotic era, alternative 
treatment options should be investigated. 
In this thesis, we investigated several biomarkers as indicators for bacterial and viral 
disease. However, these biomarkers themselves also have physiological functions. 
In a study in septic hamsters who were administered exogenous PCT, mortality rose 
significantly compared to the control group who did not receive exogenous PCT. In 
another experiment, septic hamsters were treated with an anti-serum to hamster 
PCT. The group of hamsters who received the anti-serum to PCT, and had a sub-
sequent neutralization of PCT, had a lower mortality rate than the control group, 
who did not receive PCT neutralization23. In another study, mice with a S. pneumo-
niae lung infection were treated with exogenous TRAIL. The intervention group of 
mice had a higher survival rate than the control group24. These animal experiments 
show that there may be possibilities to target therapies on the host organism it-
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self, instead of on the pathogen. However, these findings have to be validated and 
developed into treatments for humans first, and then tested rigorously for efficacy 
and safety before they can be utilized in clinical practice. A recently rediscovered, 
and possible future treatment is bacteriophage therapy. Bacteriophages are viruses 
that target specific bacteria. Bacteriophage treatment was investigated in the early 
twentieth century. Because of the success of antibiotics, research on bacteriophage 
therapy was discontinued in the Western world. Today, in a search for alternatives 
for antibiotics, bacteriophage therapy could be a solution to the problem of antibi-
otic resistance. Further well-conducted studies are required to determine the role 
of bacteriophage therapy25. 
Putting it in perspective
The rationale of this thesis was to find and investigate ways to address the problem 
of antibiotic resistance. We focused our question on how we could reduce antibi-
otic prescriptions to patients who did not need antibiotics, and limited our studies 
to a specific clinical setting, the ED. We concluded that PCT-guided therapy did not 
effectively reduce antibiotic prescriptions in our study setting. Hence, we investi-
gated two strategies, one to make the differentiation of bacterial and non-bacterial 
disease more accurate, another to determine disease severity. For both strategies, 
we presented our plans for further study. This is where we are now. We have added 
our tiny bits of evidence and insights to the vast quantity of medical evidence in 
the field of infectious diseases, that started with Alexander Fleming, when he dis-
covered penicillin. Antibiotic resistance remains a threat to global health. However, 
current strategies will be refined. Newer and more accurate diagnostics will become 
available. New treatments will be discovered. And, following the principle of natural 
selection, with continuous effort of physicians and scientists, with hits and misses, 
failures and successes, we will find a way. 
Closing comments
Although the ultimate goal of is this thesis is investigating ways to combat antibiotic 
resistance, the practice of medicine revolves around people. The primary interest of 
physicians should always be their patients. Therefore, physicians who treat patients 
with infectious diseases have the self-proclaimed duty to critically appraise all evi-
dence on antibiotic resistance, in order to decide what will keep their patients from 
harm. Moreover, physicians have to think critically about their own clinical judge-
ment. Because eventually, it is the physician who will make the decision, whether 
– to treat or not to treat -.
149
General discussion
REFERENCES
1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentra-
 tions in patients with sepsis and infection. Lancet 1993;341:515-8.
2. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels
 as markers of bacterial infection: a systematic review and meta-analysis. Clinical infectious diseases : 
 an official publication of the Infectious Diseases Society of America 2004;39:206-17.
3. Soni NJ, Samson DJ, Galaydick JL, et al. Procalcitonin-guided antibiotic therapy: a systematic review 
 and meta-analysis. Journal of hospital medicine 2013;8:530-40.
4. Croskerry P. Achieving quality in clinical decision making: cognitive strategies and detection of bias.
 Acad Emerg Med 2002;9:1184-204.
5. van der Does Y, Rood PP, Haagsma JA, Patka P, van Gorp EC, Limper M. Procalcitonin-guided therapy
  for the initiation of antibiotics in the ED: a systematic review. The American journal of emergency 
 medicine 2016;34:1286-93.
6. Limper M, Eeftinck Schattenkerk D, de Kruif MD, et al. One-year epidemiology of fever at the Emergency
 Department. The Netherlands journal of medicine 2011;69:124-8.
7. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guide-
 lines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial.  
 JAMA - Journal of the American Medical Association 2009;302:1059-66.
8. Limper M, Gerstenbluth I, Duits AJ, van Gorp EC. Epidemiology of febrile diseases in the emergency 
 department of a Caribbean island: the Curacao experience. The West Indian medical journal 
 2012;61:76-80.
9. Limper M, van der Does Y, Brandjes DP, De Kruif MD, Rood PP, van Gorp EC. Procalcitonin guided 
 antibiotic therapy in patients presenting with fever in the emergency department. The Journal of 
 infection 2014;69:410-2.
10. van der Does Y, Limper M, Schuit SC, et al. Higher diagnostic accuracy and cost-effectiveness using 
 procalcitonin in the treatment of emergency medicine patients with fever (The HiTEMP study): a multi-
 center randomized study. BMC emergency medicine 2016;16:17.
11. Yealy DM, Fine MJ. Measurement of serum procalcitonin: a step closer to tailored care for respiratory  
 infections? JAMA : the journal of the American Medical Association 2009;302:1115-6.
12. van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a 
 general emergency department population: a multicenter noninferiority randomized clinical trial 
 (HiTEMP study). (submitted for publication) 2018.
13. Tversky A, Kahneman D. Judgment under Uncertainty: Heuristics and Biases. Science (New York, NY) 
 1974;185:1124-31.
14. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis: For the Third 
 International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA : the journal of the
 American Medical Association 2016;315:762-74.
15. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe
 sepsis and septic shock from the first hour: results from a guideline-based performance improvement  
 program. Critical care medicine 2014;42:1749-55.
16. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Manage-
 ment of Sepsis and Septic Shock: 2016. Intensive care medicine 2017;43:304-77.
17. Vouloumanou EK, Karageorgopoulos DE, Kazantzi MS, Kapaskelis AM, Falagas ME. Antibiotics versus  
 placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials. The  
 Journal of antimicrobial chemotherapy 2009;64:16-24.
18. van Houten CB, de Groot JAH, Klein A, et al. A host-protein based assay to differentiate between 
 bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, valida-
 tion study. The Lancet Infectious diseases 2017;17:431-40.
19. Srugo I, Klein A, Stein M, et al. Validation of a Novel Assay to Distinguish Bacterial and Viral Infections.  
 Pediatrics 2017;140.
20. van der Does Y, Rood PPM, Ramakers C, et al. Identifying patients with bacterial infections using a 
 combination of biomarkers in the emergency department. (unpublished manuscript).
150
General discussion
21. Fontana JM, Alexander E, Salvatore M. Translational research in infectious disease: current paradigms 
 and challenges ahead. Translational research : the journal of laboratory and clinical medicine
 2012;159:430-53.
22. Jean Beltran PM, Federspiel JD, Sheng X, Cristea IM. Proteomics and integrative omic approaches for 
 understanding host-pathogen interactions and infectious diseases. Molecular systems biology 
 2017;13:922.
23. Nylen ES, Whang KT, Snider RH, Jr., Steinwald PM, White JC, Becker KL. Mortality is increased by 
 procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Critical  
 care medicine 1998;26:1001-6.
24. Steinwede K, Henken S, Bohling J, et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts thera-
 peutic efficacy for the treatment of pneumococcal pneumonia in mice. The Journal of experimental   
 medicine 2012;209:1937-52.
25. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to
  antibiotics for the treatment of bacterial pathogens. Virulence 2014;5:226-35.
151
General discussion
152
153
CHAPTER 10
PART III 
CONCLUSIONS
Yuri van der Does MD
SUMMARY OF FINDINGS
154
Summary of findings
SUMMARY OF FINDINGS
Part I Procalcitonin-guided therapy
Chapter 2: In this systematic review, we report on prospective studies on PCT-guided 
antibiotic therapy. In the six studies on adult patients with respiratory complaints, 
PCT-guided therapy reduced antibiotic prescriptions. In three studies on pediatric 
populations, there was no reduction in antibiotics, due to nonadherence to the 
PCT-guided therapy protocol. PCT-guided therapy did not increase adverse events. 
Chapter 3: In this pilot study, we randomized 106 patients with fever in the ED be-
tween PCT-guided antibiotic therapy and standard care. There was no significant 
reduction in antibiotics in the PCT-guided group, although a trend was noted (92% 
vs 80% of patients received antibiotics). The PCT-guided group had significantly less 
ICU admissions and mortality. We concluded that the sample size was insufficient 
and hypothesized that effects could be shown in a sufficiently powered study. Chap-
ter 4: The protocol of the HiTEMP study: Higher diagnostic accuracy and cost-effec-
tiveness using procalcitonin in the treatment of emergency medicine patients with 
fever. Chapter 5: In the HiTEMP study, 551 patients were included. We found no 
significant reduction in antibiotics in the PCT-guided group (73% vs 77%, p = 0.28). 
PCT-guided therapy was noninferior by means of adverse events. The accuracy of 
PCT ≥0.5μg/L for confirmed bacterial infections was low, with a sensitivity 0.52(95% 
CI 0.45–0.60) and a specificity 0.74(95% CI 0.68–0.78). However, the accuracy for 
confirmed bacterial infections was higher for PCT than for CRP. The costs of treat-
ment were equal between groups, € 5386 for patients in the control group, and € 
4853 for patients in the PCT-guided group, with a mean difference of -€533(95% CI 
-€1570 to €505). Our hypothesis was that low accuracy of PCT for bacterial infec-
tions explained the lack of effect of PCT-guided therapy. 
Part II Additional biomarker strategies
Chapter 6: In this pilot study of 54 patients with confirmed infections, we showed 
that the blood concentrations of biomarkers TRAIL and IP-10 were significantly high-
er in patients with viral disease compared to patients with non-viral disease (TRAIL: 
p <0.001) (IP-10: p = 0.05). A combined model of PCT, TRAIL and IP-10 resulted in 
an area under curve (AUC) of 0.84 (95% CI 0.72 – 0.97) for identifying confirmed 
viral disease. Chapter 7: In this study of 315 patients from the HiTEMP cohort, we 
used a combined biomarker model of CRP, PCT, TRAIL and IP-10 for the prediction 
of suspected and confirmed bacterial infections resulted in an AUC of 0.77 (95% CI 
0.70 – 0.83). Chapter 8: In a study on disease severity on 353 patients of the HiTEMP 
cohort, we found that the biomarkers proADM, proET-1 and suPAR predicted ICU 
admission with similar accuracy as the clinical score SIRS and qSOFA, and predicted 
mortality with a higher accuracy than the clinical scores. CRP and PCT had limited 
predictive value for ICU admission, and predicted mortality to a lesser extent than 
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proADM, proET-1 and suPAR, but more accurate than SIRS and qSOFA.
Part III Conclusions
Chapter 9: In this last part, we summarize the findings of the studies in this thesis. 
PCT-guided therapy did not reduce antibiotics in a general population with fever in 
the ED. Combinations of biomarkers (CRP, PCT, TRAIL and IP-10) could discriminate 
between bacterial and non-bacterial disease with higher accuracy than individual 
markers. Biomarkers (CRP, PCT, proADM, proET-1 and suPAR) could identify patients 
who were at risk for a severe course of illness and mortality.
Furthermore, two new research projects are described. The first project will con-
tinue differentiating bacterial from non-bacterial disease using the combined bio-
marker model of CRP, PCT, TRAIL and IP-10 in the ED. The second project will further 
deepen the knowledge on severity of disease in patients with suspected infections 
in the acute and critical care setting. The future diagnostic modalities of systems 
biology are addressed, and future treatments, including bacteriophage therapy, are 
described. 
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Deel I Procalcitonine-geleide therapie
Hoofdstuk 2: In deze systematische review beschrijven we de prospectieve studies 
over PCT-geleide antibiotische therapie. In de zes onderzoeken in volwassen pa-
tiënten met luchtwegklachten, werd het percentage patiënten dat antibiotica kreeg 
kleiner door PCT-geleide therapie. In drie onderzoeken bij pediatrische patiënten 
was er geen afname van antibiotica, als gevolg van het niet volgen van het PCT-ad-
vies door de artsen. PCT-geleide therapie leidde niet tot meer morbiditeit of mor-
taliteit. Hoofdstuk 3: In deze pilotstudie hebben wij 106 patiënten met koorts op de 
SEH gerandomiseerd tussen PCT-geleide antibiotische therapie en standaardzorg. 
Er was geen significante afname van antibiotica in de PCT-geleide groep, hoewel 
er wel een trend werd opgemerkt (92% versus 80% van de patiënten kreeg antibi-
otica). De PCT-groep had statistisch significant minder IC-opnames en mortaliteit. 
We concludeerden dat de steekproefomvang onvoldoende was en veronderstelden 
dat effecten konden worden aangetoond in een onderzoek met voldoende power. 
Hoofdstuk 4: Dit hoofdstuk is het protocol van de HiTEMP-studie: Higher diagnostic 
accuracy and cost-effectiveness using procalcitonin in the treatment of emergency 
medicine patients with fever. Hoofdstuk 5: In de HiTEMP-studie werden 551 pa-
tiënten geïncludeerd. We vonden geen significante vermindering van antibiotica in 
de PCT-geleide groep (73% versus 77%, p = 0.28). PCT-geleide therapie was 
niet-inferieur in termen van veiligheid. De nauwkeurigheid van PCT ≥ 0,5 μg/l voor 
bewezen bacteriële infecties was laag, met een sensitiviteit van 0,52 (95% BI 0,45-
0,60) en een specificiteit van 0,74 (95% CI 0,68-0,78). Echter, de nauwkeurigheid 
voor bewezen bacteriële infecties was hoger voor PCT dan voor CRP. De behan-
delingskosten waren gelijk voor beide groepen, € 5386 voor patiënten in de contro-
legroep en € 4853 voor patiënten in de PCT-begeleide groep, met een gemiddeld 
verschil van - € 533 (95% BI -€ 1570 tot € 505). Onze hypothese was dat een lage 
nauwkeurigheid van PCT voor bacteriële infecties het gebrek aan effect van PCT-ge-
leide therapie verklaarde.
Deel II Additionele biomarker strategieën
Hoofdstuk 6: In deze pilotstudie onder 54 patiënten met bewezen infecties toonden 
wij aan dat de bloedconcentraties van biomarkers TRAIL en IP-10 significant hoger 
waren bij patiënten met een virale ziekte, in vergelijking met patiënten met niet-vi-
rale aandoeningen (TRAIL: p <0,001) (IP-10: p = 0.05). Een gecombineerd model 
van PCT, TRAIL en IP-10 resulteerde in een area-under-curve (AUC) van 0,84 (95% 
CI 0,72 - 0,97) voor het identificeren van bewezen virale ziekte. Hoofdstuk 7: In 
deze studie onder 315 patiënten uit het HiTEMP-cohort gebruikten we een gecom-
bineerd biomarkermodel van CRP, PCT, TRAIL en IP-10 voor de predictie van ver-
moedelijke en bewezen bacteriële infecties. Dit model resulteerde in een AUC van 
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0,77 (95% CI 0,70 - 0,83). Hoofdstuk 8: In een onderzoek naar ernst van ziekte bij 
353 patiënten van het HiTEMP-cohort, ontdekten wij dat de biomarkers proADM, 
proET-1 en suPAR ICU-opnames voorspelden met dezelfde nauwkeurigheid als de 
klinische score SIRS en qSOFA. Daarnaast voorspelden deze biomarkers mortaliteit 
met een hogere nauwkeurigheid dan de klinische scores. CRP en PCT hadden 
beperkte voorspellende waarde voor ICU-opname. CRP en PCT voorspelden mor-
taliteit minder nauwkeurig dan proADM, proET-1 en suPAR, maar alle biomarkers 
voorspelden mortaliteit nauwkeuriger dan SIRS en qSOFA.
Deel III Conclusies
Hoofdstuk 9: In dit laatste deel vatten we de bevindingen van de studies in dit 
proefschrift samen. PCT-geleide therapie verminderde antibiotica niet bij een al-
gemene patiëntenpopulatie met koorts op de SEH. Combinaties van biomarkers 
(CRP, PCT, TRAIL en IP-10) waren nauwkeuriger in het maken van een onderscheid 
tussen bacteriële en niet-bacteriële ziekte dan individuele markers. Biomarkers 
(CRP, PCT, proADM, proET-1 en suPAR) konden patiënten identificeren die het risico 
liepen op een ernstige ziekte en sterfte.
Verder worden in dit laatste deel twee nieuwe toekomstige onderzoeksprojecten 
beschreven. Het eerste project zal verder gaan op de vraag hoe bacteriële en 
niet-bacteriële ziekten van elkaar onderscheden kunnen worden, met behulp van 
het gecombineerde biomarkermodel van CRP, PCT, TRAIL en IP-10. Deze studie zal 
op de spoedeisende hulp worden uitgevoerd. Het tweede project heeft als doel om 
de kennis over ernst van ziekte bij patiënten met infecties in de acute zorg verd-
er verdiepen. Aan het einde van het hoofdstuk worden toekomstige diagnostische 
modaliteiten van systeembiologie en toekomstige behandelingen, waaronder bac-
teriofaagtherapie, beschreven.
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